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ABSTRACT 
 
 Metabolomics, the study and characterization of small molecule metabolites, faces 
challenges due to the size and diversity of the metabolome.  No current instrumentation is 
capable of measuring the entire metabolome.  Liquid chromatography with mass spectrometry 
detection is widely used in metabolomics for its sensitivity and selectivity.  Detection is limited 
to metabolites which are compatible with the selected column chemistry.  Many small molecule 
neurochemicals are polar and thus not well retained with the popular reversed phase 
chromatography.  Hydrophilic interaction liquid chromatography is better suited for this 
application, but the observed limits of detection are not sufficient for trace neurochemicals. 
 One way to overcome this limitation is through the use of chemical derivatization.  Polar 
metabolites are labeled with a hydrophobic moiety, increasing retention and ionization efficiency 
in reversed phase chromatography, allowing for lower limits of detection.  Additionally, internal 
standards are easily produced using stable isotope labeled derivatization reagents, allowing for 
improved quantification.  Previous work in the Kennedy lab has been performed with benzoyl 
chloride, which reacts primarily with amines and phenols.  This reaction is virtually 
instantaneous at room temperature and increases sensitivity by up to 1,000 fold.  Benzoyl 
chloride derivatization was previously described for analysis of 17 neurochemicals in 
microdialysate with reversed phase liquid chromatography and triple quadrupole mass 
spectrometry. 
  
xiv 
 
 In this work, benzoyl chloride derivatization is expanded upon in both metabolome 
coverage and applicability.  To allow benzoyl chloride derivatization of proteinaceous samples 
such as plasma or tissue, a sample preparation method was developed and optimized.  The 
resulting solvent precipitation method is fast, simple, and compatible with very small sample 
volumes.  This was demonstrated in two brief applications monitoring epinephrine in mouse 
plasma and serotonin in Drosophila tissue. 
 With sample preparation optimized, we then aimed to expand metabolome coverage and 
subsequently developed a method for the analysis of 70 benzoylated neurochemicals.  With 
nanomolar limits of detection and internal standards for each metabolite, this method has many 
advantages over other methods of comparable scale.  We make use of this expanded coverage by 
investigating plasma metabolic changes in Parkinson's disease as well as wine analysis.  Thirteen 
metabolites were found to be linked to Parkinson's disease or disease severity, though current 
evidence suggests L-DOPA treatment plays a major role in these findings.  Using a 56-
metabolite panel, we were able to distinguish wines based on their varietal and area of 
production. 
 Finally, we move away from benzoyl chloride and introduce a novel derivatization 
reagent, benzylamine.  Benzylamine derivatization is complementary to benzoyl chloride, 
reacting with carboxylic acids, carbonyls, and phosphates.  Moreover, the two reagents are 
compatible so derivatized samples can be mixed for analysis within a single run.  Two short 
methods are introduced, using benzylamine as a standalone reagent to monitor energy 
metabolites, or in conjunction with benzoyl chloride to monitor phenylalanine metabolism.  
Together, the two reagents have the potential to cover the majority of the metabolome. 
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CHAPTER 1 
Introduction 
Introduction to metabolomics 
 There is a wealth of information contained within the biomolecular makeup of a living 
organism, so a variety of approaches have been developed for the analysis of these biomolecules. 
Often referred to as the "omics cascade," these techniques help to establish a connection between 
biochemistry and the observed phenotype (Figure 1-1). Significant work has been done in the 
analysis of large biomolecules, including proteins and nucleic acids, as early sequencing 
techniques have been established for over 50 years.
1–3
 The analysis of small molecules in 
biological samples is not new, but it was not given the name "metabolomics" until recently. As 
an established "omics" technique, metabolomics has been rapidly gaining popularity in the past 
20 years.
4
 
 A major challenge facing metabolomics is the sheer size of the metabolome. The Human 
Metabolome Database (HMDB) contains over 40,000 entries for known or expected endogenous 
Figure 1-1:  The "omics cascade" illustrates the relationship between complementary approaches to the analysis of 
biomolecules. Reproduced from Patti et. al., 2012. 
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metabolites and approximately 70,000 more entries for external metabolites.
5
 Depending on the 
biological matrix, these metabolites can range from sub-nanomolar to millimolar concentrations, 
and the physical properties of the metabolites are widely varied. To measure all metabolites, the 
ideal methodology would be sensitive, selective, and reproducible, with a large dynamic range 
and unbiased detection. Currently, no instrumentation is capable of measuring the entire 
metabolome, so different approaches have been developed, each encompassing some of these 
desired qualities.
6,7
 
 The goal of "untargeted" metabolomics is to measure as many metabolites as possible. 
Untargeted methods are created without prior knowledge of which metabolites are in the sample 
and are thus capable of identifying novel or unexpected metabolites. A general workflow for 
untargeted metabolomics is shown in Figure 1-2a. Metabolic fingerprinting is one subset of 
untargeted metabolomics which does not seek to identify specific metabolites but rather to 
distinguish sample groups based on the results, which are typically NMR or liquid 
chromatography - mass spectrometry (LC-MS) spectra. Metabolic profiling, on the other hand, 
attempts to identify metabolites to determine specific differences between sample groups which 
can lead to greater understanding of the metabolic pathways involved. 
 Identification of metabolites from untargeted methods can be challenging. A vast amount 
of data is generated, so rather than attempt to identify everything, the first step is generally to 
determine which features differ between groups. In LC-MS metabolomics, a "feature" is defined 
by a specific m/z and retention time which provides good Gaussian peak shape in the 
chromatogram. Thousands of features may be detected with untargeted methods.
8,9
 Additional 
validation is required to confirm features as metabolites, as a single metabolite can produce 
multiple chromatographic features due to isotopes, adducts, or in-source fragmentation. Once 
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features of interest are identified, database searches can be performed to putatively identify 
metabolites. A number of metabolite databases exist for this purpose.
5,10,11
 Finally, following 
putative identification, authentic standards can be used to compare retention times and tandem 
mass spectrometry (MS/MS) fragmentation patterns.  
 Although untargeted metabolomics cannot currently measure the entire metabolome, it is 
still a powerful technique. Analysis is not limited to metabolites for which standards are 
available. Method development is typically fast, as generic methods are used to allow detection 
of as many metabolites as possible. As a result, a large number of metabolites can be detected. 
Data analysis is time consuming, however, due to the large amount of data generated, and 
quantification is limited due to the lack of calibration. With these properties, untargeted 
metabolomics is best suited for hypothesis generating applications such as biomarker 
discovery.
12–14
 
Figure 1-2:  Approaches to metabolomics. a. Untargeted metabolomic seeks to analyze all metabolites within a sample and 
requires separate MS/MS analysis for metabolite identification. b. Targeted metabolomics develops methods based on 
authentic standards are can provide quantitative comparison of samples. Reproduced from Patti et. al., 2012. 
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 In contrast to untargeted metabolomics, "targeted metabolomics" focuses on specific, 
known metabolites.
15
 Methods are generated through the use of authentic standards, so no 
identification is required following sample analysis. A workflow for targeted metabolomics is 
shown in Figure 1-2b. LC-MS/MS is typically used, though gas chromatography or capillary 
electrophoresis may also be used when compatible with the metabolites of interest. Analysis is 
limited to only metabolites which are known or selected, but the resulting methods are sensitive 
and selective. Up to hundreds of metabolites have been targeted in a single method.
16–18
 
Compared to untargeted metabolomics, method development for targeted metabolomics is 
slower, as conditions are optimized for the selected metabolites. Data analysis is much simpler, 
however. Metabolome coverage is limited in scope, but calibration curves can be prepared to 
allow for absolute quantification. Targeted metabolomics is most suited for hypothesis testing 
applications. 
 
Instrumentation for metabolomics 
 Nuclear magnetic resonance spectroscopy (NMR) is commonly used in 
metabolomics.
19,20
 NMR spectra are produced from the free induction decay of nuclei excited in 
a magnetic field. Proton NMR is the most common, but 
13
C and 
15
N are amongst other NMR 
active nuclei. For metabolomics, NMR offers unbiased detection, as anything with protons can 
be observed. The resulting spectra are very reproducible, and can provide structural and 
quantitative information. One of the major limitations for NMR in metabolomics, however, is 
sensitivity. Limits of detection for NMR are typically in the mid to high micromolar range.
20
 
Additionally, the spectra that result from the biological samples typical of metabolomics are 
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quite complex, making metabolite identification challenging. Despite these limitations, NMR can 
still be suitable for some untargeted metabolomics applications.
13,21
 
 Mass spectrometry (MS) has grown to become the most popular instrumentation for 
metabolomics.
6
 A chromatographic separation is usually employed prior to MS detection to 
increase peak capacity and to remove salts and interfering compounds from the chromatographic 
regions of interest. Gas chromatography (GC) is one separation technique that can be used for 
metabolomics.
22
 In GC, samples are volatilized and carried through a column by an inert carrier 
gas. The interior of a GC column is coated with the stationary phase, as rapid diffusion in the gas 
phase allows sufficient interaction between the analytes and the stationary phase despite the 
reduced surface area compared to packed columns. GC columns can be meters long, and thus 
provide good resolution of metabolites. However, metabolites which are not volatile require 
additional sample preparation to be compatible with GC, and degradation of thermally unstable 
metabolites may occur. 
 Liquid chromatography (LC) allows for separation in the liquid phase. LC columns are 
packed with small (typically ≤ 5 μm) particles which are coated with stationary phase. The 
packing material is generally silica based, and may be left bare or functionalized to create 
specific selectivity. The mobile phase is a solvent or mixture of solvents which is used to carry 
the sample through the column. Elution can occur with a constant mobile phase composition, 
called "isocratic" elution, or solvent composition can change over time through use of multiple 
pumps, called "gradient" elution. Analytes are separated based on their interactions between the 
stationary phase on the packing material and the mobile phase carrying them through the 
column. The specific combination of stationary phase and mobile phase determines the 
selectivity of the separation. 
6 
 
 Compared to GC, LC is typically slower, requiring minutes to hours for analysis time. 
GC also provides better resolution. However, LC does not require analytes to be volatile and is 
less prone to sample degradation. A wide range of LC stationary phases exist and based on the 
selected stationary and mobile phases, different separation modes can be achieved. Reversed 
phase liquid chromatography (RPLC) is widely used, and employs a hydrophobic stationary 
phase (often C18) and a polar stationary phase. Gradients composed of water and polar organic 
solvents such as acetonitrile or methanol are commonly used. Hydrophobic analytes are well 
resolved with RPLC. However, many metabolites are polar and are not retained well with RPLC. 
 Normal phase liquid chromatography (NPLC) uses polar stationary phases such as silica 
or alumina, and nonpolar mobile phases such as hexanes to efficiently separate polar analytes. 
However, polar metabolites may have poor solubility in the nonpolar, organic mobile phases 
used. Additionally, water readily adsorbs to the polar stationary phases which can lead to poor 
retention time reproducibility. Biological samples are typically aqueous, so standard NPLC is not 
well suited for metabolomics. 
 A subtype of NPLC called hydrophilic interaction liquid chromatography (HILIC) was 
introduced in 1990.
23
 This technique uses polar stationary phases, like NPLC, with blends of 
water and water-miscible organic mobile phases, similar to RPLC. Water preferentially adsorbs 
to the polar stationary phase, creating a water-enriched region at the stationary phase, with an 
adjacent water-depleted organic region in the mobile phase. Analytes are separated based on 
partitioning between the regions. Polar metabolites are generally soluble in HILIC mobile phases 
so the separation is not adversely affected by water in aqueous biological samples, and the 
mobile phases are more compatible with MS than NPLC. This makes HILIC a suitable choice for 
metabolomics, and indeed, it has been widely used for metabolomic studies.
24–28
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 A variety of detection techniques are compatible with LC, including spectrophotometric 
and electrochemical techniques as well as MS. In MS, analytes are ionized and resolved on basis 
of their mass to charge ratio, m/z. With limits of detection at nanomolar concentrations or lower, 
MS has greater sensitivity than NMR. MS selectivity is better than spectrophotometric 
techniques, as coeluting compounds can be resolved based on their m/z. MS instruments vary in 
their ionization strategy and mechanism for resolving ions based on m/z. The initially developed 
ionization techniques, such as electron impact, are considered "hard," meaning they cause 
fragmentation of analytes in-source. While this can be useful for structure determination of 
single analytes, it increases spectral complexity and makes analysis of mixtures complicated. For 
metabolomics, "soft" ionization methods are typically used, which limit in-source fragmentation 
of the analytes.  
 Matrix-assisted laser desorption ionization (MALDI) is one such "soft" technique, in 
which a sample is mixed with a matrix which readily absorbs laser photons. The sample is 
ionized by ablation of the matrix with a pulsed laser. MALDI is relatively unaffected by the salt 
content of the original sample and can illustrate spatial distributions of metabolites. However, the 
MALDI matrix is also detected, which can cause significant background in the low m/z range 
where metabolites are typically detected. As a pulsed technique, it is not especially compatible 
with the continuous flow of LC. MALDI can be used with LC by spotting the effluent onto 
MALDI plates, but this leads to offline analysis and can be slow. 
 Flow based techniques, such as electrospray ionization (ESI), are better suited for LC-MS 
analysis. In ESI, the sample solution is passed through a nebulizer with a voltage applied to the 
spray tip, producing charged droplets. Solvent evaporates from the droplets in the heated source. 
As the droplets shrink, the charge-to-volume ratio increases until it hits the Rayleigh limit, 
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causing Coulombic fission of the droplets. This repeats as the droplets get smaller and smaller. 
The exact mechanism for the final production of individual gas phase ions through ESI is not 
fully understood but there are a few well-supported theories. One is called the "charge residue 
model" which claims increasingly smaller and smaller droplets are formed until they contain on 
average a single ion per droplet (Figure 1-3a).
29
 The ion enters the gas phase as the remaining 
solvent evaporates. Another theory, the "ion evaporation model," proposes the field strength at 
the surface of the droplet increases as the droplets shrink until it becomes high enough to 
desolvate and eject analyte ions from the droplet (Figure 1-3b).
30,31
 Evidence suggests small 
molecules, such as metabolites, are primarily ionized by ion evaporation.
32
 
 Atmospheric pressure chemical ionization (APCI) is another soft, flow based ionization 
technique.
33
 In APCI, the LC effluent is passed through a heated nebulizer, leading to 
vaporization but not ionization. A corona discharge electrode is placed between the nebulizer tip 
Figure 1-3:  Proposed mechanisms for electrospray ionization. a. The charge residue model. Solvent evaporation and fission 
leads to progressively smaller droplets, until droplets contain on average a single ion. Ions enter the gas phase as any 
remaining solvent evaporates off. b. The ion evaporation model. As droplets shrink from solvent evaporation and fission, 
electrostatic repulsion grows until ions are ejected from the droplet into the gas phase. 
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and the MS inlet. The mobile phase, which is in excess relative to the analytes, is ionized by the 
corona discharge, and charged analyte ions are produced via proton transfer. APCI ionization 
efficiency is very high and is less subject to matrix effects than ESI. APCI is compatible with 
low-polarity mobile phases so it is better suited for low-polarity analytes. Metabolites which are 
polar or ionized in solution, such as amino acids, are more compatible with ESI. Thermal 
stability of the metabolites must also be considered, as labile metabolites may degrade during the 
thermal vaporization of APCI. Both APCI and ESI have applications in metabolomics, but this 
work will focus exclusively on ESI. 
 Various mass analyzers are used in mass spectrometers. The different qualities of each 
mass analyzer, such as mass resolution and scan rate, lead to advantages in different applications. 
Mass resolution is the ability for a mass spectrometer to distinguish between two similar m/z 
values. This can be calculated from equation 1-1, where R is the resolution, m is the m/z value of 
the peak, and Δm is the peak width: 
  
 
  
  (Equation 1-1) 
Peak width is often calculated as the full width at half maximum (FWHM), but other metrics can 
be used and should be specified. Mass accuracy is how close to the exact mass of an ion the mass 
spectrometer is capable of achieving, typically measured in ppm. 
 One common type of mass analyzer is the quadrupole.
34,35
 A quadrupole consists of four 
parallel rod electrodes. A positive DC current is applied to one set of rods opposite each other, 
while a negative DC current is applied to the other two rods. An AC voltage is superimposed on 
both sets of rods. As ions traverse the quadrupole, the field leads to a spiraling pattern of the ions 
through the length of the quadrupole. Based on the applied voltages, only ions with a specific 
m/z can traverse the entire quadrupole without hitting one of the electrodes. The applied voltages 
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can be set to allow a wide m/z range to pass through, or it can be limited to let only a specific 
m/z pass. 
 Placing three quadrupoles in series produces the triple quadrupole (QQQ) mass 
spectrometer. This arrangement leads to great flexibility in analysis modes. For basic mass 
spectrometry, the first or third quadrupole can scan through a mass range producing a 
comprehensive mass spectrum. The second quadrupole can be used as a collision cell for tandem 
mass spectrometry, introducing additional scan types. A product ion scan selects a specific mass 
in the first quadrupole and scans for the product ions in the third quadrupole. A precursor ion 
scan, alternatively, scans through precursor ions in the first quadrupole, and selects for a specific 
product ion in the third quadrupole. In single or multiple reaction monitoring mode (SRM or 
MRM), specific precursor and product ions are selected. 
 MRMs can be considered the "gold standard" for targeted metabolomics.
6
 They are 
sensitive, as noise in the mass spectrum is greatly reduced. QQQ mass spectrometers are limited 
to unit mass resolution, but MRMs are still selective as unique m/z transitions can be chosen for 
each metabolite. The acquisition rate of a QQQ is relatively slow and depends on the mass range 
or number of MRMs are being cycled through. MRMs can be time segmented, so MRMs are 
only scanned for at during a specified time window, reducing the number of MRMs being 
scanned at a given time point. Fewer MRMs allow for faster scan rates overall. All of the work in 
this thesis utilizes time segmented MRMs, also called "dynamic" MRMs in Agilent 
instrumentation. 
 In contrast to QQQ mass spectrometers, time-of-flight (TOF) mass spectrometers are 
considered to be high resolution mass spectrometers (HRMS).
36
 TOF instruments operate by 
accelerating ions in an electric field, giving ions with the same charge the same kinetic energy. 
11 
 
Ions with a higher mass will have a slower velocity in the following field-free flight tube, so m/z 
is determined by measuring the time it takes ions to reach the detector. 
 To further increase mass resolution, a reflectron can be added, which acts as a mirror for 
ions.
37
 This allows the path length to be increased without significantly increasing the size of the 
instrument. Additionally, a reflectron compensates for kinetic energy distributions. If two ions 
with the same m/z have differences in kinetic energy, they will arrive at the detector at different 
times. An ion with greater kinetic energy will penetrate deeper into the reflectron than an ion 
with lower kinetic energy, increasing path length for the higher energy ion, so the two can reach 
the detector at the same time. 
 TOF mass spectrometers have a very fast acquisition rate. The acquisition rate does not 
depend on the selected mass range, which can be particularly advantageous as TOF instruments 
have a wide mass range. Mass resolution of around 10,000 is typical. The high scan rate makes 
TOF mass spectrometers compatible with fast separations, while the high mass resolution is 
advantageous for untargeted metabolomics. For especially complex samples where even greater 
resolution is needed, an Orbitrap mass spectrometer can be used.
38
 
 In an Orbitrap instrument, ions first enter a curved, rf-only quadrupole called a C-trap. 
Ions are then ejected from the C-trap into the Orbitrap mass analyzer by a DC pulse. The mass 
analyzer contains a central spindle shaped electrode, enclosed by two split outer electrodes. Ions 
oscillate along the length of the spindle while moving around the spindle in a circular orbit. As 
ions oscillate, they induce a current in the outer electrodes. A Fourier transform is performed to 
convert the induced current to a mass spectrum. 
 Orbitrap instruments are expensive, but cheaper and easier to maintain than other Fourier 
transform based mass spectrometers such as the Fourier transform ion cyclotron resonance (FT-
12 
 
ICR) instrument. Orbitrap instruments can provide mass resolution of 100,000 or higher and 
mass accuracy within 2 ppm or less. Orbitraps are a relatively new instrument, being 
commercially introduced in 2005.
39
 Newer hybrid models of the instrument include linear ion 
traps and quadrupoles to allow for MS/MS, increasing the versatility of the instrument.
40
 For 
many applications, the high resolution of an Orbitrap may be unnecessary, making the more 
inexpensive TOF mass spectrometer an appealing choice. However, for extremely complex 
samples, the mass resolution and mass accuracy of an Orbitrap may be necessary. Both 
untargeted and targeted metabolomics provide important information about a biological system, 
but the work in this dissertation will focus specifically on targeted metabolomics using LC with 
QQQ mass spectrometry. 
  
Chemical derivatization in metabolomics 
 Although it is desirable to minimize sample preparation to reduce analysis time, chemical 
derivatization is an example of additional sample preparation which can increase sensitivity for 
polar metabolites. Polar metabolites typically elute at or near the void volume in RPLC, where 
ESI efficiency is low due to the high aqueous content. Metabolites can be labeled with a 
hydrophobic moiety, allowing them to be better retained with RPLC. By eluting later, with 
higher organic content in the mobile phase, and fewer components to cause ion suppression, ESI 
efficiency is increased.
41
 Additionally, hydrophobic analytes are more likely to be found at the 
surface of droplets produced in ESI. These analytes at the surface are more likely to be ionized 
than the polar metabolites located at the center of the droplets.
42,43
 Combined, these effects can 
lead to increases in sensitivity of 10-1,000 fold.
41,43
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 As an additional benefit of derivatization, internal standards can be readily produced for 
all targeted metabolites through use of a stable isotope labeled (SIL) derivatizing reagent. 
Without derivatization, SIL metabolites or analogous exogenous compounds are used for internal 
standards. Analogues do not always behave the same chromatographically or in the presence of 
run to run ionization differences. SIL metabolites behave similarly to the target metabolites, but 
obtaining SIL metabolites for each targeted metabolite can be prohibitively expensive. With 
derivatization, only the derivatization reagent needs to be SIL. A mixture of all targeted 
metabolites can be derivatized with the SIL derivatization reagent to prepare SIL internal 
standards for all targeted metabolites in a single reaction. 
 Because of these advantages, a number of derivatization reagents have been explored for 
metabolomics. Alkylation and silylation are commonly used in GC-MS metabolomics to increase 
volatility of metabolites.
44
 Reductive amination has been used for the analysis of polar 
metabolites including sugars, sugar phosphates, and amino acids.
45,46
 A number of derivatization 
reagents, including O-phthaldialdehyde, have been used to allow for fluorescence or UV 
detection of otherwise undetectable metabolites, and have more recently been explored for LC-
MS metabolomics.
47–49
 One of the most widely used is dansyl chloride (DnsCl).
41,50,51
 DnsCl 
reacts with amine and phenol containing metabolites, increasing hydrophobicity and 
subsequently retention in RPLC (Figure 1-4a). DnsCl also features a dimethylamino group which 
can be readily ionized in ESI, thereby increasing ionization efficiency and resulting sensitivity. 
DnsCl has been used for a wide range of applications,
41,50,52–54
 but the reaction procedure is long. 
Recent advances have decreased the reaction time, but it still requires an hour.
54
 Additionally, 
samples are heated during DnsCl derivatization, which could lead to degradation of the samples 
during the labeling process. 
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  In searching for an alternative to DnsCl, the Kennedy group explored benzoyl chloride 
(BzCl).
55,56
 BzCl has been commonly used for derivatization of amines and hydroxyls for LC 
with UV detection (Figure 1-4b). By optimizing reaction conditions, a method was developed for 
derivatization of amines, phenols, and ribosyl hydroxyls.
57
 The reaction time is virtually 
instantaneous at room temperature, so sample degradation is less of a concern than with DnsCl. 
Individual samples can be processed in less than a minute, causing minimal increases in analysis 
time. The benzoylated metabolites are well retained with RPLC and ionization efficiency is 
increased up to 1,000-fold, greatly increasing sensitivity. The resulting derivatives are stable for 
at least a week at room temperature. 
57
  
 
Neurochemical metabolomics 
 One application where derivatization has been especially advantageous is neurochemical 
metabolomics. Neurochemical analysis can provide important information for understanding 
Figure 1-4:  Reaction schemes for derivatization reagents. a. Dansyl chloride reacts with amines and phenols, requiring an 
hour at 40 °C. b. Benzoyl chloride reacts with amines and phenols requiring less than a minute at room temperature. 
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behavior and disease. Common sample matrices include brain tissue, cerebrospinal fluid (CSF), 
and blood plasma. However, there are many challenges associated with the analysis of 
neurochemicals. Many of the model systems used are small, leading to limited sample size 
availability. Larger samples can be produced by pooling samples from multiple animals, but this 
obscures information about variation between individuals, and it is preferable to limit the number 
of animals used in a study if possible. Limited sample availability is especially important for low 
abundance metabolites. Depending on the matrix, neurochemicals are often at nanomolar or 
lower concentrations. Thus, method sensitivity is especially important for neurochemical 
analysis. 
 Additionally, many neurochemicals are polar and not well retained with RPLC. HILIC 
allows for good retention of polar neurochemicals. However, there are a variety of HILIC 
column chemistries and retention is not as predictable as in RPLC. Thus, HILIC method 
development can be more time consuming than RPLC method development as column 
optimization is required
58
. . Additionally, the sensitivity afforded by HILIC-MS is not always 
sufficient to detect low abundance (i.e. < 5 nM) neurochemicals.
25,26
 Derivatization can be used 
to increase sensitivity as well as compatibility with RPLC. Most common neurotransmitters and 
their metabolites contain amine or phenol groups, making them compatible with BzCl 
derivatization. Previously in the Kennedy lab, a targeted method was developed for the analysis 
of 17 targeted neurochemicals and metabolites in microdialysate samples (Figure 1-5).
57
 
 
Dissertation overview 
 Based upon the success of BzCl derivatization for LC-MS/MS neurochemical analysis, 
the goal of the work in this dissertation is to improve and expand upon this initial work. In  
16 
 
 
 
Chapter 2, additional sample preparation is explored to allow analysis of proteinaceous samples 
with BzCl. Previous work in our lab with BzCl has only been performed in microdialysis 
samples, which are filtered during collection and can be considered relatively clean. High protein 
concentrations, such as those found in tissue or plasma, can be detrimental for both LC 
separations and MS sensitivity. Various methods for protein removal are investigated, and two 
applications are described. The first investigates the role of epinephrine in the counter regulatory 
response to hypoglycemia (Figure 1-6),
59,60
 while the second explores the role of serotonin in the 
protein valuation process. 
 Chapter 3 describes a significant increase in scope of targeted neurochemical analysis 
with BzCl. The previously described method for 17 neurochemicals was expanded upon to 
include 70 neurotransmitters and metabolites. Using the sample preparation detailed in Chapter 
2, this method was applied to a variety of sample matrices, including rat brain dialysate and 
Figure 1-5:  Ion chromatogram of 17 neurotransmitters and metabolites using benzoyl chloride derivatization. Reproduced 
from Song et. al., 2012. 
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Drosophila hemolymph. Chapter 4 combines advancements from Chapters 2 and 3 to explore 
plasma metabolomics in Parkinson's disease. Parkinson's disease is characterized by the loss of 
dopamine neurons in the brain, and differences in cysteine and polyamine metabolism have been 
noted as well.
61–64
 Plasma samples from approximately 100 each of Parkinson's patients and 
healthy controls were compared with a specific focus on dopamine, cyteine, and polyamine 
metabolism. The observed differences may further the understanding of Parkinson's disease 
progression as well as the metabolic effects of Parkinson's treatment. 
 Chapter 5 moves away from neurochemical analysis and uses BzCl derivatization for a 
new application - food metabolomics. In a similar vein to Chapter 3, a method was developed for 
over 50 relevant amines and phenolic acids in wine. This method was able to distinguish 
Figure 1-6:  Schematic of glucose regulation in the liver. Insulin reduces blood glucose by promoting glycogen synthesis. 
Counter regulatory hormones, such as epinephrine, increase blood glucose by promoting glycogenlysis. Reproduced from 
Han et. al., 2016. 
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different wines by their location of origin and varietal using the observed metabolite profiles. 
This work in this chapter demonstrates that BzCl derivatization is extremely versatile and not 
limited to bioanalysis. 
 Chapter 6 describes a new derivatization reagent, benzylamine (BnA). BnA has 
complimentary reactivity to BzCl and can thus be used for applications where BzCl cannot label 
the desired metabolites. In this chapter, a BnA method is developed for the analysis of sugar 
phosphates and citric acid cycle metabolites. Additionally, the combination of BzCl and BnA is 
demonstrated in the context of phenylalanine metabolism. Combining the two techniques has the 
potential to greatly increase metabolome coverage with derivatization without significant 
increases in analysis time. 
 Chapter 7 concludes this dissertation by proposing two approaches to use BzCl 
derivatization outside of targeted metabolomics. Both approaches make use of dual 
derivatization with 
12
C- and 
13
C-BzCl to produce peak pairs from labeled metabolites in the 
resulting mass spectra. Untargeted metabolomics using high resolution mass spectrometry as 
well as "pseudotargeted" metabolomics with QQQ mass spectrometry are described, and 
preliminary work shows the approaches are viable. These methods could even further expand the 
versatility of BzCl derivatization for metabolomics. 
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CHAPTER 2 
Benzoyl chloride derivatization of proteinaceous samples 
 Reproduced in part from Flak, Patterson et al, Nat. Neurosci. 2014, 17, 1744-1750, where Malec 
contributed plasma catecholamine measurements, and Ro et al, eLife, 2016, 5, e16843, where Malec contributed 
serotonin measurements. Copyright 2014 Nature Publishing Group and 2016 Ro et al. 
 
Introduction 
 Reliable, quantitative methods for metabolomics are desirable in neuroscience to relate 
neurochemical changes to behaviors, disease states, or stimuli. Microdialysis allows direct 
sampling from the brain and is compatible with a variety of analytical techniques for 
neurochemical detection.
1–3
 Liquid chromatography - mass spectrometry (LC-MS) is sensitive 
and selective, which is ideal for neurochemical analysis; however, small polar neurochemicals 
are poorly retained in reversed phase chromatography, so benzoyl chloride (BzCl) derivatization 
has been previously described as a way to overcome these limitations while providing additional 
advantages for sensitivity and quantification.
1,3–5
 
 BzCl derivatization has been proven compatible with microdialysis experiments where 
the samples are filtered during collection and relatively free of large matrix interferents such as 
protein. In addition to microdialysis, analysis of biofluids and tissue can also provide important 
neurochemical information. In this work, we sought to extend the BzCl LC-MS/MS method to 
more complex sample such as serum and brain tissue. To prevent ion suppression and instrument 
contamination, these proteinaceous samples require extraction or clean-up steps prior to LC-MS 
analysis.  
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 A variety of techniques have been used for metabolite extraction, including filtration, 
solid phase extraction (SPE), and solvent precipitation.
6–8
 For our work, we were interested in 
developing a fast, inexpensive method which was compatible with small samples (i.e. less than 
20 μL) and BzCl derivatization. Filtration with syringe filters or spin column filters is fast and 
does not dilute the sample, but requires consumables, which can be expensive, and requires large 
volumes (i.e. more than 50 μL). Thus, filtration was determined to not be generally applicable, 
but could be an option when large samples were available. 
 Like filtration, SPE requires expensive consumables and requires relatively large sample 
volumes, but samples can be preconcentrated when larger volumes are available. SPE can be 
rather slow, and due to high cost, we chose to investigate other options. Solvent precipitation is 
fast, inexpensive, and compatible with any sample volume. Solvent precipitation does result in 
sample dilution which can lower sensitivity but we chose to investigate solvent precipitation 
despite this due to its simplicity and low volume compatibility. 
  A variety of organic solvent and solvent mixes have been previously used for protein 
precipitation from biological fluids as well as metabolite extraction from homogenized tissue, 
although there is generally no consensus as to which solvent is optimal.
7,9,10
 In this chapter, we 
evaluate three commonly used extraction solvents on basis of recovery and repeatability. 
Additionally, we explore two biological applications of the final method using solvent 
precipitation followed by BzCl derivatization in biofluids and tissue. These applications focused 
on single metabolites, but related metabolites were monitored in each study. Subsequent chapters 
discuss in greater depth the application of the sample preparation techniques developed here to 
wider ranges of metabolites. 
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 The first application is related to the counter-regulatory response (CRR) to 
hypoglycemia. When blood glucose rises, such as after a meal, insulin is produced, which acts to 
reduce glucose to normal levels. If glucose drops too low, CRR hormones are released to 
suppress insulin release and to promote the breakdown of glycogen into glucose. Epinephrine is 
one of the CRR hormones which is released when blood glucose drops too low. Epinephrine 
promotes gluconeogenesis and ketogenesis, increasing blood glucose.
11
 In diabetes, insulin-
induced hypoglycemia can be quite common from insulin injections. Thus, the CRR is 
particularly important for diabetics to maintain normal blood glucose. Understanding the 
mechanism of the CRR could uncover drug targets which may help prevent insulin-induced 
hypoglycemia. 
 A population of leptin receptor (LepRb) containing neurons was identified in the 
parabrachial nucleus (PBN) which are activated by hypoglycemia. It was hypothesized that these 
neurons may be involved in the CRR. These neurons coexpress cholecystokinin (CCK), while 
hypothalamus LepRb neurons do not, allowing selective knockout of LepRb in the PBN neurons. 
Wild type and LepRb
CCK
 knockout (KO) mice were challenged with 2-deoxyglucose (2DG), 
which mimics hypoglycemia. We monitored plasma concentrations of epinephrine, a CRR 
hormone, following 2DG challenge to determine if CRR differences exist between the WT and 
LepRB
CCK
 KO mice. 
 The second application investigates the link between dietary protein and longevity in 
Drosophila. Calorie restriction has been shown to increase lifespan in many animals, including 
flies
12
, and has been shown to have health benefits in humans as well.
13
 Interestingly, this effect 
is not simply a direct effect of reduced calories in flies. Sensory perception is involved, as flies 
exposed to food odors will not experience the same benefits from a low calorie diet.
14
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Additionally, the effect seems to result from a low protein diet as opposed to a low calorie diet.
15
 
A low protein diet has also been shown to be beneficial to humans.
16
 There is some evidence that 
serotonin is involved in macronutrient selection.
17,18
 Here we investigate the role of serotonin in 
protein preference and aging in Drosophila by measuring serotonin in fly heads. 
 
Experimental 
Chemicals and reagents 
 All chemicals were from Sigma Aldrich (St. Louis, MO) unless otherwise noted. Water, 
acetonitrile, and methanol were Burdick & Jackson HPLC grade from VWR (Radnor, PA). Stock 
solutions of 20 mM GABA, Glu, 5HT, E, and DA were prepared in water and stored at -80 °C. 
13
C5-Glu, d6-GABA, d4-5HT, d6-E, and 
13
C6-DA were purchased from C/D/N Isoptopes 
(Pointe-Claire, Canada) and were used to prepare stock solutions at 20 mM in water. Calibration 
standards and internal standards were prepared as previously described
1
 and stored in single use 
aliquots at -80 °C. On each day, an internal standard aliquot was thawed, diluted 100 fold in 20% 
(v/v) acetonitrile with 1% (v/v) sulfuric acid. This is referred to as the "internal standard 
solution." A fresh BzCl solution was prepared daily. Pooled human serum from the American 
Red Cross Detroit National Testing Lab was provided by the Michigan Regional Comprehensive 
Metabolomics Resource Core (MRC
2
). 
 
Metabolite analysis by LC-MS/MS 
 Separation of benzoylated metabolites was performed using a Waters nanoAcquity 
UPLC. The column was an Acquity HSS T3 C18 (1 mm x 100 mm, 1.8 μm, 100 Å pore size). 
The column was kept at 27 °C and the autosampler was at ambient temperature. Mobile phase A 
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was 10 mM ammonium formate with 0.15% (v/v) formic acid, and mobile phase B was 
acetonitrile. The flow rate was 100 μL/min, and unless specified otherwise, the gradient was:  
initial, 0% B; 0.01 min, 17% B; 0.5 min, 17% B; 3 min, 25% B; 3.3 min, 56% B; 4.99 min, 70% 
B; 5 min, 100% B; 6 min, 100% B; 6.1 min, 0% B; 8 min, 0% B. Partial loop injection mode was 
used for 5 μL injections. 
 Detection was performed using an Agilent G6410B triple quadrupole mass spectrometer 
operating in dynamic multiple reaction monitoring (dMRM) mode. Positive electrospray 
ionization mode was used at 4 kV.  The gas temperature was 350 °C, gas flow was 11 L/min, and 
the nebulizer was at 15 psi. MRM conditions are listed in Table 2-1. Peak integration was 
performed using Agilent MassHunter Quantitative Analysis for QQQ, version B.05.00. All peaks 
were visually inspected to ensure proper integration. 
Analyte 
Precursor 
(m/z) 
Product 
(m/z) 
Fragmentor 
(V) 
Collision Energy 
(V) 
Bz-GABA 208 105 120 10 
Bz-d6-GABA 214 105 120 10 
13
C6-Bz-GABA 214 111 120 10 
Bz-Glu 252 105 120 20 
Bz-
13
C5-Glu 257 105 120 20 
13
C6-Bz-Glu 258 111 120 20 
Bz-5HT 385 264 140 20 
Bz-d4-5HT 389 268 140 20 
13
C6-Bz-5HT 391 270 140 20 
Bz-E 496 105 120 15 
Bz-d6-E 502 105 120 15 
13
C6-Bz -E 514 111 120 15 
13
C6-Bz-d6-E 520 111 120 15 
Bz-DA 466 105 140 20 
Bz-
13
C6-DA 472 105 140 20 
13
C6-Bz-DA 484 111 140 20 
Table 2-1:  MRM conditions for benzoylated metabolites. Cell accelerator voltage was 4 V for all analytes. 
 
Serum extraction with organic solvents 
 Acetonitrile, methanol, and a 1:1:1 mixture of methanol, acetonitrile, and acetone (MAA) 
were selected as common extraction solvents for comparison. Each solvent was kept at -20 °C. A 
mixture of 25 μM 13C5-Glu and 2.5 μM d6-GABA, d4-5HT, and 
13
C6-DA was prepared in water, 
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and 1 μL was spiked into nine aliquots of 50 μL of pooled human serum. The spiked serum was 
vortexed and three aliquots each were diluted with 200 μL cold acetonitrile, methanol, or MAA. 
These were vortexed briefly then centrifuged for 10 min at 12,100g, after which 20 μL of 
supernatant were derivatized by sequential addition of 10 μL 100 mM sodium carbonate, 10 μL 
2% (v/v) BzCl in acetonitrile, and 10 μL internal standard solution. An additional 50 μL of water 
were added to reduce the organic content of the samples. Each sample was analyzed in triplicate 
by UPLC-MS/MS. Calibration standards were prepared in water, diluted with four volumes of 
each of the solvents, and derivatized in the same manner as the serum supernatant. 
 
Comparison of extraction solvents 
 Extraction recovery was determined by comparing the calculated concentration of the 
spiked samples to the expected concentration. The relative standard deviation of the recovery 
was used to compare extraction repeatability. Matrix factor, a measure of ion suppression or 
enhancement from matrix components, is the ratio of analyte signal in matrix to the same 
concentration in matrix free standards. Matrix factors were calculated using the internal standard 
signal, as this is constant in all samples. 
 
Mouse plasma collection 
 All of the procedures listed in this chapter were approved by the University of Michigan 
(UM) Committee on the Use and Care of Animals. C57BL/6 males were from Jackson 
Laboratories. LepRb
Cck
 KO study animals (along with Cck
cre
, Lepr
flox/flox
 and wild-type controls) 
were generated in our colony by crossing Cck
cre
; Lepr
flox/+
 and Lepr
flox/+
 animals; these animals 
were on the segregating C57BL/6; 129Sv background. Mice were kept in a temperature-
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controlled room on a 12-h light, 12-h dark cycle and provided with ad libitum food and water 
unless otherwise noted. Samples for the determination of epinephrine concentrations were 
obtained from animals with an arterial catheter (placed by the U M Animal Phenotyping Core 
(APC)). Data reported are from single-housed male animals studied during the light cycle. 
Investigators were blinded to genotype and treatment. 
 
Mouse plasma analysis 
 Individual plasma samples were thawed, and 5 μL were spiked with 1.25 μL of d6-
epinephrine (final concentration 50 nM) as an internal standard. Proteins were removed by the 
addition of 25 μL of ice-cold acetonitrile, followed by centrifugation for 10 min at 12,100g. The 
supernatant was removed and 20 μL were derivatized by sequential addition of 10 μL of 100 mM 
sodium tetraborate, 10 μL of 2% (v/v) BzCl in acetonitrile and 10 μL of 1% (v/v) sulfuric acid in 
dimethylsulfoxide. 
 Standard solutions of epinephrine were prepared in aCSF to create a calibration range of 
0.1–20 nM. Standards were spiked with the internal standard, diluted with acetonitrile and 
derivatized as described above. Calibration curves were prepared based on the peak area ratio of 
the standard to the internal standard by linear regression. All samples and standards were 
analyzed by UPLC-MS/MS in triplicate. The gradient used was as follows: initial, 0% B; 0.01 
min, 23% B; 2.51 min, 23% B, 3 min, 50% B; 5.3 min, 60% B; 6.46 min, 65% B; 6.47 min, 
100% B; 7.49 min, 100% B; 7.5 min, 0% B; 8.5 min, 0% B. Example chromatograms are shown 
in Figure 2-1. 
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Fly stocks 
 The following stocks were obtained 
from Bloomington Stock center; Canton S. 
(RRID:FlyBase_FBst1000081), w1118, 
Trh
c1440 
(RRID:BDSC_10531),
19
 
5HT2a
PL00052
 (RRID:BDSC_19367),
20
 JhI-
21
GE15185
 (RRID:BDSC_26889). 
21
 UAS-
dTrpA1,
22
 UAS-shi
ts1
 
(RRID:BDSC_44222),
23
 Trh-GAL4
24
 were gifts from P. Garrity (Brandeis University, Waltham, 
MA), T. Kitamoto (U of Iowa, Iowa city, IA), and B.G. Condron (U of Virginia, Charlottville, 
VA), respectively. Trh
c1440
, 5HT2a
PL00052
, and JhI-21
GE15185
 mutants were backcrossed at least 8 
generations to w1118 prior to any followed up experiments after the candidate screens. 
 
Fly husbandry 
 All fly stocks were maintained on a standard cornmeal-based larval growth medium and 
in a controlled environment (25 °C, 60% humidity) with a 12 Light: 12 dark cycles. If flies 
contained temperature-sensitive transgenes, they were reared in 23 °C and maintained at this 
temperature as adults until the experiments. Developmental larval density was controlled by 
manually aliquoting 32 μL of collected eggs into individual bottles containing 25 ml of food.25 
Following eclosion, mixed sex flies were kept on SY10% medium for 4–10 days until they were 
used for experiments. Unless otherwise noted, mated female flies that were between 5–14 days 
old were used for the choice experiments. When starvation was required for the feeding assay, 
1% agar medium was used to deprive food but prevent dehydration. 
Figure 2-1:  Extracted ion chromatograms from a. 
calibration standards and b. mouse plasma. 
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Fly tissue analysis 
 Female flies were snap frozen in liquid nitrogen and vigorously vortexed to remove 
heads. The heads were homogenized with three volumes of ice cold acetonitrile (a single head 
was assumed to be 1 μL) using a pestle grinder. The homogenates were centrifuged at 18,000g 
for 5 min and the supernatant was collected as a tissue extract. To derivatize the samples prior to 
the UPLC-MS/MS analysis, 12 μL of each sample were benzoylated by the sequential addition 
of 6 μL of 100 mM sodium carbonate, 6 μL of 2% (v/v) BzCl in acetonitrile, and 6 μL of the 
internal standard solution. 
 Standards were prepared in aCSF and diluted with three volumes of acetonitrile. The 
diluted standards were derivatized in the same manner as the tissue extract samples. Samples and 
standards were analyzed by UPLC-MS/MS. The gradient used was: initial, 0% B; 0.01 min, 17% 
B; 0.5 min, 17% B; 3 min, 25% B; 3.3 min, 56% B; 4.99 min, 70% B; 5 min, 100% B; 6.5 min; 
100% B; 6.51 min, 0% B; 8.5 min, 0% B. Example chromatograms are shown in Figure 2-2. 
 
Results and siscussion 
Comparison of extraction solvents 
 Recovery, repeatability, and matrix 
factors for the stable isotope labeled 
metabolites spiked into serum are compared in 
Figure 2-3. Recovery across the solvents and 
metabolites ranged from 25% to 85%. 
Recovery was lowest for glutamate and 
GABA with acetonitrile extraction, while Figure 2-2:  Extracted ion chromatograms from a. 
calibration standards and b. fly tissue homogenate. 
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MAA had the highest average recovery. RSDs were below 10%, with the exception of dopamine 
following extraction with MeOH. MeOH had the highest RSDs, while acetonitrile and MAA 
were comparable. Matrix factors were highest for all metabolites with acetonitrile extraction, 
while methanol and MAA were similar. Although recovery was low for some metabolites, 
acetonitrile was selected as the optimal extraction solvent for its high repeatability and low 
matrix effects.  
 Importantly, the recovery and matrix effects varied between metabolites. For the 
neurochemicals tested, acetonitrile performed the best on average; but, it is possible that a 
different solvent would be more suitable when other metabolites are targeted. Thus, extraction 
solvent optimization is something that should be considered when designing a sample 
preparation method for targeted metabolomics. Additionally, the metabolite to metabolite 
variability in matrix effects further demonstrates the need for internal standards for each targeted 
metabolite. While it is common in metabolomics to use a single internal standard for all targeted 
metabolomics, this approach can lead to inaccurate quantification. For example, based on the 
data shown, using only 
13
C6-Bz-GABA as an internal standard would underestimate the 
concentration of glutamate and dopamine by 54% and 12% respectively, while overestimating 
the concentration of serotonin by 16%. The simple creation of internal standards for all 
Figure 2-3:  Comparison of extraction solvents. Recovery was determined by spiking pooled human serum with 
stable isotope labeled metabolites. Repeatability was calculated as the relative standard deviation of three spiked 
serum samples. Matrix factor was calculated by comparing the internal standard signal in serum samples to the 
internal standard signal in matrix-free standard solutions. 
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metabolites with 
13
C6-BzCl is thus a substantial advantage of derivatization for accurate 
quantification. 
 
Comparison to existing methods 
 A number of methods exist for LC-MS/MS analysis of neurochemicals in proteinaceous 
biological samples.
26–30
 Solvent precipitation is widely used for removal of proteins from 
biological fluids, though solvent compositions varied. Supernatants are often dried down and 
reconstituted prior to analysis. In this work, samples were not dried down prior to derivatization 
with BzCl as the extract was compatible with the derivatization procedure. This step could be 
added if preconcentration is desired, though it adds additional preparation time and could lead to 
degradation of thermally unstable metabolites. For metabolite extraction from tissue, organic 
solvents or perchloric acid are commonly added during homogenization.
10,31
 BzCl requires basic 
samples, so we chose to use ACN for extraction when moving from biological fluids to tissue. 
 Because many neurochemicals are polar, HILIC is commonly used. While HILIC allows 
for good retention, chemical derivatization generally allows for greater sensitivity. A recently 
published method allows for analysis of 20 neurochemicals and metabolites with HILIC-
MS/MS.
26
 This method features lower limits of detection (LOD) than previously published 
HILIC methods. A comparison between this method and the BzCl method described here is 
summarized in Table 2-2. 
Metabolite 
LOD (nM) Repeatability (%) Injection Volume (μL) Gradient Time (min) 
HILIC BzCl HILIC BzCl HILIC BzCl HILIC BzCl 
Glu 17 30 18 5.9 
5 5 20 8 
GABA 190 4 4.2 2.6 
5HT 0.6 3 1.6 3.3 
DA 36 2 2.7 7.5 
Table 2-2:  Comparison of LC-MS/MS methods for neurochemicals with HILIC or BzCl derivatization with RPLC. 
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 While LODs for this HILIC method are better than previous HILIC methods, LODs are 
similar or better with BzCl. The HILIC LODs for glutamate and serotonin were approximately 2- 
and 6-fold better respectively, while BzCl LODs for dopamine and GABA were roughly 20- and 
50-fold better. Repeatability between methods were similar. Analysis time with the BzCl method 
is less than half that of the HILIC method. Stable isotope labeled internal standards were used for 
nearly all analytes in the HILIC method, but BzCl derivatization allows for production of stable 
isotope labeled internal standards for all analytes. All BzCl work throughout this dissertation 
employs internal standards for each analyte.  
 
Determination of epinephrine in mouse plasma 
 For this work, we monitored plasma epinephrine from wild type and knockout mice 
following 2DG challenge. Measuring epinephrine in plasma is challenging, as it is a stress 
hormone in addition to a counter-regulatory hormone. Common blood sampling techniques for 
mice such as decapitation or tail vein incision are stressful to the mice, leading to increased 
epinephrine which may obscure trends.
32
 A lower stress technique, arterial catheterization, was 
chosen, but this leads to its own challenges. Since multiple time points were being taken from 
living mice, a limited volume of blood could be taken for each sample. An advantage of solvent 
precipitation is that it does not have a minimum volume requirement. In comparison, filtration 
requires enough sample volume to pass through the filter.   
 Plasma was sampled from mice via arterial catheterization every 30 min for 120 min 
following 2DG challenge. The resulting plasma was derivatized with BzCl and epinephrine 
concentrations were determine. All mice, regardless of genotype, showed an increase in 
epinephrine after 2DG challenge (Figure 2-4). Basal epinephrine levels were similar for all mice 
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and were around 1-2 nM,which is consistent 
with previous findings from catheterized 
mice.
32
 It was found that plasma epinephrine 
was significantly higher in the LepRb
CCK
 
knockout mice compared to wild type mice 
following 2DG challenge (Figure 2-5a). 
 Glucagon and corticosterone, other 
CRR hormones, were also increased in 
LepRb
CCK
 KO mice relative to wild type 
(Figure 2-5b-c). These results suggest a more robust CRR in the LepRB
CCK
 KO mice and indeed, 
increased blood glucose was observed in the KO mice relative to the wild type (Figure 2-5d). 
Additional work revealed that selective inhibition of these neurons blunted the CRR, while 
selective activation enhanced the CRR. Together, this work shows that these LepRb
CCK
 neurons 
are involved in the CRR and are inhibited by leptin. The results lead to a greater understanding 
of the role of the central nervous system in the CRR, which may be beneficial in the treatment of 
diseases such as diabetes where inadequate responses to hypoglycemia can be lethal. 
 
Role of serotonin in Drosophila protein preference and aging 
 In wild type flies, no preference was observed between a sugar-only food source and a 
protein-containing food source. However, when starved for 24 h prior to the food choice 
experiment, a preference for the protein-containing food was observed (Figure 2-6). In mutants 
where tryptophan hydroxylase (Trh), the rate limiting enzyme in serotonin production, was 
reduced, this protein preference following starvation was abolished (Figure 2-7). 
Figure 2-4:  Plasma epinephrine over time following 2DG 
challenge (t = 0). Each line corresponds to an individual 
mouse. Data shown is average ± standard deviation of 
triplicate analysis at each time point. For all mice tested, 
epinephrine increases in response to hypoglycemia. 
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This loss of preference suggests a role for serotonin in protein preference following starvation. 
 To determine if serotonin is involved in protein choice or post-ingestive reward, 
serotonin levels were measured in fly heads at varying points of the experiment. Serotonin does 
not change between fully fed flies and starved flies, but increases upon refeeding with protein 
containing food sources (Figure 2-8). Since serotonin does not increase prior to protein 
consumption, it is assumed that serotonin is involved in protein reward following starvation. 
  Protein consumption has been shown to impact longevity so lifespan of wild type control 
and mutant flies were compared. On a diet containing a fixed ratio of macronutrients, Trh 
Figure 2-5:  Counterregulatory response in LepRbCCK KO mice 90 min following 2DG challenge. a. Epinephrine (n = 11 
(control) and 8 (KO)); b. glucagon (n = 11 per condition); c. corticosterone (n = 11 per condition) were all increased in 
LepRbCCK KO mice relative to controls. d. A greater increase in blood glucose was observed in LepRbCCK KO mice (n = 13) 
relative to controls (n = 11). 
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mutant flies showed increased lifespan compared to control flies. The serotonin receptor 5HT2a 
was shown to be involved in protein reward, but mutants which do not express this receptor did 
not show increased lifespan relative to controls. However, when presented with a complex 
dietary environment where flies could choose between carbohydrate or protein containing foods, 
both the Trh and 5HT2a mutants had longer lifespans than the control flies, and this increase was 
larger relative to that in a fixed diet (Figure 2-
9). There was no difference in macronutrient 
consumption between control and mutant 
flies, so this evidence suggests the process of 
protein valuation impacts longevity 
independent of actual dietary consumption. 
 To further understand the mechanism, 
mutations upstream of serotonin signaling 
Figure 2-6:  Preference index (PI) of WT flies presented the choice between sugar-containing or protein-containing food. A 
PI of 1 represents a complete preference for protein, while -1 represents a complete preference for sugar. White and gray 
periods indicate light and dark periods respectively. a. A preference for protein is observed when starved 24 h prior to the 
choice experiment. b. This preference is abolished when flies are fully fed prior to the experiment. 
Figure 2-7:  Preference index (PI) of control and tryptophan 
hydroxylase knockdown (Trhc1440) flies following 24 h of 
starvation. A PI of 1 corresponds to a complete preference 
for the protein containing food, autolyzed yeast. The Trhc1440 
flies showed no preference for protein. 
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were tested and it was found that mutations in the amino 
acid transporter gene juvenile hormone inducible 21 (JhI-
21) also abolished protein preference following 
starvation (Figure 2-10a). An increase in serotonin was 
not observed in these flies upon protein refeeding, 
confirming that JhI-21 acts upstream of serotonin 
production (Figure 2-10b). Similarly to Trh and 5HT2a 
mutants, JhI-21 mutants showed an increase in lifespan in 
a choice food environment relative to controls (Figure 2-
10c). We can conclude from this data that JhI-21 acts 
together with serotonin signaling in this protein valuation and reward process. JhI-21 is 
homologous to the SLC7 family of amino acid transporters in vertebrates, so it is possible this 
family may be implicated in other species. 
 Many factors make dietary research difficult. Mammalian models require relatively large 
housing and resources, and long lifespans make research slow. Drosophila and other insect 
models are attractive due to their small size and short lifespans, while maintaining many 
analogous systems to humans. Drosophila are genetically tractable so multiple genetic 
manipulations were used in this work to elucidate roles of specific enzymes and metabolites. 
Additionally, a number of fixed and choice dietary environments were used to determine if 
observed results are a product of protein consumption or the dietary choice process itself. The 
results here identify a role for serotonin signaling and protein valuation in the modulation of 
lifespan. The combination of BzCl derivatization with the Drosophila model is demonstrated as a 
powerful tool for dietary and metabolomic research. 
Figure 2-8:  Serotonin concentrations in 
control fly heads at experimental timepoints. 
Serotonin does not increase during starvation, 
showing it is not involved in the protein 
choice stage. Serotonin does increase upon 
refeeding with protein containing foods, yeast 
or BSA, suggesting serotonin is involved in 
post-ingestive reward. 
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Conclusions 
 BzCl derivatization is a simple, rapid reaction which allows for greater retention and 
ionization efficiency of amines and phenols in RPLC-MS. While this method has been 
established in the filtered samples which result from microdialysis, additional sample preparation 
is required for proteinaceous samples such as plasma or tissue. Solvent precipitation was chosen 
as a method for protein removal, as it is fast, inexpensive, and compatible with large or small 
samples. In this chapter, multiple solvents were compared to determine the best choice for 
protein precipitation prior to BzCl derivatization. Acetonitrile was chosen as the optimal solvent 
for its high repeatability and limited matrix effects. Developing sample preparation for 
proteinaceous samples greatly expands the versatility of BzCl derivatization, which was 
demonstrated through applications using plasma and tissue as sample matrices. 
Figure 2-9:  Lifespan of control flies and mutants for serotonin production and signaling. a. In a fixed diet environment, only 
the Trhc1440 flies showed an increased lifespan relative to controls. b. When allowed to choose between carbohydrate and 
protein containing foods, both Trhc1440 and 5HT2aPL00052 flies had longer lifespans than control flies, though no difference in 
macronutrient consumption was observed. These data suggest the protein valuation process has an impact on longevity 
independent of dietary consumption. 
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 Two applications were explored using this optimized sample preparation. Epinephrine 
was measured in plasma from mice to confirm the role of PBN LepRb neurons in the CRR. 
These neurons were found to be inhibited by leptin and knocking out LepRb in these neurons 
produced an enhanced CRR relative to wild type mice. Epinephrine was increased, as well as 
other CRR hormones following 2DG challenge. This increase suggests that these neurons act to 
ensure an adequate blood glucose level through a robust CRR even during hypoglycemia, when 
normal endocrine signaling is reduced. The CRR is especially important in diabetic patients who 
are prone to insulin-induced hypoglycemia. Finding potential drug targets, such as these neurons, 
may help prevent insulin-induced hypoglycemia in diabetic patients. 
 We also investigated the role of serotonin in protein preference and aging in Drosophila. 
Flies were found to have a preference for protein-containing food following modest starvation. 
This preference was lost in Trh mutants, which are defective in serotonin production. The role of 
serotonin in this preference was further established as serotonin was found to increase in the 
heads of flies following refeeding on protein-containing food. The protein valuation process was 
found to be implicated in longevity, as Trh and 5HT2a mutants had longer lifespans than control 
flies independent of diet.  
Figure 2-10:  Behavior of amino acid transport mutants JhI-21GE15185 compared to control flies. a. Like Trh mutants, no 
protein preference was observed in JhI-21GE15185 flies following starvation. b. Unlike control flies, no increase in serotonin 
was observed following protein refeeding. This suggests that JhI-21 is involved upstream of serotonin production in the 
protein valuation process. c. In a choice food environment, JhI-21 mutants show an increased lifespan relative to control flies. 
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 Additionally, an amino acid transporter, JhI-21, was identified which acts upstream of 
serotonin signaling in this process. JhI-21 mutant flies, like the serotonin mutants, were found to 
have no protein preference following starvation and did not produce an increase in serotonin 
upon protein refeeding. These flies also exhibited longer lifespans than control flies. These 
results demonstrate that the lifespan increasing properties observed from a low protein diet in 
flies are not exclusively a product of reduced protein consumption, and start to elucidate the 
mechanism for this. While this study was performed in flies, similar effects from calorie or 
protein restriction have been observed in other species, so the results could provide insight for 
other species as well. 
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CHAPTER 3 
Benzoyl chloride derivatization with liquid chromatography - mass spectrometry for 
targeted metabolomics of neurochemicals in biological samples 
 Reproduced in part from (Wong, Malec et al. 2016). Copyright 2016 Elsevier. Equal authorship was 
awarded to Wong and Malec. Malec contributed selection of compounds assayed, extraction optimization and 
applications in human serum and Drosophila tissue.  
 
Introduction 
 Metabolomics is a valuable approach for studying physiological mechanisms and 
identifying biomarkers. Both untargeted and targeted assays, also called metabolite profiling, are 
used in such studies. Targeted assays measuring a limited number of metabolites allow focus on 
important known compounds or pathways and offer better quantification, but they provide lower 
metabolome coverage compared to untargeted methods. Targeted assays that measure relatively 
large numbers of compounds (i.e., over 50) help mitigate the disadvantage of limited 
metabolome coverage. Gas chromatography-mass spectrometry (MS) and high performance 
liquid chromatography (HPLC)-MS are well-suited platforms for developing such widely 
targeted assays. Several methods for measuring over 100 known metabolites in a single assay 
using these techniques have been reported.
1–6
 These widely targeted assays are powerful, but 
they rarely use more than a few internal standards, and for HPLC often make use of ion-pairing 
reagents
3,6
 or multiple LC pumps
4,5
 to account for the wide polarity range of the metabolites. 
Here we report a targeted method for 70 neurochemicals that uses HPLC-MS/MS with benzoyl 
chloride (BzCl) as a derivatizing agent and avoids these limitations. 
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 HPLC-tandem mass spectrometry (MS/MS) using a triple quadrupole mass spectrometer 
is well established as a sensitive, quantitative, and selective technique for metabolite profiling.
7,8
 
Although compounds can be detected by MS/MS without labeling, the use of BzCl provides 
numerous advantages with only minor drawbacks. In particular, addition of a phenyl group to the 
polar analytes increases retention on reversed phase columns, which aids resolution and 
decreases ion suppression. Many compounds are detected with greater sensitivity after labeling, 
e.g. 1,000-fold increases in sensitivity have been reported for BzCl labeling.
9
 The labeling step 
allows rapid creation of stable-isotope labeled internal standards by using 
13
C-BzCl for labeling 
standards, thereby improving quantification for every analyte. BzCl is widely applicable because 
it derivatizes primary and secondary amines, phenols, thiols, and some alcohols (e.g., ribose 
hydroxyls and glucose). Indeed, it has previously been used with MS or ultraviolet absorption 
detection for monitoring neurochemicals in dialysate,
9,10
 plasma,
10
 and human cerebrospinal fluid 
(CSF).
11
 It has also been used for other amine
12,13
 and alcohol
14,15
 containing compounds. These 
previous assays targeted a relatively narrow group of compounds.  
 Although we focus on BzCl, other reagents such as dansyl chloride may provide similar 
utility for metabolomics.
16–19
 We favor BzCl because it reacts faster (seconds at room 
temperature compared to 20 min at elevated temperature), has a wider pH range for reaction, is 
less prone to photodegradation, and is commercially available in 
13
C-labeled form. Additionally 
benzoylated products are stable for a week at room temperature,
9
 and standards and internal 
standards are stable for six months at -80 °C (data not shown). 
 The 70 compound assay described here targets neurochemicals. Neurons specialize in 
storing and transmitting information using neurotransmitters and neuromodulators. Low 
molecular weight polar compounds represent an important class of neurotransmitters including 
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acetylcholine, adenosine, catecholamines, indoleamines, amino acids, trace amines, and 
dipeptides. A variety of other compounds, such as energy metabolites, antioxidants, and 
polyamines that affect neuronal function or have been linked to neurological disease are also 
included in the assay. This assay focuses on these compounds and their precursors and 
degradation products, as their measurement can provide insights into neuronal function to better 
understand the neurochemical changes in brain diseases. Although this is not a comprehensive 
assay for all neurochemicals, it demonstrates the wide applicability of BzCl derivatization. The 
method is an improvement over previous neurochemical assays which were limited to even 
smaller subsets of neurochemicals,
10,20–26
 including our previously described 17 compound 
method based on similar technology.
9
 
 This report demonstrates the utility of BzCl with HPLC-MS for targeted metabolomics 
on several sample types including tissue, serum, CSF, and microdialysate. Tissue samples are 
used to characterize concentrations at fixed time points and are best used for determining the 
overall production and metabolism of neurochemicals. We demonstrate the assay for Drosophila 
melanogaster tissue and hemolymph, an important neurochemical model system. Serum and 
CSF assays are useful for biomarker studies and assessment of overall physiological state. 
Microdialysis samples the brain extracellular space and enables the measurement of released 
neurochemicals over time, making it valuable for correlating neurochemical dynamics to 
behavior, monitoring drug effects, and assessing the effect of disease states on neurochemical 
concentrations. However, the low samples volumes of microdialysate in our studies (typically 1 
µL) make analysis challenging. 
 Although BzCl labeling with HPLC-MS/MS has been used for neurochemicals before, 
the current work increases the number of analyzed compounds by 4-fold, streamlines reagent 
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addition, and improves labeling conditions to give better sensitivity and reproducibility for some 
compounds. Finally, the assay is shown to be useful for a wider range of sample types.  
 
Experimental 
Chemicals and reagents 
 All chemicals were purchased from Sigma Aldrich (St. Louis, MO) unless otherwise 
noted. Water, methanol, and acetonitrile for mobile phases are Burdick & Jackson HPLC grade 
purchased from VWR (Radnor, PA). Stock solutions of 500 mM Glc; 10 mM DOMA, DOPAC 
(Acros Organics, Geel, Belgium), MOPEG, GABA, 5HIAA, 5HTP, Agm, Ala, Ans, Arg, Asn, 
Asp, βAla, Carn, Cit, CA, Cys, DA, E, ETA, Glu, Gln, GSH, Gly, Hist, His, HCA, HCY, HSer, 
HVA (Tocris, Bristol, UK), HTau, Kyo (MP Biomedicals, Santa Ana, CA), Leu, Lys, Met, NAP, 
NAS, NE, NM, OA, Orn (Acros Organics, Geel, Belgium), PhEt (MP Biomedicals, Santa Ana, 
CA), Pro, Put, Ser, 5HT, Spd, Spm, Syn, Tau, Thr, Val, and VMA; 5 mM ACh, 5HTOL 
(Cayman Chemical, Ann Arbor, MI), Ado, Kyn, LDOPA, Phe, and Trp; 2.5 mM 3HK; 2 mM 
Tyr; 1 mM DOPEG, 3HAA, 3MT, KA, and TyrA; 0.25 mM TrpA; and 20 mM isotopically 
labeled d4-ACh and d4-Ch (C/D/N isotopes, Pointe-Claire, Canada); were made in HPLC water 
and kept at -80 °C. A standard mixture was diluted from stocks with artificial cerebrospinal fluid 
(aCSF) consisting of 145 mM NaCl, 2.68 mM KCl, 1.4 mM CaCl2, 1.0 mM MgSO4, 1.55 mM 
Na2HPO4, and 0.45 mM NaH2PO4 adjusted pH to 7.4 with NaOH. Calibration curves were made 
using standards at 0.1, 0.5, 1, 5, 10, 25, 50 μM for Glc; 10, 50, 100, 500, 1000, 250, 5000 nM for 
3HK, Asn, Asp, CA, GSH, Gly, HTau, Ser, and Tau; 1, 5, 10, 50, 100, 250, 500 nM for Ch, 
3HAA, MOPEG, 5HIAA, 5HTP, 5HTOL, Ado, Agm, Ala, Ans, βAla, Carn, Cit, Cys, ETA, Glu, 
Gln, His, HCA, HCY, HSer, HVA, KA, Kyn, Met, NAP, Orn, Phe, Pro, Thr, Trp, Val, and 
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VMA; 0.1, 0.5, 1, 5, 10, 25, 50 nM for ACh, DOMA, DOPAC, DOPEG, 3MT, GABA, Arg, DA, 
E, Hist, Kyo, LDOPA, Leu, Lys, NAS, NE, NM, OA, PhEt, Put, 5HT, Spd, Spm, Syn, TrpA, 
TyrA, and Tyr. An internal standard stock was prepared with 5 mM Glc; 500 μM 3HK, Asn, 
Asp, CA, GSH, Gly, HTau, Ser, and Tau; 50 μM 3HAA, MOPEG, 5HIAA, 5HTP, 5HTOL, 
Ado, Agm, Ala, Ans, βAla, Carn, Cit, Cys, ETA, Glu, Gln, His, HCA, HCY, HSer, HVA, KA, 
Kyn, Met, NAP, Orn, Phe, Pro, Thr, Trp, Val, and VMA; 5 μM DOMA, DOPAC, DOPEG, 
3MT, GABA, Arg, DA, E, Hist, Kyo, LDOPA, Leu, Lys, NAS, NE, NM, OA, PhEt, Put, 5HT, 
Spd, Spm, Syn, TrpA, TyrA, and Tyr; and derivatized with 
13
C6-BzCl using a similar procedure 
as 
12
C reagents. 
 Calibration standard and internal standard stocks were frozen at -80 °C in aliquots to 
prevent multiple freeze/thaw cycles. A single internal standard stock aliquot was thawed the day 
of use, diluted 100-fold in 20% (v/v) acetonitrile containing 1% (v/v) sulfuric acid, and spiked 
with deuterated acetylcholine and choline (C/D/N isotopes, Pointe-Claire, Canada) to a final 
concentration of 20 nM. A fresh benzoyl chloride solution was made daily. 
 
Microdialysis in anesthetized rat 
 Adult male Sprague-Dawley rats (Harlan, Indianapolis, IN) weighing 250-275 g were 
used for microdialysis collection. Rats were housed with access to food and water ad libitum in a 
temperature and humidity controlled room with 12 h light/dark cycles. All animals were treated 
as approved by the University Committee on Use and Care of Animals at the University of 
Michigan, the National Institute of Health Guidelines for the Care and Use of Laboratory 
Animals. All precautions were taken to prevent animal discomfort through the course of the 
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experiments. In addition, all animal experiments were conducted within the guidelines of Animal 
Research Reporting in vivo Experiments. 
 A custom-made concentric microdialysis probe (4 mm dialyzing membrane), made using 
regenerated cellulose (Spectrum Laboratories, Inc., Rancho Dominguez, CA, USA), was 
implanted into the striatum. Rats were anesthetized with 1-4% isoflurane and placed into a 
stereotaxic frame (David Kopf, Tujunga, CA). A burr hole was placed above the striatum using 
the anterior-posterior +1.0 mm and lateral ±3.0 mm coordinates from bregma. The microdialysis 
probe was flushed with artificial CSF (aCSF) at a flow rate of 2 μL/min using a Fusion 400 
syringe pump (Chemyx, Stafford, TX) as it was lowered -6.15 mm from top of skull. Once the 
probe was positioned, the probe was flushed at 2 μL/min for 30 min followed by 30 min at 1.0 
μL/min prior to collection. 10 μL dialysate was derivatized using the modified method reported: 
5 μL of 100 mM sodium carbonate, 5 μL BzCl (2% (v/v) in acetonitrile), and 5 μL internal 
standard mixture were added sequentially, with vortex mixing after each addition. At the 
completion of the experiment, animals were euthanized, brains were extracted and stored at 4 °C 
in 4% paraformaldehyde. Probe placement was confirmed with histology.  
 
Human CSF 
 Pooled human CSF from healthy patients was obtained from the Batemen lab at 
Washington University School of Medicine, St. Louis, MO.
27
 Samples were diluted 100-fold in 
water, and a 10 μL aliquot was derivatized using 5 μL of 100 mM sodium carbonate, 5 μL BzCl 
(2% (v/v) in acetonitrile), and 5 μL internal standard mixture before LC-MS analysis.  
 
Human serum 
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 Pooled human serum from the American Red Cross Detroit National Testing Lab was 
provided by the Michigan Regional Comprehensive Metabolomics Resource Core. To remove 
proteins, 20 µL of serum were diluted with 80 µL of ice-cold acetonitrile. The samples were 
vortexed briefly, then centrifuged for 10 min at 12,100 × g. 20 μL of the supernatant was 
derivatized by sequential addition of 10 μL of 100 mM sodium carbonate, 10 μL of BzCl (2% 
(v/v) in acetonitrile), and 10 μL of the internal standard mixture. 50 μL of water were added to 
reduce the organic content of the samples. Calibration standards were prepared in aCSF, which is 
similar in composition to serum without proteins.
28
 Five μL aliquots of the standards were 
diluted with 20 μL acetonitrile to match the sample composition, and then derivatized in the 
same manner as the serum supernatant. 
 
Fly tissue homogenate 
 Homogenized Drosophila samples were provided by the Pletcher lab at the University of 
Michigan, Ann Arbor. Female flies were treated with 250 μM 5HTP for four days prior to 
harvesting. The flies were snap frozen in liquid nitrogen and vortexed to remove heads. The 
heads were homogenized in 4 μL of ice cold acetonitrile per head, and 20 μL ice-cold acetonitrile 
per body, using a pestle grinder. The homogenate was centrifuged at 18,000 × g for 5 min and 
the supernatant was removed and stored at -80 °C until derivatization. 20 μL of the supernatant 
was derivatized by sequential addition of 10 μL of 100 mM sodium carbonate, 10 μL of BzCl 
(2% (v/v) in acetonitrile), and 10 μL of the internal standard mixture. Finally, 50 μL of water 
were added to reduce the organic content of the samples. Calibration standards were prepared in 
aCSF. Five μL aliquots of the standards were diluted with 20 μL acetonitrile to match the sample 
composition, and then derivatized in the same manner as the tissue homogenate supernatant. 
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Fly hemolymph 
 Hemolymph from Drosophila was provided by the Dus lab at the University of Michigan. 
Flies were reared in standard cornmeal-glucose medium at 25 °C in a 12:12 light/dark cycle. 
After eclosion groups of 100 w1118
CS
 (w1118 backcrossed to CS for 10 generations) males were 
placed in bottles and aged for 7-10 days until the time of hemolymph collection. Fresh food was 
provided every 2 days.  
 Hemolymph collection was performed as previously described, with modifications to the 
sated condition.
29
 w118
CS
 males in groups of 100 were moved into bottles containing agar and 
fasted for 24 h. For the starved condition, males were collected directly from the starvation 
bottles; for the sated condition, males were moved to bottles containing 5% sucrose agar and red 
food dye for 1 h, and then gathered for hemolymph collection. To generate a sufficient sample 
volume, multiple collections of hemolymph each from 100 males were pooled together. 
Hemolymph was stored at -80 °C until derivatization. 
 20 µL of hemolymph were diluted with 80 µL of ice cold acetonitrile. The samples were 
vortexed, then centrifuged for 10 min at 12,100g. 20 μL of the supernatant was derivatized by 
sequential addition of 10 μL of 100 mM sodium carbonate, 10 μL of BzCl (2% (v/v) in 
acetonitrile), and 10 μL of the internal standard mixture. 50 μL of water were added. Calibration 
standards were prepared in aCSF. 5 μL aliquots of the standards were diluted with 20 μL 
acetonitrile to match the sample composition, and then derivatized in the same manner as the 
hemolymph supernatant. 
 
Protein precipitation method validation 
50 
 
 To validate the method and test recovery of the solvent precipitation, we spiked a mixture 
of stable isotope labeled metabolites (500 nM 
13
C5-glutamate, 50 nM d6-GABA, 50 nM d4-
serotonin, and 50 nM 
13
C6-dopamine) into 50 µL of pooled human serum. The spiked serum was 
diluted with 200 µL ice cold acetonitrile, followed by centrifugation for 10 minutes at 12,100g. 
20 µL of supernatant was derivatized by sequential addition of 10 µL of 100 mM sodium 
carbonate, 10 µL of BzCl (2% (v/v) in acetonitrile), and 10 µL of the internal standard mixture. 
Three spiked serum samples were extracted and derivatized in parallel for triplicate analysis. 
Calibration standards were prepared in aCSF, and 5 μL aliquots of the standards were diluted 
with 20 μL acetonitrile to match the sample composition, and then derivatized in the same 
manner as the serum supernatant. 
 
Small molecule neurochemical analysis using QQQ MS/MS 
 Derivatized samples were analyzed by LC-MS (as further described in the results section) 
using a Waters nanoAcquity UPLC (Milford, MA) coupled to an Agilent 6410 (Santa Clara, CA) 
triple quadrupole mass spectrometer operating in dynamic multiple reaction monitoring (dMRM) 
mode. Five µL were injected onto an Acquity HSS T3 C18 column (1 mm x 100 mm, 1.8 µm, 
100 Å pore size) in partial loop injection mode. Samples were analyzed in triplicate. Mobile 
phase A was 10 mM ammonium formate with 0.15% formic acid, and mobile phase B was 
acetonitrile. The flow rate was 100 µL/min and the elution gradient was as follows: initial, 0% B; 
0.01 min, 15% B; 0.5 min, 17% B; 14 min, 55% B; 14.5 min, 70% B; 18 min, 100% B; 19 min, 
100% B; 19.1 min, 0% B; and 20 min, 0% B. An additional 10 min of column equilibration at 
0% B were required to achieve reproducible chromatography. The required pressure over the 
gradient was from 2,500 - 8,000 psi. The autosampler was kept at ambient temperature and the 
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column was kept at 27 °C. Electrospray ionization was used in positive mode at 4 kV. The gas 
temperature was 350 °C, gas flow was 11 L/min, and the nebulizer was at 15 psi. Automated 
peak integration was performed using Agilent MassHunter Workstation Quantitative Analysis 
for QQQ, version B.05.00; all peaks were visually inspected to ensure proper integration. 
 
Statistical analyses 
 All statistical analyses were performed in Prism 7 (GraphPad, La Jolla, CA). For 
statistical analysis unpaired Student’s t test were applied. Differences were deemed significant if 
p < 0.05.  
 
Results and discussion 
 BzCl labeling has been previously reported for the analysis of small molecule 
neurotransmitters, polyamines and steroids with HPLC-MS or ultraviolet-absorption 
detection.
9,10,30,31
 Here we identify new reaction conditions that improve sensitivity for LC-
MS/MS for many of the neurochemicals tested and demonstrate the wide applicability of BzCl 
derivatization for low molecular weight metabolites in a variety of complex sample matrices. 
 
Effect of buffer and solvents on reaction conditions  
 The initial report of using BzCl with HPLC-MS/MS for neurochemicals utilized four 
reagent addition steps
9
: 1) sodium tetraborate buffer (100 mM) to the sample to achieve basic pH 
conditions required for BzCl labeling; 2) 2% (v/v) BzCl in acetonitrile; 3) internal standards 
diluted in dimethyl sulfoxide (DMSO) with 1% (v/v) formic acid, 4) d4-ACh in water to provide 
an internal standard for this neurotransmitter that does not react with BzCl. Tetraborate buffer 
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was originally selected because it forms a reversible complex with catechol groups to prevent 
oxidation under high pH conditions.
9,32
 Our present work first focused on modifying reaction 
conditions to improve sensitivity and reduce the number of steps. These initial studies used 17 
neurochemicals as test analytes (Figure 3-1, Table 3-1) 
 We found that sodium carbonate instead of borate buffer significantly improved 
sensitivity (i.e. slope of the calibration curve; Figure 3-1) for compounds containing a 1,2 diol 
Figure 3-1:  Normalized effect of sodium borate versus sodium carbonate buffer on calibration slope for select analytes. 
Standards made using sodium borate buffer and sodium carbonate buffer were analyzed with LC-MS in triplicate. A 6-point 
calibration curve for all analytes of interest was made to determine the average calibration slope for each analyte (n = 3 for 
each concentration tested). For the calibrations, the high concentrations were 20 nM for ACh, 5HT, NE, NM, DA and 3MT; 
200 nM for Hist, GABA, 5HIAA, HVA, and DOPAC; and 2 μM for Tau, Ser, Asp, Ado, Gly, and Glu; followed by serial 
dilution. Analyte to internal standard ratios were plotted against known concentrations and a linear trend line was applied to 
determine slope (A). Sodium carbonate slopes were normalized to sodium borate slopes. Significant improvements to Ado, 
Gly, Hist, NE, DA, and DOPAC occurred when using 100 mM sodium carbonate as the buffer. Slopes were decreased for 
5HT, NM, 3MT, and HVA. Unpaired two-tailed Students t test statistics were performed (B). Data expressed as percent 
borate ± SD. *p < 0.05, n = 3. 
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group, such as dopamine, norepinephrine, and DOPAC (Figure 3-2). Use of 100 mM carbonate 
buffer instead of 100 mM borate increased the slope of norepinephrine 221% (t(4) = 19.6, p < 
0.0001), dopamine 170% (t(4) = 27.7, p < 0.0001), and DOPAC 330% (t(4) = 39.5, p < 0.0001). 
The slope was increased 2550% for adenosine (t(4) = 52.0, p < 0.0001), which is also a diol. The 
slope increased slightly for two compounds without diols: glycine 103% (t(4) = 5.6, p < 0.01) 
and histamine 110% (t(4) = 5.4, p < 0.01). Although these compounds improved, the calibration 
slope was reduced 25% for serotonin (t(4) = 4.2, p < 0.05), 10% for normetanephrine (t(4) = 5.3, 
p < 0.01), 20% for 3MT (t(4) = 7.7, p < 0.01), and 10% for HVA (t(4) = 2.9, p < 0.05). These 
small decreases in slope are a reasonable trade-off for the large gains for the diols. 
 Improved catechol detection sensitivity may relate to how the buffers interact with 1,2 
diol groups. Both borate and carbonate can be used as protecting groups for 1,2 diols; however, 
cyclic borates are deprotected using dilute acid, while cyclic carbonates hydrolyze in water.
33–35
 
The protection of the carbonate group is more readily reversed than borate due to the high 
aqueous content of the sample, allowing for greater access of the diols for BzCl. The reason for 
the decreases in sensitivity of some compounds is unclear, but several of the compounds with 
decreased slopes have an ortho configuration of an alcohol and methoxy group (Figure 3-2a). A 
potential problem with the BzCl assay is that organic solvent in the injected sample could cause 
poor peak shape for the most polar analytes, particularly acetylcholine (Figure 3-3) However, 
some organic solvent is needed to maintain solubility of the hydrophobic internal standards that 
are added to the sample. Replacing DMSO in the internal standard mixture with 20% (v/v) 
acetonitrile improved peak shape and signal intensity for acetylcholine, while retaining sufficient 
organic content to maintain solubility of hydrophobic compounds. The peak area for 
acetylcholine standards treated with internal standards in 20% (v/v) acetonitrile increased 5-fold 
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relative to samples treated with internal standards in DMSO. This change in solvent reduces the 
final organic content of the samples, so band broadening is reduced for polar metabolites such as 
acetylcholine, as the sample composition is more closely matched in elution strength to the initial 
gradient conditions.  
Analyte 
Retention Time Concentration Formic Acid Sulfuric Acid Increase with 
(min) (nM) Peak Area Peak Area Sulfuric (%) 
ACh 1.2 50 9409 8219 87 
Tau 2.3 2000 17373 17723 102 
Hist 2.3 200 78624 81494 104 
Ser 2.6 5000 19108 20770 109 
Asp 2.8 200 1118 1324 118 
Gly 2.9 5000 4163 4695 113 
Glu 3.1 2000 19442 23809 122 
GABA 3.7 200 23076 30285 131 
Ado 4.6 200 8894 12443 140 
5HIAA 5.2 500 12758 16814 132 
HVA 5.3 500 54869 69455 127 
NM 5.5 20 13240 31391 237 
DOPAC 5.9 500 158474 261578 165 
5HT 5.9 20 2221 10703 482 
NE 6.0 20 5974 28457 476 
3MT 6.0 20 16229 71462 440 
DA 6.4 20 21510 100588 468 
Table 3-1:  Improvements in sensitivity using sulfuric acid compared to formic acid additive to reagent mixture. Standards were 
derivatized with sodium carbonate (100 mM), BzCl (2% (v/v) in acetonitrile), and an internal mixture that contained 20% (v/v) 
acetonitrile with 1% (v/v) formic acid or sulfuric acid.  
 
 Substituting 1% (v/v) sulfuric acid for 1% (v/v) formic acid in the internal standard 
mixture improved signals of late eluting compounds by 237% for normetanephrine, 165% for 
DOPAC, 481% for serotonin, 476% for norepinephrine, 440% for 3MT, and 468% for dopamine 
(Table 3-1). While the explanation for this increased signal is unclear, we hypothesize that it is 
due to the decreased formation of formate adducts late in the gradient. The production of 
undetectable formate adducts limits the production of detectable proton adducts. Formic acid is 
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Figure 3-3:  Replacement of DMSO with acetonitrile as solvent 
for internal standards improves the peak shape and area for early 
eluting metabolite ACh. Standards were derivatized with 2% 
BzCl (v/v in acetonitrile), 100 mM sodium carbonate, and an 
internal standard mixture diluted in either DMSO or 20% (v/v) 
acetonitrile. ACh ion chromatograms were extracted and 
normalized to the ACh peak in acetonitrile and overlaid. 
used in our mobile phase A, so 
early eluting compounds may still 
form formate adducts; whereas 
later eluting compounds have less 
likelihood of formate adducts due 
to the lack of formic acid in 
sample and mobile phase B.  
 To reduce the number of 
reagent addition steps and the 
dilution associated with 
derivatization, we added the d4-acetylcholine internal standard to the 
13
C-labeled internal 
standards and introduced all internal standards in one step. This modification had no effect on 
d4-acetylcholine or the 
13
C-labeled compounds. 
 
Addition of new compounds  
 To illustrate the potential for more 
comprehensive measurement of 
neurochemical pathways with this assay, 
53 compounds were added to the original 
17 compound assay. The selected 70 
compounds include 19 proteinogenic 
amino acids and intermediates in the 
metabolism of phenylalanine, tyrosine, 
Figure 3-2:  Chemical structures of neurochemicals enhanced by sodium 
carbonate buffer (A). Structures of neurochemical reduced with carbonate 
buffer (B). 
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tryptophan, and arginine. Phenylalanine and tyrosine are precursors to the catecholamines and 
several trace amines, so many metabolites in this pathway were added. These include several 
norepinephrine metabolites (e.g. VMA and MOPEG), as well as tyrosine derivatives such as 
tyramine and octopamine. Trace amines (tyramine, octopamine, tryptamine, and 
phenethylamine) play prominent roles in many invertebrate species,
36–40
 and are present as 
metabolic by-products in the mammalian central nervous system, where they may neuromodulate 
biogenic amine signaling.
40,41
 Serotonin is derived from tryptophan, so several intermediates in 
tryptophan metabolism were included (Figure 3-4). These include 5HTP, the direct precursor to 
serotonin, as well as serotonin metabolite N-acetylserotonin, which is particularly relevant in 
flies.
42,43
 Monoamine oxidase (MAO) activity is limited in flies, so metabolites produced via 
MAO (e.g., 5HIAA) are not typically observed. Instead, monoamines are preferentially 
metabolized by N-acetylation, producing compounds such as N-acetylserotonin.
42–44
 Tryptophan 
is also the precursor to kynurenine and its metabolites, which may have both neuroprotective and 
neurotoxic properties.
45
 
 Several intermediates in arginine metabolism were also included in the method. Arginine 
is involved in the urea cycle and nitric oxide production. Ornithine, another member of the urea 
cycle, serves as a precursor for many polyamines, ubiquitous small molecules with a broad array 
of functions,
46
 whose dysfunction are associated with neurodegenerative disease.
47,48
 Thiol-
containing dipeptide glutathione, and histidine-containing dipeptides, carnosine and metabolite 
anserine, have antioxidative effects in the brain,
49–51
 and decreased glutathione activity is 
associated with oxidative stress. Postmortem prefrontal-cortex tissue from human patients with 
psychiatric conditions such as bipolar, depression, and schizophrenia, show decreased levels of 
glutathione.
51
 Carnosine may be neuroprotective by inhibiting the formation of β-amyloid 
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Figure 3-4:  Tryptophan Metabolic Pathway. Abbreviations:  aromatic amino acid decarboxylase (AADC), aralkylamine N-
acetyltransferase (AANAT), aldehyde dehydrogenase (ALDH), aldehyde reductase (ALDR), indoleamine 2,3-dioxygenase 
(IDO), kynurenine aminotransferase (KAT), kynurenine 3-monooxygenase (KMO), kynureninase (KYNU), monoamine 
oxidase (MAO), tryptophan 2,3-dioxygenase (TDO), and tryptophan hydroxylase (TPH). 
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polymerization and α-synuclein oligomerization, toxic species in Alzheimer’s and Parkinson’s 
diseases.
50
 Glucose indicates neuronal energy expenditure, and alterations of normal glucose 
metabolism can lead to synaptic dysfunction, including glucose hypometabolism in Alzheimer’s 
disease and Parkinsonian patients with dementia.
52–55
 
 All 70 analytes of interest and their internal standards are benzoylated, except 
acetylcholine and choline, and detected by MS/MS (Table 3-2 and Table 3-3). Analytes were 
labeled 1-4 times with BzCl depending on the functional groups. In all cases, only the fully 
labeled compounds were observed, indicating quantitative (i.e., complete labeling) reactions. As 
an example, dopamine is triply labeled; singly and doubly labeled dopamine were not detectable.  
Protonated benzoylation products (MW + 1) were observed for most compounds with ESI in 
positive mode. A protonated water loss was observed for octopamine, normetanephrine, and 
synephrine (MW – 18 + 1), and the ammonium adduct (MW + 18) was detected for VMA, 
MOPEG, 5HIAA, HVA. DOMA, DOPEG, and DOPAC. A sodium adduct was observed for 
glucose (MW + 23). Other hexoses (e.g. fructose, mannose, and galactose) were resolved 
chromatographically or by MRM. For acetylcholine and choline, the unlabeled molecular ions 
were used for detection. 
  Analytes were detected by MS/MS under collision activated dissociation (CAD) 
conditions. The fragmentation of each analyte was examined to determine the best product ion to 
use for quantification (Table 3-2 and Table 3-3). For benzoylated analytes, the benzoyl fragment 
of 105 m/z was usually the most abundant product ion, and used for dMRM. Unique fragments 
for acetylcholine, choline, histidine, carnosine, phenylalanine, kynurenine, adenosine, 
tryptamine, 5HIAA, tryptophan, 5HTOL, spermidine, ornithine, kyotorphin, agmatine, N-
acetylputrescine, VMA, glucose, lysine, 3HAA, 3HK, N-acetylserotonin, serotonin, 5HTP, and 
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Analyte 
Precursor Product Fragmentor Collision Energy Retention Time 
(m/z) (m/z) (V) (V) (min) 
ACh 146 87 120 15 1.30 
Ch 104 60 120 20 1.30 
Bz-CA 274 105 120 10 2.31 
Bz-His 260 110 130 20 2.33 
Bz-Ans 345 105 130 30 2.40 
Bz-Carn 331 110 135 20 2.40 
Bz-HTau 214 105 120 20 2.48 
Bz-Tau 230 105 120 10 2.49 
Bz-Arg 279 105 135 30 2.58 
Bz-Hist 216 105 120 20 2.61 
Bz-Asn 237 105 120 20 2.62 
Bz-Ser 210 105 120 20 2.71 
Bz-Gln 251 105 120 20 2.72 
Bz-HSer 224 105 120 20 2.88 
Bz-Cit 280 105 120 20 2.91 
Bz-ETA 166 105 120 20 2.93 
Bz-Asp 238 105 120 10 2.98 
Bz-Agm 235 176 110 30 3.02 
Bz-Glc 307 185 130 20 3.10 
Bz-Gly 180 105 120 10 3.10 
Bz-Glu 252 105 120 20 3.28 
Bz-BAla 194 105 120 20 3.53 
Bz-Ala 194 105 120 20 3.78 
Bz-NAP 235 176 135 20 3.85 
Bz-GABA 208 105 120 10 3.99 
Bz-Pro 220 105 120 20 4.60 
Bz-Ado 372 136 120 30 6.28 
Bz-Val 222 105 120 30 6.63 
Bz-Met 254 105 120 15 6.73 
Bz-Orn 341 174 120 15 7.50 
Bz-GSH 516 105 120 15 8.28 
Bz-Lys 355 188 120 20 8.35 
Bz-Put 297 105 120 30 8.79 
Bz-Leu 236 105 120 30 9.30 
Bz-Phe 270 120 120 10 9.67 
Bz-Thr 224 105 140 20 9.67 
Bz-VMA 320 181 120 10 9.77 
Bz-Trp 309 159 120 10 9.96 
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Analyte 
Precursor Product Fragmentor Collision Energy Retention Time 
(m/z) (m/z) (V) (V) (min) 
Bz-MOPEG 306 105 120 20 10.08 
Bz-Kyo 546 175 110 30 11.35 
Bz-Cys 330 105 120 20 11.64 
Bz-KA 294 105 120 30 11.78 
Bz-Spd 458 162 120 30 12.00 
Bz-PhEt 226 105 120 15 12.23 
Bz-TrpA 265 144 130 30 12.38 
Bz-NAS 323 264 120 15 12.39 
Bz-5HIAA 313 146 120 15 12.60 
Bz-5HTOL 282 160 130 20 12.73 
Bz-HCY 344 105 120 20 13.00 
Bz-3HAA 362 240 120 10 13.07 
Bz-HCA 288 105 120 10 13.13 
Bz-HVA 304 105 120 15 13.13 
Bz-DOMA 410 105 130 20 13.35 
Bz-Kyn 417 122 120 10 13.35 
Bz-Spm 619.6 497 135 25 13.52 
Bz-DOPEG 396 105 120 20 13.59 
Bz-5HTP 429 279 120 15 13.82 
Bz-OA 344 105 140 20 13.84 
Bz-NM 374 105 140 15 13.88 
Bz-Tyr 390 105 120 30 14.12 
Bz-3HK 537 240 135 25 14.40 
Bz-Syn 358 105 140 20 14.43 
Bz-5HT 385 264 140 20 15.46 
Bz-DOPAC 394 105 140 20 15.49 
Bz-3MT 376 105 120 20 15.67 
Bz-LDOPA 510 105 120 25 15.67 
Bz-TyrA 346 105 135 25 15.73 
Bz-NE 482 105 140 30 15.77 
Bz-E 496 105 120 15 15.96 
Bz-DA 466 105 140 20 16.40 
Table 3-2:  MRM conditions of 70 targeted metabolites. 
 
spermine were identified. These correspond to immonium ions for histidine, phenylalanine, and 
tryptophan, y ions for kyotorphin and carnosine, and the adenine moiety for adenosine. Several 
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fragmentation patterns are shown in Figure 3-5. When possible, unique fragments were chosen 
for quantification to increase the selectivity of the assay for these compounds, reducing the 
likelihood of interferences from unknowns with similar precursor masses. The unique fragments 
have comparable or increased sensitivity relative to the 105 fragments for those compounds.  
Analyte 
Precursor Product Fragmentor Collision Energy Retention Time 
(m/z) (m/z) (V) (V) (min) 
d4-Ach 150 91 120 15 1.30 
d4-Ch 108 60 120 20 1.30 
13
C6Bz-CA 280 111 120 10 2.31 
13
C6Bz-His 266 110 130 20 2.33 
13
C6Bz-Ans 351 111 130 30 2.40 
13
C6Bz-Carn 337 110 135 20 2.40 
13
C6Bz-HTau 220 111 120 20 2.48 
13
C6Bz-Tau 236 111 120 10 2.49 
13
C6Bz-Arg 285 111 135 30 2.58 
13
C6Bz-Hist 222 111 120 20 2.61 
13
C6Bz-Asn 243 111 120 20 2.62 
13
C6Bz-Ser 216 111 120 20 2.71 
13
C6Bz-Gln 257 111 120 20 2.72 
13
C6Bz-HSer 230 111 120 20 2.88 
13
C6Bz-Cit 286 111 120 20 2.91 
13
C6Bz-ETA 172 111 120 20 2.93 
13
C6Bz-Asp 244 111 120 10 2.98 
13
C6Bz-Agm 241 182 110 30 3.02 
13
C6Bz-Glc 313 185 130 20 3.10 
13
C6Bz-Gly 186 111 120 10 3.10 
13
C6Bz-Glu 258 111 120 20 3.28 
13
C6Bz-BAla 200 111 120 20 3.53 
13
C6Bz-Ala 200 111 120 20 3.78 
13
C6Bz-NAP 241 182 135 20 3.85 
13
C6Bz-GABA 214 111 120 10 3.99 
13
C6Bz-Pro 226 111 120 20 4.60 
13
C6Bz-Ado 378 136 120 30 6.28 
13
C6Bz-Val 228 111 120 30 6.63 
13
C6Bz-Met 260 111 120 15 6.73 
13
C6Bz-Orn 353 180 120 15 7.50 
13
C6Bz-GSH 528 111 120 15 8.28 
13
C6Bz-Lys 367 194 120 20 8.35 
13
C6Bz-Put 309 111 120 30 8.79 
13
C6Bz-Leu 242 111 120 30 9.30 
13
C6Bz-Phe 276 120 120 10 9.67 
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Analyte 
Precursor Product Fragmentor Collision Energy Retention Time 
(m/z) (m/z) (V) (V) (min) 
13
C6Bz-Thr 230 111 140 20 9.67 
13
C6Bz-VMA 326 181 120 10 9.77 
13
C6Bz-Trp 315 159 120 10 9.96 
13
C6Bz-
MOPEG 
312 111 120 20 10.08 
13
C6Bz-Kyo 558 175 110 30 11.35 
13
C6Bz-Cys 342 111 120 20 11.64 
13
C6Bz-KA 300 111 120 30 11.78 
13
C6Bz-Spd 476 168 120 30 12.00 
13
C6Bz-PhEt 232 111 120 15 12.23 
13
C6Bz-TrpA 271 144 130 30 12.38 
13
C6Bz-NAS 329 270 120 15 12.39 
13
C6Bz-5HIAA 319 146 120 15 12.60 
13
C6Bz-5HTOL 288 160 130 20 12.73 
13
C6Bz-HCY 356 111 120 20 13.00 
13
C6Bz-3HAA 374 246 120 10 13.07 
13
C6Bz-HCA 294 111 120 10 13.13 
13
C6Bz-HVA 310 111 120 15 13.13 
13
C6Bz-DOMA 422 111 130 20 13.35 
13
C6Bz-Kyn 429 128 120 10 13.35 
13
C6Bz-Spm 643.6 515.6 135 25 13.52 
13
C6Bz-DOPEG 408 111 120 20 13.59 
13
C6Bz-5HTP 441 285 120 15 13.82 
13
C6Bz-OA 356 111 140 20 13.84 
13
C6Bz-NM 386 111 140 15 13.88 
13
C6Bz-Tyr 402 111 120 30 14.12 
13
C6Bz-3HK 555 246 135 25 14.40 
13
C6Bz-Syn 370 111 140 20 14.43 
13
C6Bz-5HT 397 270 140 20 15.46 
13
C6Bz-
DOPAC 
406 111 140 20 15.49 
13
C6Bz-3MT 388 111 120 20 15.67 
13
C6Bz-LDOPA 528 111 120 25 15.67 
13
C6Bz-TyrA 358 111 135 25 15.73 
13
C6Bz-NE 500 111 140 30 15.77 
13
C6Bz-E 514 111 120 15 15.96 
13
C6Bz-DA 484 111 140 20 16.40 
Table 3-3:  Transitions for 13C6-BzCl labeled internal standards. 
 
 After determining the MS/MS transitions, a gradient was developed to separate the 
analytes (Figure 3-6). The gradient was not designed to fully resolve all analytes but to spread 
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the analytes out over the 20 min 
separation time and minimize the 
number of dMRMs at any given 
time. The gradient results show 
that even very polar compounds 
like dopamine can be well retained 
after benzoylation. Total analysis 
time for each sample is around 33 
min including injection time, 
elution and column re-
equilibration on the Waters 
nanoAcquity system. Higher 
throughput may be possible. In 
preliminary tests, the method was 
transferred to a higher flow rate HPLC with higher pressure limits and the separation time was 
reduced to 12 min, with a total analysis time around 14 min. Further reductions in the analysis 
time per sample can be achieved as LC pressure limits and MS scan rates continue to increase. 
 The method yields good detection limits, linearity, reproducibility and low carryover for 
all detected compounds (Table 3-4). All detection limits were better than 10 nM except for 
glutathione, alanine, citrulline, glycine, serine, and glucose.
56
 While limits of detection (LOD) 
for these select compounds were higher than other reported compounds in the assay, these levels 
were below the observed concentrations in dialysate and CSF. 
  
Figure 3-5:  Fragmentation patterns for select benzoyl labeled compounds. 
Analytes were detected by MS/MS under collision activated dissociation 
(CAD) conditions. While the benzoyl fragment of 105 m/z was the most 
abundant product ion for most analytes detected, unique fragments were 
chosen for detection to increase the selectivity of the assay for these 
compounds. 
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Application of 70 compound assay in various matrices  
 To test the versatility of the assay, we analyzed several types of biological samples, 
including rat striatal dialysate, human CSF, human serum, and Drosophila tissue homogenate 
(Table 3-5, Table 3-6, Table 3-7). 57 compounds were detected in dialysate samples, whereas 35 
and 50 compounds were above the limits of detection in human CSF and serum samples, 
respectively. Drosophila heads and bodies were isolated and analyzed separately, with detection 
of 44 compounds in head and 42 compounds in bodies. 54 compounds were detected in 
hemolymph from Drosophila. 
  
Figure 3-6:  Reconstructed ion chromatogram of 70 compounds detected in 20 min. Extracted ion chromatograms for each 
compound at the highest concentration calibration standard run, were normalized to highest intensity and overlaid. 
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Analyte 
LoD Carryover RSD Fit 
Analyte 
LoD Carryover RSD Fit 
(nM) (%) (%) (R
2
) (nM) (%) (%) (R
2
) 
ACh 1 1 0.7 0.9996 Thr 5 0.3 1 0.9995 
Ch 3 0.2 1 0.9997 VMA 1 0.1 1 0.9999 
CA 4 0.02 2 1.0000 Trp 1 0.1 0.9 0.9997 
His 2 0.1 2 0.9996 MOPEG 0.7 0.08 0.6 0.9999 
Ans 0.4 0.03 2 0.9999 Kyo 0.2 0.2 2 0.9998 
Carn 0.8 0.04 2 0.9999 Cys 1 0.1 5 0.9971 
HTau 7 0.05 4 0.9977 KA 1 0.1 0.9 0.9997 
Tau 3 0.02 1 0.9998 Spd 0.09 0.1 0.5 0.9994 
Arg 1 0.5 3 0.9576 PhEt 0.08 0.09 2 0.9989 
Hist 0.09 0.04 3 0.9996 TrpA 0.1 0.09 3 0.9993 
Asn 2 0.1 2 0.9999 NAS 0.09 0.06 0.8 0.9997 
Ser 70 0.6 1 0.9976 5HIAA 0.7 0.08 0.8 0.9999 
Gln 4 0.2 3 0.9998 5HTOL 0.9 0.07 1 0.9997 
HSer 11 0.5 3 0.9994 HCY 0.9 0.08 1 0.9968 
Cit 20 2 2 0.9965 3HAA 1 0.1 0.9 0.9996 
ETA 6 0.4 2 0.9997 HCA 1 0.09 2 0.9998 
Asp 8 0.05 1 0.9999 HVA 0.6 0.07 0.4 1.0000 
Agm 1 0.03 4 0.9997 DOMA 0.3 0.2 3 0.9998 
Glc 160 0.06 6 0.9997 Kyn 1 0.1 3 0.9994 
Gly 30 0.09 7 0.9997 Spm 0.1 0.1 2 0.9984 
Glu 0.3 0.2 1 1.0000 DOPEG 0.1 0.1 1 0.9992 
BAla 5 0.09 1 1.0000 5HTP 2 0.2 3 0.9996 
Ala 20 2 2 0.9994 OA 0.2 0.2 1 0.9983 
NAP 0.5 0.05 1 0.9999 NM 0.08 0.09 2 0.9988 
GABA 0.5 0.4 2 0.9997 Tyr 4 2 3 0.9950 
Pro 5 0.5 0.4 0.9996 3HK 8 0.06 2 0.9941 
Ado 1 0.1 0.2 0.9956 Syn 0.2 0.2 0.1 0.9982 
Val 7 0.6 3 0.9998 5HT 0.4 0.4 1 0.9970 
Met 0.7 0.09 1 0.9998 DOPAC 0.2 0.2 2 0.9999 
Orn 7 0.4 0.2 0.9963 3MT 0.2 0.2 2 0.9987 
GSH 10 0.1 2 0.9999 LDOPA 1 0.9 2 0.9999 
Lys 4 2 0.7 0.9867 TyrA 0.2 0.3 1 0.9964 
Put 0.1 0.1 1 0.9999 NE 0.3 0.2 2 0.9970 
Leu 5 4 2 0.9894 E 0.3 0.2 1 0.9964 
Phe 3 0.2 0.8 0.9999 DA 0.3 0.3 3 0.9965 
Table 3-4:  Summary of limits of detection (LOD), carryover, relative standard deviation (n = 3), and R2 value of a six-point 
calibration for aqueous standards. 
 
 All commonly studied neurotransmitters (i.e. GABA, glutamate, and monoamines) were 
within expected ranges in rat striatal dialysate (Table 3-5). Several detectable compounds were 
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not previously reported in rat dialysate or tissue homogenate studies, and include homoserine, a 
precursor to amino acids threonine and methionine; N-acetylputrescine, a metabolite of 
polyamine putrescine; and DOMA, a norepinephrine metabolite. Polyamines putrescine, 
spermidine, and spermine were also detected in the dialysate sample. The norepinephrine and 
normetanephrine metabolites MOPEG, DOPEG, and DOMA (but not epinephrine or VMA) 
were detected in rat dialysate, demonstrating the potential for analysis of metabolic pathways.  
 Analysis of human serum, derivatized after protein precipitation, revealed kyotorphin at 
31 nM concentration. Kyotorphin is an endogenous analgesic dipeptide with potential 
neuroprotective properties. It has previously been found in rat brain tissue and human CSF 
samples.
57,58
 This is the first report of quantitative detection of kyotorphin in human serum. 
Kyotorphin is proposed to have indirect opioid-like actions by modulating enkephalin release.
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Kyotorphin does not cross the blood brain barrier, and is a candidate biomarker for 
neurodegenerative diseases such as Alzheimer’s disease.57 While previous studies detected 
kyotorphin in CSF samples obtained from lumbar puncture, less invasive blood sample 
collection would be beneficial for patients, with subsequent detection as reported here. 
Interestingly, kyotorphin was not detected in our analysis of pooled human CSF from healthy 
patients, which did not undergo a protein precipitation step prior to analysis.  
 Fly tissue homogenate contained detectable levels of tyramine and octopamine, which 
was expected as they are the fly analogs of epinephrine and norepinephrine, respectively. 5HTP 
pretreatment of the flies resulted in high levels of 5HTP in both bodies and heads. 5HTP 
metabolites serotonin and N-acetylserotonin were also elevated, though the effect was more 
pronounced in the bodies. Interestingly, 5HIAA was observed in both bodies and heads, despite 
the expected lack of MAO activity in flies, likely due to the excess of 5HTP.
44
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 Analyte 
Concentration (nM) 
 Analyte 
Concentration (nM) 
Rat Dialysate Human CSF Rat Dialysate Human CSF 
ACh 12.2 ± 0.1 1.19 ± 0.04 Thr 691 ± 7 65 ± 2 
Ch 1212 ± 5 14 ± 2 VMA 
      
CA 2170 ± 90 300 ± 30 Trp 141 ± 4 20.9 ± 0.2 
His 930 ± 10 91.4 ± 0.8 MOPEG 4.3 ± 0.3 
   
Ans 
      
Kyo 
      
Carn 14.0 ± 0.4 
   
Cys 503 ± 9 
   
HTau 
      
KA 
      
Tau 1820 ± 70 33 ± 2 Spd 2.38 ± 0.08 0.19 ± 0.02 
Arg 1380 ± 70 211 ± 6 PhEt 0.53 ± 0.02 
   
Hist 0.76 ± 0.08 0.20 ± 0.03 TrpA 
      
Asn 40 ± 1 6.6 ± 0.3 NAS 0.23 ± 0.02 
   
Ser 4100 ± 250 570 ± 40 5HIAA 390 ± 6 2.4 ± 0.2 
Gln 37300 ± 1300 4080 ± 60 5HTOL 1.9 ± 0.1 
   
HSer 2920 ± 20 266 ± 7 HCY 4.91 ± 0.03 
   
Cit 390 ± 10 
   
3HAA 
      
ETA 6980 ± 310 124 ± 4 HCA 1050 ± 30 4.7 ± 0.3 
Asp 108 ± 7 15 ± 2 HVA 1130 ± 40 4.4 ± 0.4 
Agm 
      
DOMA 0.47 ± 0.02 
   
Glc 633000 ± 85000 55400 ± 840 Kyn 7.1 ± 0.3 
   
Gly 690 ± 10 52 ± 5 Spm 2.9 ± 0.1 
   
Glu 21 ± 1 4.9 ± 0.1 DOPEG 1.26 ± 0.03 
   
BAla 5.8 ± 0.9 
   
5HTP 
      
Ala 5260 ± 160 306 ± 8 OA 
      
NAP 1.0 ± 0.1 0.74 ± 0.02 NM 0.30 ± 0.01 
   
GABA 40.5 ± 0.6 3.3 ± 0.2 Tyr 350 ± 20 76.6 ± 0.3 
Pro 1326 ± 8 13.8 ± 0.2 3HK 
      
Ado 112.8 ± 0.6 
   
Syn 
      
Val 1760 ± 20 104 ± 2 5HT 0.89 ± 0.02 
   
Met 855 ± 6 26.2 ± 0.5 DOPAC 598 ± 5 0.6 ± 0.1 
Orn 196 ± 3 54.9 ± 0.8 3MT 8.5 ± 0.2 
   
GSH 74 ± 2 
   
LDOPA 4.00 ± 0.04 
   
Lys 4030 ± 170 249 ± 7 TyrA 0.21 ± 0.02 
   
Put 0.83 ± 0.03 0.41 ± 0.03 NE 1.00 ± 0.08 
   
Leu 2200 ± 140 102 ± 4 E 
      
Phe 710 ± 5 66.9 ± 0.8 DA 29.4 ± 0.8 
   
 
Table 3-5:  Application of 70 compound method to analyze rat dialysate and human CSF. The average of 3 repeated injections 
with standard deviation is reported below. Values for analytes were reported only if they were above the limit of detection. 
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Analyte 
LoD Concentration (nM) 
Analyte 
LoD Concentration (nM) 
(nM) Human Serum (nM) Human Serum 
ACh 4 380 ± 10 Thr 30 62000 ± 5000 
Ch 50 15200 ± 200 VMA 20 
   
CA 50 
   
Trp 30 51000 ± 3000 
His 30 37000 ± 1000 MOPEG 5 20 ± 5 
Ans 3 160 ± 20 Kyo 5 31 ± 3 
Carn 6 14 ± 3 Cys 30 1600 ± 100 
HTau 500 160000 ± 10000 KA 40 220 ± 30 
Tau 60 115000 ± 2000 Spd 2 41 ± 0.6 
Arg 10 7100 ± 300 PhEt 1 
   
Hist 2 41 ± 2 TrpA 2 
   
Asn 70 20900 ± 800 NAS 2 5 ± 4 
Ser 700 45000 ± 4000 5HIAA 5 67 ± 4 
Gln 10 180000 ± 10000 5HTOL 10 16 ± 2 
HSer 100 65000 ± 2000 HCY 30 
   
Cit 20 9400 ± 200 3HAA 20 76 ± 6 
ETA 10 6300 ± 100 HCA 10 56 ± 7 
Asp 200 2300 ± 200 HVA 20 57 ± 1 
Agm 20 
   
DOMA 6 
   
Glc 500 1050000 ± 90000 Kyn 40 2380 ± 50 
Gly 200 102000 ± 4000 Spm 2 39 ± 3 
Glu 30 21800 ± 700 DOPEG 2 
   
BAla 20 2300 ± 400 5HTP 30 
   
Ala 70 254000 ± 8000 OA 2 
   
NAP 7 24 ± 2 NM 2 
   
GABA 4 115 ± 4 Tyr 40 56000 ± 1000 
Pro 30 24300 ± 3000 3HK 200 
   
Ado 3 
   
Syn 4 
   
Val 40 160000 ± 10000 5HT 3 300 ± 40 
Met 8 21800 ± 300 DOPAC 5 
   
Orn 200 27400 ± 300 3MT 4 
   
GSH 90 
   
LDOPA 2 390 ± 20 
Lys 40 37000 ± 1000 TyrA 8 
   
Put 0.4 13 ± 1 NE 3 3.2 ± 0.7 
Leu 40 139000 ± 3000 E 4 
   
Phe 30 63000 ± 3000 DA 2 
   
Table 3-6:   Application of 70 compound method after protein precipitation for human serum. The average of 3 repeated 
injections with standard deviation is reported below. Values for analytes were reported only if they were above the limit of 
detection (LOD).   
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 Analyte 
Amount (pmol/fly) 
 Analyte 
Amount (pmol/fly) 
Fly Bodies Fly Heads Fly Bodies Fly Heads 
ACh 2.64 ± 0.08 0.212 ± 0.011 Thr 18.4 ± 1.8 0.98 ± 0.04 
Ch 312 ± 8.8 66.36 ± 1.14 VMA 
      
CA 
      
Trp 17.1 ± 0.9 0.44 ± 0.02 
His 2.7 ± 0.1 0.27 ± 0.04 MOPEG 
      
Ans 
      
Kyo 
      
Carn 
      
Cys 
      
HTau 21 ± 6 
   
KA 1.9 ± 0.1 0.4 ± 0.04 
Tau 278.5 ± 4.1 88.81 ± 3.19 Spd 0.03 ± 0.002 0.01 ± 0.0003 
Arg 0.45 ± 0.01 0.06 ± 0.004 PhEt 0.336 ± 0.015 0.005 ± 0.0004 
Hist 1.92 ± 0.13 0.772 ± 0.011 TrpA 1.85 ± 0.09 0.024 ± 0.002 
Asn 6.5 ± 0.7 0.74 ± 0.04 NAS 29.61 ± 0.7 4.24 ± 0.242 
Ser 
   
0.8 ± 0.4 5HIAA 0.47 ± 0.07 0.025 ± 0.001 
Gln 54.99 ± 0.59 5.61 ± 0.14 5HTOL 
      
HSer 4.5 ± 1.1 0.4 ± 0.01 HCY 
      
Cit 
      
3HAA 
      
ETA 44.03 ± 0.92 5.56 ± 0.27 HCA 0.07 ± 0.01 
   
Asp 
      
HVA 
      
Agm 
      
DOMA 
      
Glc 3170 ± 295 1111.5 ± 0.2 Kyn 8 ± 0.7 
   
Gly 8 ± 1 0.8 ± 0.004 Spm 
      
Glu 1.1 ± 0.2 0.21 ± 0.03 DOPEG 
      
BAla 83.5 ± 0.7 3.04 ± 0.13 5HTP 184.1 ± 3.6 1.83 ± 0.04 
Ala 90.4 ± 5.4 22.84 ± 2.69 OA 
   
0.003 ± 0.0002 
NAP 0.16 ± 0.01 0.009 ± 0.0001 NM 
      
GABA 6.25 ± 0.18 1.661 ± 0.055 Tyr 8.4 ± 0.2 0.35 ± 0.007 
Pro 614.3 ± 2.8 100.46 ± 2.2 3HK 36 ± 3 1.7 ± 0.1 
Ado 31.1 ± 0.12 2.599 ± 0.038 Syn 
      
Val 22.3 ± 0.3 2.17 ± 0.1 5HT 81.66 ± 10.34 5.98 ± 0.666 
Met 16.17 ± 0.58 1.186 ± 0.025 DOPAC 0.09 ± 0.003 0.013 ± 0.001 
Orn 
      
3MT 
      
GSH 
      
LDOPA 1.5 ± 0.13 0.541 ± 0.026 
Lys 0.2 ± 0.02 
   
TyrA 11.89 ± 0.64 0.062 ± 0.001 
Put 0.08 ± 0.001 0.0074 ± 0.0003 NE 
      
Leu 53.6 ± 1.9 3.84 ± 0.04 E 
      
Phe 18.4 ± 0.3 1.02 ± 0.03 DA 0.22 ± 0.01 0.005 ± 0.0001 
Table 3-7:  Application of 70 compound method with a protein precipitation step for fly bodies and heads. The average of 3 
repeated injections with standard deviation is reported below. Values for analytes were reported only if they were above the limit 
of detection. 
 
 Of the 54 compounds detected in fly hemolymph, 10 showed significant (p < 0.05) 
changes between starved and sated states (Figure 3-7). These compounds were Ch (t(4) = 9.7, p 
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< 0.0001); Ser (t(4) = 10.5, p < 0.0001), 
Cit (t(4) = 39.3, p < 0.0001), Pro (t(4) = 
80.2, p < 0.0001), Orn (t(4) = 9.8, p < 
0.0001), OA (t(4) = 17.9, p < 0.0001), Tyr 
(t(4) = 29.5, p < 0.0001), DOPAC (t(4) = 
11.0, p < 0.0001), TyrA (t(4) = 13.1, p < 
0.0001), DA (t(4) = 27.2, p < 0.0001). Of 
particular note was a nearly 5 fold 
increase of octopamine in starved flies 
relative to sated flies. Increased 
octopamine activity has been reported in 
flies upon starvation, and has been linked to foraging-like behaviors as the flies presumably try 
to locate food.
60,61
 The roles of other implicated metabolites are currently undergoing further 
investigation. 
  Protein removal prior to analysis of bodily fluids and tissue homogenate prevents column 
contamination and exposure of the HPLC-MS to high protein concentrations. Many extraction 
techniques are used in metabolomics.
62–64
 These methods vary in effectiveness based on the 
sample type and target metabolites, and require optimization for each assay. Solvent precipitation 
with cold acetonitrile was selected for its simplicity and reproducibility. To evaluate the effect of 
protein precipitation on recovery and reproducibility we spiked known amounts of isotopically 
labeled glutamate, GABA, serotonin, and dopamine into serum prior to solvent precipitation. We 
then measured concentrations of the isotopically labeled compounds after solvent precipitation 
and derivatization, and compared these measured concentrations to the known amount spiked 
Figure 3-7:  Metabolites showing significant differences between 
sated and starved states in fly hemolymph. Metabolite 
concentrations were normalized to total protein content, and then 
normalized to the sated sample. Each sample was run in 
triplicate. Unpaired two-tailed Students t tests were performed, 
and the Holm-Bonferroni correction was used. Data expressed as 
average ± SD. *p < 0.05; **p < 0.01; ***p < 0.001. 
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into serum to determine the relative recovery 
(Figure 3-8). The recovery varied for each 
tested metabolite, but was reproducible (RSD 
< 8%). As such, we concluded that fair 
comparison could be made between samples 
analyzed using this method, though 
comparisons to other methods would require 
correction for recovery. 
 
Conclusions 
 These results demonstrate the utility of BzCl derivatization with HPLC-MS/MS for 
targeted neurochemical metabolomics. Improvements to the benzoylation of small 
neurochemicals resulted in a comprehensive, robust, and quantitative method to monitor 70 
neurochemicals. This modified method improves sensitivity for compounds containing 1,2-diols 
and early eluting peaks such as acetylcholine, and was expanded to 4-fold more neurochemicals 
compared to prior studies. The method is suitable for multiple samples types, including CSF, 
serum, and tissue homogenate. 
 The results also indicate considerable potential for even wider use of BzCl as a MS 
labeling reagent. For example, the Michigan Regional Comprehensive Metabolomics Resource 
Core maintains a library of over 1,000 metabolites. Based on the reactivity of BzCl towards 
amines, phenols, thiols, and some alcohols, we estimate it could be used to label approximately 
25% of these compounds. BzCl labeling is fast and simple to implement. Benzoylation improves 
Figure 3-8: Recovery of four isotopically labeled 
metabolites spiked into plasma prior to solvent precipitation 
and derivatization. Percent recovery calculated as measured 
concentration after precipitation, relative to concentration 
spiked into serum. The average of three extraction replicates 
is shown. Error bars represent the standard error of the 
mean.  
72 
 
sensitivity, retention, and quantification via easily generated internal standards with few 
drawbacks compared to direct detection of analytes. 
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CHAPTER 4 
Plasma metabolomics with benzoyl chloride derivatization reveals metabolic effects of 
Parkinson's disease 
 
Introduction 
 Metabolomics can play an important role in understanding disease. In Chapters 2 and 3, 
we developed targeted metabolomic methods for neurochemicals in biological samples using 
benzoyl chloride (BzCl) derivatization. In this chapter, we explore the application of these 
methods to the study of Parkinson's disease (PD) with the goal of identifying metabolic 
perturbations resulting from the disease which may lead to the identification of putative 
biomarkers. 
 A biomarker is a measurable characteristic which is used to predict a biological outcome. 
Biomarkers can range from DNA sequences or specific patterns in brain scans to biomolecules 
such as proteins or metabolites.
1–3
 They can be used for diagnostic purposes or for risk 
prediction, e.g. likelihood to develop a disease. The ideal metabolite biomarker would be readily 
accessible, meaning minimally invasive measurement and at detectable concentrations. The 
biomarker must be sensitive enough to distinguish between diseased and control groups. 
Selectivity is required to distinguish one disease state from another. Additionally, a biomarker 
should be stable enough to not be influenced by external factors such as diet.
4,5
 
 Many studies are quick to define differential metabolites as "biomarkers," but further 
validation is required to establish metabolites as robust biomarkers, so these differential 
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metabolites are best thought of as putative biomarkers.
4,6
 Even identifying putative metabolite 
biomarkers can be challenging, however. The metabolome is susceptible to external influences, 
so finding a metabolite robust enough to avoid these influences is difficult. 
 With a hypothesis generating goal, metabolite biomarker identification is generally 
performed using untargeted methods.
4,5
 Some work has been done with "pseudotargeted" 
metabolomics, which will be described in more depth in Chapter 7.
7,8
 The limited scope of 
targeted methods can reduce the likelihood of discovering unexpected changes in metabolites, 
but the use of a "widely" targeted method, such as that described in Chapter 3, can increase the 
odds. The increased sensitivity afforded by BzCl derivatization adds the potential to identify 
changes in low abundance metabolites which may be overlooked by other methods. 
 In this chapter, we use BzCl metabolomics to investigate PD. PD is a neurodegenerative 
disease characterized by the death of dopamine neurons in the substantia nigra, along with the 
buildup of aggregates of α-synuclein, which are termed "Lewy bodies."9–12 Physical symptoms 
include rigidity, resting tremor, and postural instability. Cognitive decline and psychiatric 
disturbances are also common. Though some genes have been linked with hereditary PD, the 
exact cause remains unknown.
13–15
 Despite the fact that PD is the second most prevalent 
neurodegenerative disease, it is not well understood and diagnosis relies heavily on clinical 
measures and response to treatment.
16
 
 The discovery of biomarkers for PD could serve many purposes. A predictive biomarker 
would inform patients of their risk of developing the disease, and could help elucidate the cause 
of PD. A sensitive, diagnostic biomarker could allow for earlier, more accurate diagnosis, 
allowing for appropriate treatment before symptoms become severe. Thus, there is significant 
interest in identifying biomarkers for PD. The Michael J. Fox Foundation (MJFF) for Parkinson's 
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Research sponsors several studies for furthering the understanding of PD, including the BioFIND 
project.
17
 
 The BioFIND project is a collaborative study across academic sites intended to 
compliment its clinical counterpart, the Parkinson's Progression Markers Initiative.
18
 Clinical 
samples are provided to researchers across various sites to search for putative biomarkers. 
Available samples include DNA, plasma, urine, and cerebrospinal fluid (CSF), and as a multi-
site collaborative project, a variety of techniques can be used to screen for biomarkers. The work 
in this chapter was performed as part of the BioFIND project, with the goal of identifying 
metabolites which are correlated with PD. Plasma samples were used, which unlike CSF, is 
easily collected, and unlike urine, does not require normalization. These factors make plasma a 
convenient matrix for diagnostic purposes. 
 We used the 70 compound method described in Chapter 3 as an initial screen for this 
study. It was observed that many of these metabolites were either undetected or showed no 
change between groups. Most of the metabolites which differed between groups were outside of 
the calibration range. Based on these results, we developed a more specific method with a faster 
analysis time and a suitable calibration range for the samples. For this method, we chose to focus 
on polyamines,
19–21
 dopamine metabolites,
22–24
 and homocysteine metabolites,
25–27
 which 
showed differences in the initial screen and have all been previously implicated in PD. These 
results were used to identify metabolic differences in the plasma of PD patients and healthy 
controls. 
 
Experimental 
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 Clinical data used in this study were obtained from the Fox Investigation for New 
Discovery of Biomarkers (BioFIND) database. For up-to-date information on the study, visit 
www.michaeljfox.org/biofind. 
 
Chemicals and reagents 
 All chemicals were purchased from Sigma Aldrich (St. Louis, MO) unless otherwise 
noted. Water and acetonitrile are Burdick & Jackson HPLC grade from VWR (Radnor, PA). 
Stock solutions were prepared of 50 mM Arg, Cit, Met, Orn (Acros Organix, Geel, Belgium), 
Phe; 10 mM 3-OMD (MP Biomedicals, Santa Ana, CA), βAla, DOPAC (Acros Organics), HCY, 
HVA (Tocris, Bristol, UK), Spm; 5 mM 3MT, Agm, DA, DOPA, NAP, NE, Put, Spd, TyrA; 2 
mM Tyr in HPLC water and stored at -80 °C. A standard mixture was prepared in artificial 
cerebrospinal fluid (aCSF) consisting of 145 mM NaCl, 2.68 mM KCl, 1.4 mM CaCl2, 1 mM 
MgSO4, 1.55 mM Na2HPO4, and 0.45 mM NaH2PO3 adjusted to pH 7.4 with NaOH. Calibration 
standards and internal standards were prepared as described previously.
28
 Single use aliquots of 
each were stored at -80 °C. On the day of use, an internal standard aliquot was thawed and 
diluted 100-fold in 20% (v/v) acetonitrile containing 1% (v/v) sulfuric acid. This mixture is 
referred to as the internal standard solution. A fresh BzCl solution was prepared daily. 
 
QC sample preparation 
 Pooled human serum from the American Red Cross Detroit National Testing Lab was 
provided by the Michigan Regional Comprehensive Metabolomics Resource Core (MRC
2
). To 
ensure all targeted metabolites were detectable in the serum, select standards were spiked in to a 
final concentration of 2.5 µM for HCY, HVA, DOPA; 500 nM for 3-OMD; 250 nM for DOPAC; 
79 
 
125 nM for TyrA; 25 nM for Agm, 3MT, NE, and DA. Single use aliquots of the spiked serum 
were prepared and stored at -80 °C. On the day of use, a 10 µL aliquot of spiked serum was 
thawed, and 40 µL of ice cold acetonitrile were added to precipitate proteins. The mixture was 
vortexed briefly, and centrifuged for 10 min at 12,100g. 40 µL of supernatant were transferred to 
an HPLC autosampler vial, and derivatized by sequential addition of 20 µL 100 mM sodium 
carbonate, 20 µL 2% (v/v) BzCl in acetonitrile, 20 µL internal standard solution, and 100 µL 
water. The derivatized QC sample was run every 10 injections. 
 
Plasma sample preparation 
 Plasma from healthy controls (n = 76) and PD patients (n = 98) was provided by the 
BioFIND Project of the Michael J. Fox Foundation. Demographics for the patients are listed in 
Table 1. Plasma was collected in the early morning prior to medication, following a fasting 
period of at least 8 hours. Upon receipt, plasma was stored at -80 °C until use. On the day of use, 
40 µL of ice cold acetonitrile were added to 10 µL of plasma. After vortexing, the mixture was 
centrifuged for 10 min at 12,100g. 20 µL of the supernatant were transferred to an HPLC 
autosampler vial, and derivatized by sequential addition of 10 µL 100 mM sodium carbonate, 10 
µL 2% (v/v) BzCl in acetonitrile, 10 µL internal standard solution, and 100 µL water. Calibration  
 
Diagnosis Gender 
Age 
Range 
# 
Samples 
HC 
F 55-82 37 
M 55-84 39 
PD 
F 55-82 35 
M 57-81 63 
Table 4-1:  Sample demographics for healthy controls (HC) and Parkinson's patients (PD) used in this study. 
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standards were prepared in aCSF and diluted in acetonitrile to match the solvent composition of 
the plasma samples. Standards were derivatized in the same manner as the plasma. A new 
calibration was prepared each day. Derivatized plasma was analyzed in triplicate. Researchers 
were blinded to sample identity until all data collection was completed. 
 
LC-MS analysis 
 Derivatized samples were analyzed using a Waters nanoAcquity UPLC (Milford, MA) 
coupled to an Agilent 6410B triple quadrupole mass spectrometer (Santa Clara, CA) operating in 
dynamic MRM mode. An example chromatogram is shown in Figure 4-1. The injection volume 
was 5 µL. An Acquity UPLC HSS T3 C18 column (100 x 1 mM, 1.8 µM, 100 Å) was used. 
Mobile phase A was 10 mM ammonium formate with 0.15% formic acid in water, and mobile 
phase B was acetonitrile. The flow rate was 100 µL/min, and the gradient was:  Initial, 0% B; 0.1 
min, 25% B; 1.5 min, 26% B; 1.51 min, 49% B; 4.00 min, 49% B; 4.01 min, 68% B; 4.99 min, 
68% B; 5.00 min, 100% B; 6.00 min, 100% B; 6.01 min, 0% B; 8 min, 0% B. The autosampler  
was kept at ambient temperature, 
and the column was at 27 °C. 
Electrospray ionization was used 
in positive ion mode at 4 kV. The 
gas temperature was 350 °C, gas 
flow was 11 L/min, and nebulizer 
was at 15 psi. MRM conditions are 
listed in Table 2. Automated peak 
integration was performed using  Figure 4-1:  Extracted ion chromatogram of Parkinson's related 
metabolites in standard solution. Gradient is overlaid as % B. 
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Metabolite 
Precursor Product Fragmentor Collision Energy Retention Time 
(m/z) (m/z) (V) (V) (min) 
Bz-3MT 376 105 
120 20 5.78 13
C6-Bz-3MT 388 111 
Bz-3OMD 420 105 
140 30 4.63 13
C6-Bz -3OMD 432 111 
Bz-Agm 235 105 
110 30 2.24 13
C6-Bz -Agm 241 111 
Bz-Arg 279 105 
135 30 2.09 13
C6-Bz -Arg 285 111 
Bz-B-Ala 194 105 
120 20 2.53 13
C6-Bz -B-Ala 200 111 
Bz-Cit 280 105 
120 20 2.23 13
C6-Bz -Cit 286 111 
Bz-Cys 330 105 
120 20 3.81 13
C6-Bz -Cys 342 111 
Bz-DA 466 105 
140 20 6.44 13
C6-Bz -DA 484 111 
Bz-DOPAC 394 105 
140 20 5.65 13
C6-Bz -DOPAC 406 111 
Bz-HCY 344 105 
120 20 4.23 13
C6-Bz -HCY 356 111 
Bz-HVA 304 105 
120 15 4.37 13
C6-Bz -HVA 310 111 
Bz-LDOPA 510 360 
120 30 5.71 13
C6-Bz -LDOPA 528 372 
Bz-Met 254 105 
120 15 3.33 13
C6-Bz -Met 260 111 
Bz-NAP 235 105 
135 20 2.59 13
C6-Bz -NAP 241 111 
Bz-NE 482 105 
140 30 5.8 13
C6-Bz -NE 500 111 
Bz-Orn 341 174 
120 15 3.31 13
C6-Bz -Orn 353 180 
Bz-Phe 270 120 
120 10 3.6 13
C6-Bz -Phe 276 120 
Bz-Put 297 105 
120 30 3.5 13
C6-Bz -Put 309 111 
Bz-Spd 458 162 
120 30 3.84 13
C6-Bz -Spd 476 168 
Bz-Spm 619.6 497.2 
135 25 4.21 13
C6-Bz -Spm 643.6 515.2 
Bz-TyrA 346 105 
135 25 5.83 13
C6-Bz -TyrA 358 111 
Bz-Tyr 390 105 
120 30 4.69 13
C6-Bz -Tyr 402 111 
Table 4-2:  MRM conditions for benzoylated metabolites and internal standards. Cell accelerator voltage was at 4 V for all 
metabolites. 
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Agilent MassHunter Workstation Quantitative Analysis for QQQ, version B.05.00. All peaks 
were manually inspected to ensure proper integration. Calibration curves were prepared using the 
ratio of analyte peak area to internal standard peak area. 
 
Data processing 
 Calculated concentrations were corrected for day-to-day variability using the average of 
the QC concentration that day relative to the overall average of all QC samples. No correction 
was performed for intra-day variability, as little variance was observed in same-day QC samples. 
Limits of detection (LOD) were calculated from triplicate calibrations using Armbruster's 
method.
29
 Results from triplicate analysis were averaged, and values below the LOD were 
discarded and imputed with half the LOD. 
 
Statistical analysis 
 Unpaired, two-tailed Student's t-tests and single factor ANOVA were performed in 
Microsoft Office Excel 2007, and differences were deemed significant if P ≤ 0.05, subject to 
Holm-Bonferroni correction.  
 
Results and discussion 
Figures of merit 
 LODs and linearity were calculated from six point calibrations in aqueous standards 
diluted in acetonitrile. Relative standard deviations (RSD) were calculated for QC standards to 
show both intra- and inter-day repeatability (Table 3). These LODs are higher than those 
reported for similar BzCl methods using aqueous dialysate samples, but are comparable to LODs 
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previously reported for other proteinaceous samples.
28,30
 All metabolites produced linear 
calibration curves (R
2
 ≥ 0.99). 
 Intra- and inter-day reproducibility was determined as the RSD of the calculated 
concentration in the QC samples. For each day, the RSD for all QC runs (n = 7-13) was 
calculated. The average intra-day RSD over the six days of analysis was below 10% for each 
metabolite. Inter-day reproducibility was calculated for all QC runs (n = 60) over the course of 
the experiment. RSDs were below 10% for all but eight metabolites, and all RSDs were below 
20%. 
Metabolite 
LOD Linearity Repeatability (%) 
(nM) (R
2
) Intra-day Inter-day 
Arg 100 0.999 4.04 10.9 
Agm 0.5 0.999 6.39 11.7 
Cit 200 0.999 1.92 11 
BAla 30 0.999 8.36 16.4 
NAP 2 0.999 3.78 6.4 
Orn 50 0.999 1.53 9.51 
Met 500 0.999 1.25 4.58 
Put 1 0.997 4.81 10.2 
Phe 1000 0.999 2.89 4.58 
Cys 20 0.998 2.34 10.5 
Spd 0.5 0.998 2.33 8.28 
Spm 1 0.994 4.04 11.4 
HCY 40 0.998 3.87 10.7 
HVA 30 0.999 2.51 5.17 
3OMD 10 0.999 4.13 5.3 
Tyr 400 0.999 1.86 3.19 
DOPAC 20 0.996 3.75 6.56 
DOPA 100 0.996 5.67 10.2 
3MT 1 0.999 5.06 6.56 
NE 1 0.999 5.42 6.64 
TyrA 5 0.999 1.6 4.39 
DA 2 0.998 3.26 9.96 
Table 4-3:  Figures of merit for the method. LODs were calculated from triplicate calibration curves. Linearity as R2 was 
calculated from the same calibrations. Repeatability was calculated as the RSD of calculated QC concentrations over each day 
and over the entire course of the experiment.  
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Metabolite differences between healthy controls and PD patients 
 Significant increases in β-alanine, N-acetylputrescine, putrescine, HVA, and 3-OMD 
were observed in the plasma of PD patients relative to controls (Figure 4-2). None of the 
metabolites assayed were found to decrease in PD patients. Polyamines, especially putrescine, 
spermidine, and spermine, have been previously implicated in PD.
19–21
 Expression of the 
catabolic enzyme, spermidine/spermine N1-acetyl-transferase (SAT1) was found to be decreased 
in the dorsal motor nucleus of the vagus (DMNV) in PD.
20
 In the periphery, polyamines were 
found to be increased in red blood cells of PD patients.
19
 Serum levels of N8-acetylspermidine 
were found to be increased in rapidly progressing PD.
21
 The effect on other plasma polyamines 
in PD has not yet been reported. Here, we observed no significant difference in spermidine or 
spermine, but putrescine and N-acetylputrescine were increased in PD patients, further 
confirming that polyamines are implicated in PD. Polyamines are essential to development and 
have been shown to have both neuroprotective and neurotoxic effects,
20,31,32
 so the exact role of 
polyamines in PD and other neurodegenerative diseases remains under investigation.  
 β-Alanine is involved in the production of carnosine, an antioxidative neuropeptide which 
is reported to increase PD treatment efficacy.
33,34
 Additionally, β-alanine is a side product of 
polyamine metabolism. The reactive aldehyde 3-aminopropanal is produced when spermine 
oxidase (SMOX) converts spermine back to spermidine. 3-Aminopropanal can then be converted 
to β-alanine via aldehyde dehydrogenase. Reactive aldehydes have been found to play a role in 
neurodegenerative diseases, and 3-aminopropanal specifically is known to cause neuronal cell 
death.
35,36
 It is unclear why this increase in β-alanine is observed, but the connection to carnosine 
and polyamines support that β-alanine is somehow implicated in PD. 
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 We observed a significant increase in plasma homovanillic acid (HVA) in PD patients 
relative to healthy controls. HVA is a metabolite of dopamine, and is decreased in the CSF of PD 
patients.
37
 Currently, the main treatment for PD is dopamine replacement therapy via its 
precursor, L-DOPA. Dopamine cannot cross the blood-brain barrier, but L-DOPA can; as a 
result, taking L-DOPA orally can increase dopamine concentrations in the brain. L-DOPA is also 
metabolized in the periphery, leading to a reported increase of HVA in the plasma of L-DOPA 
treated PD patients.
24
 No increase in HVA has been observed in the plasma of PD patients prior 
to or withdrawn from L-DOPA treatment.
23
 Our data supports these trends; the majority of the 
PD patients in this study were treated with L-DOPA, and a significant increase in plasma HVA 
was observed in PD patients relative to healthy controls. 
 3-O-Methyldopa (3-OMD) was also found to be elevated in PD patients relative to 
healthy controls. 3-OMD is a major metabolite of L-DOPA via catechol-O-methyl transferase 
(COMT). L-DOPA has a half life of roughly two hours in plasma, so increases are short-lived 
Figure 4-2:  Plasma metabolite concentrations between healthy controls (HC, n = 76) and Parkinson's patients (PD, n = 98). 
Each point represents an individual, and the line is at the mean. The Holm-Bonferroni correction was used for statistics. * p ≤ 
0.05; ** p ≤ 0.01; *** p ≤ 0.001. 
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and may not be observed depending on sampling time frame.
38
 3-OMD, on the other hand, has a 
much longer half life, so increases in 3-OMD can reflect an earlier increase in L-DOPA. The 
majority of the PD patients were treated with L-DOPA, so this likely explains the increase in 3-
OMD. 
 No increase in homocysteine was observed in PD patients. Homocysteine is part of a 
metabolic cycle with S-adensoylmethionine (SAM), which acts as a methyl transferase in the 
conversion of L-DOPA to 3-OMD. Increases in the plasma of PD patients treated with L-DOPA 
have been reported.
25–27
 The patients in this study were withdrawn from their most recent 
treatments prior to plasma sampling. The effect of L-DOPA withdrawal on homocysteine levels 
has not been established. If homocysteine levels return to normal after L-DOPA withdrawal, this 
would explain why no change was observed in this study. 
 
Metabolite correlations to Hoehn and Yahr score 
 The Hoehn and Yahr (HY) scale is a means of ranking PD severity based on specific 
clinical criteria.
9
 A HY score is assigned following assessment of the patient for the presence and 
severity of a variety of PD symptoms by a physician. A higher HY score corresponds to more 
severe PD. In this study, the most severe PD cases corresponded to an HY score of 4. Single 
factor ANOVA was used to compare each HY score to healthy controls. Of the 22 metabolites 
studied, 13 were found to be elevated in at least one group of PD patients separated by HY score. 
These include putrescine, N-acetylputresceine, β-alanine, HVA, and 3-OMD, as well as 
ornithine, spermidine, DOPAC, DOPA, 3MT, norepinephrine, tyramine, and dopamine (Figure 
4-3). All of these except ornithine, were elevated in the most severe PD cases (HY = 4) relative 
to healthy controls.  
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Figure 4-3:  Metabolite concentrations as a function of Hoehn and Yahr (HY) score. A score of 0 corresponds to healthy 
controls (HC, n = 76), and a higher score corresponds to increasing disease severity (1, n = 8; 2, n = 69; 3, n = 16; 4, n = 5). 
Each point corresponds to an individual, and the line is at the mean. Single factor ANOVA was used with post hoc Holm-
Bonferroni correction.  * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. 
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 Ornithine is a precursor to the polyamines. Elevated plasma concentrations of putrescine 
and N-acetylputrescine in this work already suggests polyamines are implicated in PD and this 
elevation in ornithine relative to healthy controls further supports the hypothesis. Although 
ornithine trends towards upregulated in HY = 4 PD patients, the difference was not significant, 
most likely due to the small sample size (n = 5) relative to healthy controls (n = 76). Spermidine, 
another polyamine, was found to be elevated in the most severe PD cases. Although many of the 
polyamines were elevated in PD, this was not observed with spermine, a metabolite of 
spermidine. A decrease in spermine synthase could explain these results, but an increase in 
spermine oxidase (SMOX) activity could also lead to an increase in spermidine. 
 While L-DOPA has a relatively short half-life, high doses administered for severe PD 
could lead to detectable levels of L-DOPA even after withdrawal from treatment. As such, L-
DOPA was below the LOD for all healthy controls, but was increasingly detected in PD patients 
with increasing disease severity. Dopamine is a direct metabolite of L-DOPA, and DOPAC, 
3MT, and norepinephrine are metabolites of dopamine via various catabolic enzymes. It is 
unsurprising that these metabolites are elevated following peripheral treatment with L-DOPA. 
 Tyramine is a naturally occurring trace amine in humans that is a particular concern in 
PD patients. Monoamine oxidase (MAO) inhibitors are common treatments for PD to prevent 
premature catabolism of dopamine. MAO is one of the primary catabolic enzymes for tyramine, 
so inhibitors can lead to a build-up of tyramine in PD patients. This can lead to hypertensive 
crisis and potentially death, so care must be taken to avoid dietary excess of tyramine. As 
medication doses increase with PD severity, it is not unexpected that tyramine catabolism would 
be reduced, explaining the observed increase in severe PD. 
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Metabolite correlation to L-DOPA treatment 
 As has been noted, several of the metabolite increases in PD can be explained as a result 
of L-DOPA treatment. The majority of PD patients tested in this study were taking L-DOPA, but 
a small number were not. To investigate whether L-DOPA treatment was linked to these 
changes, we compared metabolite concentrations between healthy controls (n = 76), PD patients 
without L-DOPA treatment (PD - DOPA, n = 10), and PD patients with L-DOPA treatment (PD 
+ DOPA, n = 88). Using single-factor ANOVA, we found that in addition to the five metabolites 
which were different between healthy controls and PD patients as a whole, ornithine was 
significantly increased in PD + DOPA patients relative to healthy controls (Figure 4-4). 
However, no metabolites were found to be significantly different between healthy controls and 
PD - DOPA patients. 
 The link between L-DOPA treatment to increases in 3-OMD and HVA is straightforward, 
as 3-OMD is a direct metabolite and HVA is a metabolite of dopamine, for which L-DOPA is a 
precursor. The connection between L-DOPA and the increased polyamine concentrations is less 
clear. One study reported an increase in putrescine in the brain and liver of rats treated with L-
DOPA.
39
 The mechanism for this increase 
was unclear, but an increase in ornithine 
decarboxylase (ODC), which converts 
ornithine to putrescine, was proposed. An 
increase in ODC would explain the increase 
in putrescine and N-acetylputrescine observed 
in our results, but would not explain the 
observed increase in ornithine. There is no 
Figure 4-4:  Ornithine concentration in healthy controls 
(HC, n = 76), Parkinson's patients not treated with L-DOPA 
(PD - DOPA, n - 10), and Parkinson's patients treated with 
L-DOPA (PD + DOPA, n = 88). Each point represents and 
individual, and the line is at the mean. The Holm-Bonferroni 
correction was used.  * p ≤ 0.05. 
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direct metabolic link between L-DOPA and ornithine or other urea cycle metabolites, so further 
investigation is needed to explain this finding.  
 We compared metabolite concentrations in PD + DOPA patients to total daily L-DOPA 
dosage (Figure 4-5). Unsurprisingly, the direct metabolite 3-OMD was found to be correlated to 
L-DOPA dosage. However, no other metabolites were found to be dependent on L-DOPA 
dosage. This observation suggests a more complex mechanism for their increase than simply by-
products of L-DOPA metabolism. Additionally, slight trends were observed in the PD-D samples 
compared to healthy controls which were not statistically significant due to the small sample 
size, but could be significant if a larger body of untreated samples was analyzed. 
 These findings illustrate an interesting challenge in studying PD. Response to L-DOPA 
treatment is typically a factor in diagnosing PD, so it is uncommon to have samples from 
untreated patients. Indeed, many investigations have a relatively small set of untreated patients 
relative to treated or treatment-withdrawn patients.
23–26
 To deconvolute effects of the disease 
from effects of treatment, larger cohorts of untreated patients will need to be compared to healthy 
controls. The information from treated patients still has value, however. Long term treatment 
with L-DOPA causes debilitating dyskinesias which are not yet fully understood.
40,41
 Gaining 
insight of the molecular mechanism leading to this could allow for treatment or even prevention 
of L-DOPA induced dyskinesia. 
 
Conclusions 
 Dopamine metabolism, as well as polyamine and homocysteine metabolism are 
frequently implicated in the study of PD. The effect of PD on these metabolites in the periphery 
(i.e. plasma) has not been well studied; targeted metabolomic methods are often used which  
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focus on a select few metabolites. We have developed a targeted method for 22 metabolites 
across these metabolic pathways to provide a more complete insight into these pathways. BzCl 
derivatization was used to increase retention and sensitivity of these metabolites in reversed 
Figure 4-5:  Metabolite concentrations as a function of total L-DOPA daily dose. Each point corresponds to an individual (n 
= 80). ANOVA was used to calcul te linear fit. *** p ≤ 0.001. 
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phase chromatography, as well as to easily create internal standards for each targeted metabolite. 
Internal standards account for instrument drift and matrix effects, leading to better quantification 
of metabolites. 
 Five metabolites were found to be significantly increased in PD patients relative to 
healthy controls. Seven more were significant when comparing healthy controls to only the most 
severe PD cases in this study. None of these implicated metabolites were found to be 
significantly elevated in PD patients who were not treated with L-DOPA, though this may be due 
to the limited availability of samples from untreated PD patients. Only 3-OMD was found to 
correlate to L-DOPA in a dose-dependent manner, which suggests the observed metabolite 
increases are more than just a byproduct of increased L-DOPA metabolism. A larger sample set 
from untreated PD patients could help confirm this hypothesis. 
  While the effects of PD alone on the plasma metabolome have been obscured by L-
DOPA, the results are not without value. L-DOPA has negative side effects, ranging from 
drowsiness and gastrointestinal distress to dyskinesias with long term treatment. By determining 
the metabolic effects of L-DOPA treatment, it may be possible to identify specific causes of 
these side effects. Co-therapies may be developed to minimize or eliminate the negative effects 
while maintaining the therapeutic potential of L-DOPA. Diagnostic biomarkers for PD could not 
be identified in this study, however, demonstrating the need for tightly controlled studies for 
biomarker discovery. 
 While we chose to focus on dopamine, polyamine, and homocysteine metabolism for this 
work, BzCl derivatization has previously been demonstrated for 70 metabolites across a wide 
variety of metabolic pathways.
28
 Dansyl chloride, a derivatization reagent with similar reactivity 
to BzCl, has been used for untargeted metabolomics to cover an even larger number of 
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metabolites and has recently been used to evaluate metabolic changes associated with PD.
42,43
 
This method could be expanded to cover more metabolites and could easily be adapted to 
investigate many other neurological disorders. 
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CHAPTER 5 
Determination of amines and phenolic acids in wine with benzoyl chloride derivatization 
and liquid chromatography - mass spectrometry 
Reproduced in part from (Malec et al. 2017). Copyright 2017 Elsevier. 
 
Introduction 
 Consumers, regulators, and producers are increasingly interested in obtaining information 
on the characteristics and the quality of food products.
1
 This interest has spawned development 
of a wide variety of methods for analyzing consumable goods (e.g., wine, honey, tea, olive oil 
and juices).
2
 With respect to wine, various national organizations require strict control over 
factors such as geographical origin and grape varieties to maintain consistency and quality.
3
 Thus, 
characterization methods are required to assess authenticity and detect wine fraud. Separation 
techniques such as LC and GC have been widely used for wine characterization and 
classification. Two important families of LC-amenable wine components are phenols and 
biogenic amines. Compositional profiles of phenolic and/or amino species have been correlated 
with significant factors such as organoleptic properties, wine-making practices, and grape 
varieties.
4,5
 In this work, we describe a new approach to assay of phenols and amines in wine 
using derivatization followed by LC-MS/MS for separation and quantification. 
 Phenols are a family of bioactive compounds found in wine that have drawn significant 
attention over the last few years. These aromatic secondary metabolites are ubiquitous in the 
plant kingdom. They comprise a complex family of more than 8,000 substances with highly 
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diverse structures and sizes from <100 Da to >30,000 Da for highly polymerized polyphenolic 
species. The main reasons for the interest in phenols are their antioxidant properties, great 
abundance in our diet, probable role in the prevention of various diseases, and contribution to 
sensorial properties.
6–8
 Wine is an excellent natural source of various phenols that range from 
phenolic acids like benzoic- or cinnamic-like derivatives to different classes of polyphenolic 
flavonoids such as flavones, flavan-3-ols, flavonols and anthocyanins.
9
 For this reason, analytical 
methods such as comprehensive LC techniques have been exploited over the last few years 
especially to quantify phenols in wine.
10–12
 
 In addition to phenols, biogenic amines have also been the subject of some studies.
13–18
 
Some of the biogenic amines usually found in wines are agmatine, spermine, spermidine, 
putrescine, cadaverine, histamine, and tyramine. These compounds are all produced by 
microorganisms during fermentation via decarboxylation of free amino acids. The consumption 
of some of them, e.g., histamine and tyramine, can lead to headaches, nausea, hot flushes, skin 
rashes, sweating, respiratory distress, and cardiac/intestinal problems
19
 Because these 
components may be responsible for the biological responses to wine consumption, their 
measurement in different wine varieties of various origins has great importance. 
 LC with UV detection has been widely used for the determination of amines and phenolic 
compounds in wine and other beverages. Phenols can be detected in their native state,
11,20–22
 
while amines require derivatization to be compatible with UV detection.
23–26
 Although these 
methods are adequate for measuring a few metabolites, the limited selectivity makes it difficult 
to characterize a large (e.g., 20+) panel of metabolites, especially in complex mixtures. Mass 
spectrometry (MS) detection offers a way to overcome these limitations. MS has much better 
selectivity than UV detection, making it possible to distinguish many more metabolites, even co-
98 
 
eluting compounds, in complex mixtures. Using tandem mass spectrometry (MS/MS) allows for 
greater confidence in peak identification from unique fragmentation patterns. Additionally, 
MS/MS is more sensitive than UV, allowing for the measurement of trace metabolites which 
may not be detected with UV. Mass spectrometry does suffer from instrument drift and matrix 
effects, but this problem can be corrected through the use of internal standards labeled with 
stable isotopes. 
 Some work has been done for the analysis of native amines and phenolic compounds in 
wine with LC-MS.
12,27–29
 However, there are still challenges which much be addressed. Polar 
amines are poorly retained with reversed phase chromatography, and sensitivity for some trace 
metabolites may still be limiting. Some of the same derivatization techniques used in UV 
detection of amines can be beneficial to mass spectrometry and help overcome these challenges. 
Tagging metabolites with a hydrophobic moiety increases retention of polar metabolites, while 
also increasing ESI ionization efficiency up to 10,000-fold.
30,31
 Additionally, derivatization 
makes it easy to generate internal standards for each targeted metabolite through the use of stable 
isotope labeled derivatizing reagents. Labeling improves quantification by accounting for 
instrument drift and matrix effects, and can aid in peak selection in the presence of background 
peaks and retention time drift. 
 Several reagents have been reported that have use for amines and phenols by LC-MS. 
Derivatization with 1,2-naphthoquinone-4-sulfonate has been used with LC-MS for wine 
analysis previously.
17
 Dansyl chloride derivatization has been used in wine for LC-UV 
analysis.
24
 This same reagent has recently been promoted for the determination of phenols and 
amine metabolites with LC-MS in a variety of samples including urine, cerebrospinal fluid, and 
plasma.
31–34
 Benzoyl chloride (BzCl) has also been used for LC-UV
35–38
 as well as LC-MS.
30,39
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Like dansyl chloride, this reagent reacts with amines, phenols, and some hydroxyls. BzCl may 
have advantages, though, over other reagents for food analysis. The reaction is near 
instantaneous at room temperature and produces photostable derivatives.
30,39
 Furthermore, 
13
C 
labeled reagent is readily available at a reasonable cost enabling routine creation of internal 
standards for all analytes. Here, we demonstrate the application of BzCl derivatization with LC-
MS/MS for determination of 56 amine and phenol metabolites in wine. To our knowledge, this 
method is unique in its capability to measure both amines and phenols in wine in a single, quick 
assay. Furthermore, the method assays a much larger panel of compounds than other methods, is 
shown to provide accurate quantitative data, and may enable distinguishing of varietals and 
location of production for wine. 
 
Experimental 
Chemicals and reagents 
 All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise 
noted. Water and acetonitrile were Burdick & Jackson HPLC grade purchased from VWR 
(Radnor, PA). Stock solutions of 2 M Glc; 1 M Ch; 50 mM Pro; 10 mM ACh, Ala, Arg, Asn, 
Asp, βAla, Cad, Cit, Cys, DA, DOMA, DOPA, DOPAC (Acros Organics, Geel, Belgium), 
DOPEG, ETA, GABA, Gln, Glu, Gly, His, Hist, HVA (Tocris, Bristol, UK), Leu, Lys, Met, 
MOPEG, NAP, Orn (Acros Organics, Geel, Belgium), Phe, PhEt (MP Biomedicals, Santa Ana, 
CA), Put, Ser, Spd, Spm, Tau, Thr, TyrA Val, VMA; 5 mM Ado, Trp; 2 mM Tyr; 250 μM TrpA, 
and 20 nM d4-ACh and d4-Ch (C/D/N Isotopes, Pointe-Claire, Canada) were prepared in water 
and stored at -80 °C. Stock solutions of 10 mM Caf, Cou (TCI Chemicals, Philadelphia, PA), Fer, 
Gal (Acros Organics, Geel, Belgium), PCA, Sin, TOH, VA, and VN were prepared in ethanol 
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and stored at -20 °C. Wine was purchased from a local retailer. The varietals selected were 
Cabernet Sauvignon and Merlot, each from California and Australia. 
 A standard mixture was prepared in water for use in calibration standards. Preparation of 
calibration standards and internal standards has previously been described.
30,39
 Calibration ranges 
for each metabolite are listed in Table 5-1. Single-use aliquots of calibration standards and 
internal standards were prepared and stored at -80 °C. On the day of use, an internal standard 
aliquot was thawed, diluted 100-fold in 20% (v/v) acetonitrile containing 1% (v/v) sulfuric acid, 
and spiked with deuterated acetylcholine and choline to a final concentration of 20 nM. A fresh 
BzCl solution was prepared daily.  
 
Sample preparation and derivatization 
 Three aliquots of 500 μL from each wine sample were filtered through Amicon Ultra spin 
filters (30k MWCO, Millipore Sigma, Billerica, MA) by centrifugation for 5 min at 12,100 g. 
The filtered wine was diluted 10-fold in water. Filtered, diluted wine was derivatized by 
sequential addition of 10 μL 100 mM sodium carbonate, 10 μL 2% (v/v) BzCl in acetonitrile, 
and 10 μL internal standard solution. Calibration standards were prepared in water and 
derivatized in the same manner.  
 
Metabolite analysis by LC-MS/MS 
 Analysis was performed using a Waters (Milford, MA) nanoAcquity UPLC. An Acquity 
HSS T3 C18 column (1 mm x 100 mm, 1.8 μm, 100 Å pore size) was used. The autosampler was 
kept at ambient temperature, and the column was kept at 27 °C. The injection size was 5 μL 
using partial loop injection mode. Mobile phase A was 10 mM ammonium formate with 0.15% 
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formic acid. Mobile phase B was acetonitrile. The flow rate was 100 μL/min, and the gradient 
used was:  initial, 0% B; 0.01 min, 15% B; 0.5 min, 17% B; 14 min, 55% B; 14.5 min, 70% B; 
18 min, 100% B; 19 min, 100% B; 19.1 min, 0% B; 20 min, 0% B. A 10 minute re-equilibration 
period followed each injection. 
Compound Calibration Range (μM) Compound Calibration Range (μM) 
ACh 0.0025 - 0.5 Hist 0.05 - 10 
Ado 0.00025 - 0.05 HVA 0.005 - 1 
Agm 0.0005 - 0.1 Leu 0.25 - 50 
Ala 0.25 - 50 Lys 0.1 - 20 
Arg 0.1 - 20 Met 0.025 - 5 
Asn 0.05 - 10 MOPEG 0.00025 - 0.05 
Asp 0.1 - 20 NAP 0.0025 - 0.5 
βAla 0.025 - 5 Orn 0.025 - 5 
Cad 0.005 - 1 PCA 0.025 - 5 
Caf 0.025 - 5 Phe 0.05 - 10 
Ch 0.25 - 50 PhEt 0.005 - 1 
Cit 0.005 - 1 Pro 10 - 2000 
Cou 0.025 - 5 Put 0.05 - 10 
Cys 0.0005 - 0.1 Ser 0.05 - 10 
DA 0.00025 - 0.05 Sin 0.0005 - 0.1 
DOMA 0.00025 - 0.05 Spd 0.0025 - 0.5 
DOPA 0.00025 - 0.05 Spm 0.00025 - 0.05 
DOPAC 0.00025 - 0.05 Tau 0.0025 - 0.5 
DOPEG 0.00025 - 0.05 Thr 0.025 - 5 
ETA 0.1 - 20 TOH 0.25 - 50 
Fer 0.25 - 50 Trp 0.005 - 1 
GABA 0.1 - 20 TrpA 0.0001 - 0.02 
Gal 0.25 - 50 Tyr 0.025 - 5 
Glc 5 - 1000 TyrA 0.025 - 5 
Gln 0.0005 - 0.1 VA 0.025 - 5 
Glu 0.25 - 50 Val 0.05 - 10 
Gly 0.25 - 50 VMA 0.00025 - 0.05 
His 0.0005 - 0.1 VN 0.0025 - 0.5 
Table 5-1:  Calibration ranges for each metabolite. 
 
 Detection was performed on an Agilent (Santa Clara, CA) 6410B triple quadrupole mass 
spectrometer in dynamic multiple reaction monitoring (dMRM) mode. Electrospray ionization 
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was used in positive mode at 4 kV. The gas temperature was 350 °C, gas flow was 11 L/min, and 
the nebulizer was at 15 psi. MRM conditions are listed in Table 5-2. Peak integration was 
performed using Agilent MassHunter Quantitative Analysis for QQQ, version B.05.00. All peaks 
were visually inspected to ensure proper integration. 
      
Compound 
Precursor Product Fragmentor Collision Energy Retention Time 
(m/z) (m/z) (V) (V) (min) 
Ch 104 60 120 20 1.25 
  108 60 120 20 1.25 
ACh 146 87 120 15 1.37 
  150 91 120 15 1.37 
Bz-His 260 110 130 20 2.44 
  266 110 130 20 2.44 
Bz-Tau 230 105 120 10 2.57 
  236 111 120 10 2.57 
Bz-Arg 279 105 135 30 2.61 
  285 111 135 30 2.61 
Bz-Hist 216 105 120 20 2.65 
  222 111 120 20 2.65 
Bz-Asn 237 105 120 20 2.66 
  243 111 120 20 2.66 
Bz-Gln 251 105 120 20 2.76 
  257 111 120 20 2.76 
Bz-Ser 210 105 120 20 2.78 
  216 111 120 20 2.78 
Bz-Cit 280 105 120 20 2.89 
  286 111 120 20 2.89 
Bz-Agm 235 176 110 30 2.96 
  241 182 110 30 2.96 
Bz-Asp 238 105 120 10 2.97 
  244 111 120 10 2.97 
Bz-ETA 166 105 120 20 2.97 
  172 111 120 20 2.97 
Bz-Glc 307 185 130 20 3.07 
  313 185 130 20 3.07 
Bz-Gly 180 105 120 10 3.1 
  186 111 120 10 3.1 
Bz-Glu 252 105 120 20 3.22 
  258 111 120 20 3.22 
Bz-BAla 194 105 120 20 3.5 
  200 111 120 20 3.5 
Bz-NAP 235 176 135 20 3.6 
  241 182 135 20 3.6 
Bz-Ala 194 105 120 20 3.7 
  200 111 120 20 3.7 
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Compound 
Precursor Product Fragmentor Collision Energy Retention Time 
(m/z) (m/z) (V) (V) (min) 
Bz-GABA 208 105 120 10 3.79 
  214 111 120 10 3.79 
Bz-Pro 220 105 120 20 4.05 
  226 111 120 20 4.05 
Bz-Ado 372 136 120 30 5.35 
  378 136 120 30 5.35 
Bz-Val 222 105 120 30 5.94 
  228 111 120 30 5.94 
Bz-Met 254 105 120 15 6 
  260 111 120 15 6 
Bz-Orn 341 174 120 15 6.4 
  353 180 120 15 6.4 
Bz-Lys 355 188 120 20 7.11 
  367 194 120 20 7.11 
Bz-Put 297 105 120 30 7.53 
  309 111 120 30 7.53 
Bz-Xle 236 105 120 30 8.12 
  242 111 120 30 8.12 
Bz-Phe 270 120 120 10 8.37 
  276 120 120 10 8.37 
Bz-Thr 224 105 140 20 8.39 
  230 111 140 20 8.39 
Bz-VMA 320 105 120 10 8.4 
  326 111 120 10 8.4 
Bz-Trp 309 159 120 10 8.5 
  315 159 120 10 8.5 
Bz-MOPEG 306 105 120 20 8.55 
  312 111 120 20 8.55 
Bz-Cad 311 105 130 30 8.56 
  323 111 130 30 8.56 
Bz-Cys 330 105 120 20 10.1 
  342 111 120 20 10.1 
Bz-Spd 458 162 120 30 10.43 
  476 168 120 30 10.43 
Bz-PhEt 226 105 120 15 10.94 
  232 111 120 15 10.94 
Bz-TrpA 265 144 130 30 10.99 
  271 144 130 30 10.99 
Bz-HVA 304 105 120 15 11.75 
  310 111 120 15 11.75 
Bz-TOH 243 105 120 20 11.77 
  249 111 120 20 11.77 
Bz-DOMA 410 105 130 20 11.95 
  422 111 130 20 11.95 
Bz-VA 273 105 120 20 12 
  279 111 120 20 12 
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Compound 
Precursor Product Fragmentor Collision Energy Retention Time 
(m/z) (m/z) (V) (V) (min) 
Bz-Spm 619.6 497 135 25 12.1 
  643.6 515.6 135 25 12.1 
Bz-DOPEG 396 105 120 20 12.2 
  408 111 120 20 12.2 
Bz-Tyr 390 105 120 30 12.78 
  402 111 120 30 12.78 
Bz-Cou 269 105 120 20 12.89 
  275 111 120 20 12.89 
Bz-Fer 299 105 120 20 13 
  305 111 120 20 13 
Bz-Sin 329 105 130 20 13.03 
  335 111 130 20 13.03 
Bz-VN 257 105 120 20 13.8 
  263 111 120 20 13.8 
Bz-DOPAC 394 105 140 20 14.22 
  406 111 140 20 14.22 
Bz-PCA 380 105 120 20 14.4 
  392 111 120 20 14.4 
Bz-DOPA 510 360 120 30 14.53 
  528 372 120 30 14.53 
Bz-TyrA 346 105 135 25 14.67 
  358 111 135 25 14.67 
Bz-Caf 406 105 120 20 14.9 
  418 111 120 20 14.9 
Bz-Gal 500 105 140 30 16 
  518 111 140 30 16 
Bz-DA 466 105 140 20 16.02 
  484 111 140 20 16.02 
Table 5-2:  MRM conditions for benzoylated metabolites and their internal standards. 
 
Method evaluation 
 Limits of detection (LOD) were calculated as three standard deviations of the blank, 
using a six point calibration with three replicates. Limits of quantification (LOQ) were calculated 
as ten standard deviations of the blank. The same calibration was used to determine linearity for 
each metabolite. Repeatability was defined as the RSD for triplicate analysis of an aqueous 
standard at relevant metabolite concentrations. Recovery was determined by spiking three 
aliquots each of 200 μL wine with 40 μL of either water or 5X concentrated standards. The 
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spiked wine was prepared and analyzed as described previously. The expected concentration was 
determined by adding the known, spiked concentration to the measured concentration of the 
sample spiked with water. Recovery was calculated by comparing the concentration of the 
standard spiked wine to the expected concentration.  
 
Statistical analysis 
 Single factor ANOVA and unpaired, two-tailed student's t-tests were performed. 
Differences were deemed significant if P ≤ 0.05 following Holm-Bonferroni correction.  
 
Results and discussion 
Metabolite selection 
 We have previously described BzCl derivatization of 70 amine and phenol metabolites in 
biological samples.
39
 We used that previous work as a basis for developing a method for analysis 
of wine to test the utility of this approach for food analysis. Of the 70 compounds previously 
assayed, 46 were selected as potentially relevant in wine. An additional 10 metabolites were 
chosen to add to the method:  hydroxybenzoic acids gallic acid, protocatechuic acid, and vanillic 
acid; hydroxycinnamic acids caffeic acid, ferulic acid, p-coumaric acid, and sinapic acid; 
phenolic aldehyde vanillin; phenylethanoid tyrosol; and polyamine cadaverine. These 
metabolites were selected based on their relevance in wine and availability. In principle, BzCl 
derivatization could be used for the assay of additional phenolic acids as well. 
 Attempts to extend the method to some other polyphenols revealed some limitations. Due 
to the excess of reagent in the reaction mixture, the BzCl reaction typically goes to completion. 
In the case of sinapic acid, a low yield of underivatized product was observed, which we believe 
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is due to steric hindrance of the 4-phenol. Linear calibrations were still achieved, so this did not 
appear to limit quantification. 
 Additionally, flavonols did not appear to label efficiently with BzCl. Quercetin, for 
example, has five potential labeling sites. Unlabeled, singly labeled, and doubly labeled 
quercetin were the primary species detected. This finding is in contrast with metabolites like 
dopamine, which has three labeling sites, and only triply labeled dopamine is detected. We 
believe the poor reaction efficiency is due to resonance stabilization and hydrogen bonding 
between the phenols. While the conditions used here are not compatible with flavonol detection, 
these metabolites can be detected directly using LC-MS,
12
 or with dansyl chloride,
33
 where the 
harsher reaction conditions allow for derivatization of flavonols. 
 
Figures of merit 
 After pilot experiments revealed that the 56 target compounds could be labeled with BzCl, 
we developed a LC-MS/MS method that utilized gradient elution and multiple reaction 
monitoring with optimized MS/MS for each compound. Figure 5-1 shows that reasonable 
separation was achieved using a 20 min gradient. No differences in peak shape were observed 
between aqueous standards and wine. LODs, repeatability, recovery, and linearity for each 
metabolite are listed in Table 5-3. LODs for all but 12 of the studied metabolites were below 10 
nM, and all were below 1 μM. Every metabolite studied was above the limit of detection in the 
wines. Thus, the sensitivity of the method is appropriate for wine analysis, and could even be 
applied to wine subject to greater dilution. RSDs were below 10% for all metabolites except 
vanillin, vanillic acid, agmatine, and vanillymandelic acid. RSDs for these metabolites were 
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below 15%. All metabolites produced linear calibrations (R
2
 > 0.99), allowing for reliable 
quantification. 
 
Figure 5-1:  Extracted ion chromatogram of 56 amine and phenolic metabolites. A. Standards in aqueous solution. Gradient is 
overlaid as % B. B. Example chromatogram from filtered, diluted wine. No significant differences in peak shape or retention 
times were observed between standards and wine samples. 
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Compound 
LOD 
(nM) 
RSD 
(%) 
Linearity 
(R
2
) 
Compound 
LOD 
(nM) 
RSD 
(%) 
Linearity 
(R
2
) 
Ch 40 0.5 0.9995 Phe 2 0.7 0.9997 
ACh 0.5 2 0.9998 Thr 2 5 0.9994 
His 1 2 0.9927 VMA 1 13 0.9958 
Tau 2 3 0.9996 Trp 4 2 0.995 
Arg 2 2 0.9993 Cad 0.4 0.4 0.9996 
Hist 1 2 0.9994 MOPEG 0.3 1 0.9993 
Asn 1 0.4 0.9958 Cys 0.2 7 0.9996 
Gln 0.4 2 0.9921 Spd 0.3 6 0.9958 
Ser 60 3 0.9998 PhEt 0.9 2 0.9986 
Cit 0.5 2 0.9999 TrpA 0.3 0.8 0.995 
Agm 0.2 12 0.9939 TOH 40 3 0.9973 
ETA 4 6 0.9995 HVA 0.7 4 0.9992 
Asp 4 4 0.999 DOMA 0.3 5 0.9989 
Glc 300 2 0.9999 VA 20 11 0.9905 
Gly 8 3 0.9942 Spm 0.2 4 0.9903 
Glu 5 0.5 0.999 DOPEG 1 2 0.9953 
BAla 1 0.5 0.9999 Tyr 10 3 0.9997 
NAP 0.2 5 0.9995 Cou 30 2 0.9961 
Ala 8 0.6 0.9999 Fer 90 8 0.9993 
GABA 3 6 0.9995 Sin 3 5 0.9971 
Pro 200 4 0.9972 VN 4 11 0.994 
Ado 0.3 0.7 0.9959 DOPAC 0.1 4 0.9999 
Val 3 2 0.9973 PCA 20 9 0.9999 
Met 1 2 0.9988 DOPA 0.5 7 0.9932 
Orn 2 3 0.9997 TyrA 20 1 0.998 
Lys 6 4 0.9947 Caf 70 0.1 0.9915 
Put 3 6 0.9973 Gal 700 5 0.9999 
Xle 7 4 0.9996 DA 0.7 5 0.9994 
Table 5-3:  Summary of limit of detection (LOD), repeatability (RSD), and linearity for a six point calibration using aqueous 
standards (n = 3). 
 
All quantification was based on comparison to internal standards consisting of 
13
C-BzCl 
labeled standards added to the samples. The significance of using internal standards was assessed 
by comparing concentrations calculated based on analyte peak area alone to analyte peak area 
normalized to internal standard peak area. Without internal standards, calculated concentrations 
ranged from 27% to 136% of the value determined through use of internal standards (Figure 5-2). 
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This result demonstrates the necessity of including internal standards for each metabolite for 
accurate quantification in complex samples. Individual internal standards are easily prepared for 
this method through the use of 
13
C-BzCl. 
 
Figure 5-2:  Accuracy of concentrations without internal standards relative to concentrations calculated with internal standards. 
Without internal standards, concentrations ranged from 27% to 136% of the concentrations normalized to internal standards. Data 
shown is average ± standard deviation (n = 3). 
 
To assess accuracy and recovery of the method, wine was spiked with a known 
concentration of standards, and the calculated concentration was compared to the expected 
concentration. If the internal standards were not sufficiently accounting for matrix effects, we 
would expect low accuracy from this experiment. However, calculated recovery ranged from 
80% to 150%, and average recovery was 101%. Of the 56 metabolites, 46 had recoveries within 
the range of 90% to 110%. Gallic acid had the lowest recovery of 80%, and adenosine, 
protocatechuic acid, and sinapic acid had the three highest recoveries, all at or above 130%. 
Inspection of the data revealed that each of these metabolites had a single deviant point 
contributing to the inaccuracy. Accuracy was greatly improved if this point is removed, so we 
expect that these problems were sample preparation errors and that a greater number of replicates 
would further improve these calculations. In general, recoveries were repeatable, further 
demonstrating that the method allows for accurate and reliable quantification. 
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Wine analysis 
 To demonstrate the suitability of the method for wine, we compared four:  a Californian 
Merlot, a Californian Cabernet Sauvignon, an Australian Merlot, and an Australian Cabernet 
Sauvignon. These choices allowed us to determine if the method could distinguish between 
region of production or varietal based on the metabolites included. The wine was filtered prior to 
analysis to remove any particulate matter. No difference was observed in calculated 
concentrations after filtration with spin columns or syringe filters, so spin columns were chosen 
for the ability to prepare multiple samples simultaneously. Filtered wine was then diluted 10 or 
100 fold in water prior to derivatization. We found that low abundance metabolites such as 
tryptamine and vanillylmandelic acid were undetectable after 100 fold dilution, so 10 fold 
dilution was selected for analysis. Calculated concentrations for each of the tested wines are 
listed in Table 5-4. 
 When compared by region of production, 24 of the 56 metabolites were found to be 
different (P < 0.05) between Australian and Californian wines (Figure 5-3). These distinguishing 
compounds were polyamines spermidine and spermine; phenolic acids caffeic acid, gallic acid, 
homovanillic acid, protocatechuic acid, and vanillic acid; amino acids asparagine, aspartate, 
histidine, leucine/isoleucine, lysine, phenylalanine, serine, threonine, tyrosine, and valine; and 
biogenic amines choline, DOPA, DOPEG, histamine, phenethylamine, tryptamine, and tyramine. 
All of these were found to be higher in Australian wines except homovanillic acid, spermine, and 
caffeic acid. Differences in amines and phenols based on geographic origin have been observed 
previously using LC with spectrophotometric detection 
15,40
, and may result from differences in 
climate, soil conditions, or fertilizers. Larger sample sizes would be required to determine if 
these differences are generalizable among the different regions. Further study would also be 
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required to determine the exact relationship between these metabolites and the location of 
production. 
 Of the 56 metabolites assayed, five were found to differ significantly (P ≤ 0.05) based on 
varietal following Holm-Bonferroni correction (Figure 5-4). These included polyamines 
cadaverine, putrescine, and N-acetylputrescine; ferulic acid, and glutamic acid. The polyamines 
were higher in Cabernets, while ferulic acid and glutamate were higher in the Merlots. It is 
important to note that wines can be labeled as a particular varietal as long as that varietal makes  
 
Figure 5-3:  Metabolites showing significant differences between locations of production. A. Biogenic amines. B. Phenolic acids. 
C. Trace metabolites. D. Amino acids. Unpaired, two-tailed Student's t-tests were performed and the Holm-Bonferroni correction 
was used. Each point is a single sample, and the horizontal bar is the mean. Data shown is uncorrected for dilution. * p ≤ 0.05; ** 
p ≤ 0.01; *** p ≤ 0.001. Aus:  Australia; CA:  California; Ch:  choline; Hist:  histamine; Spd:  spermidine; Spm:  spermine; PhEt:  
phenethylamine; TyrA:  tyramine; Caf:  caffeic acid; Gal:  gallic acid; PCA:  protocatechuic acid; VA:  vanillic acid; DOPA:  
3,4-dihydroxyphenylalanine; DOPEG:  3,4-dihydroxyphenylglycol; HVA:  homovanillic acid; TrpA:  tryptamine; Asn:  
asparagine; Asp:  aspartic acid; His:  histidine; Lys:  lysine; Phe:  phenylalanine; Ser:  serine; Thr:  threonine; Tyr:  tyrosine; Val:  
valine; Xle:  leucine/isoleucine. 
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Compound Units Australia Cabernet Australia Merlot California Cabernet California Merlot 
ACh nM 544 ± 34.6 (6.35) 467 ± 124 (26.6) 353 ± 8.87 (2.51) 356 ± 19.7 (5.53) 
Ado nM 52.3 ± 3.48 (6.56) 25.9 ± 2.65 (10.2) 15.8 ± 1.76 (11.1) 19.7 ± 2.12 (10.7) 
Agm nM 58.9 ± 2.96 (5.02) 35.9 ± 7.53 (21.0) 27.9 ± 3.15 (11.3) 16.0 ± 5.97 (37.3) 
Ala μM 35.0 ± 2.96 (8.48) 37.7 ± 2.23 (5.92) 21.7 ± 0.74 (3.42) 36.5 ± 2.79 (7.64) 
Arg μM 20.2 ± 2.02 (9.99) 18.7 ± 1.15 (6.16) 17.4 ± 0.38 (2.15) 15.4 ± 0.58 (3.74) 
Asn μM 10.5 ± 1.47 (14.0) 10.4 ± 0.74 (7.16) 7.29 ± 0.20 (2.70) 7.94 ± 0.75 (9.42) 
Asp μM 7.81 ± 0.93 (11.9) 6.82 ± 0.42 (6.16) 4.46 ± 0.11 (2.38) 5.24 ± 0.30 (5.74) 
BAla μM 17.9 ± 1.64 (9.20) 14.0 ± 1.20 (8.53) 15.7 ± 0.81 (5.15) 15.0 ± 0.93 (6.19) 
Cad nM 407 ± 40.9 (10.0) 53.8 ± 4.00 (7.44) 456 ± 4.11 (0.90) 45.3 ± 2.77 (6.11) 
Caf μM 1.42 ± 0.14 (9.53) 1.7 ± 0.14 (8.25) 3.75 ± 0.19 (5.11) 3.77 ± 0.34 (9.13) 
Ch μM 233 ± 18.7 (8.02) 202 ± 6.72 (3.33) 149 ± 0.91 (0.61) 139 ± 8.19 (5.90) 
Cit nM 392 ± 45.5 (11.6) 268 ± 27.0 (10.1) 428 ± 32.01 (7.47) 523 ± 14.6 (2.80) 
Cou μM 1.83 ± 0.20 (11.03) 1.37 ± 0.14 (10.3) 2.08 ± 0.03 (1.42) 1.82 ± 0.22 (11.9) 
Cys nM 252 ± 30.4 (12.1) 547 ± 44.9 (8.21) 518 ± 34.2 (6.61) 1250 ± 75.5 (6.06) 
DA nM 4.24 ± 0.77 (18.1) 4.56 ± 0.89 (19.4) 6.31 ± 1.53 (24.2) 4.35 ± 0.81 (18.5) 
DOMA nM 19.1 ± 2.78 (14.6) 17.2 ± 0.41 (2.36) 18.1 ± 1.04 (5.78) 14.7 ± 1.60 (10.9) 
DOPA nM 11.7 ± 0.71 (6.05) 12.3 ± 2.24 (18.1) 6.36 ± 0.80 (12.5) 5.33 ± 1.26 (23.7) 
DOPAC nM 9.95 ± 1.37 (13.8) 12.9 ± 0.67 (5.20) 11.1 ± 0.91 (8.20) 6.31 ± 0.45 (7.20) 
DOPEG nM 4.69 ± 0.54 (11.5) 5.51 ± 0.47 (8.45) 3.23 ± 0.06 (1.76) 2.60 ± 0.28 (10.7) 
ETA μM 23.1 ± 2.68 (11.6) 26.6 ± 3.21 (12.1) 26.8 ± 1.65 (6.17) 26.7 ± 2.34 (8.77) 
Fer μM 14.5 ± 1.90 (13.1) 27.8 ± 3.85 (13.9) 13.9 ± 1.60 (11.5) 22.9 ± 1.49 (6.50) 
GABA μM 29.7 ± 4.44 (14.9) 18.9 ± 1.20 (6.37) 12.0 ± 0.28 (2.29) 14.4 ± 1.14 (7.97) 
Gal μM 12.8 ± 1.91 (14.9) 15.7 ± 1.21 (7.71) 8.47 ± 0.55 (6.47) 7.83 ± 1.08 (13.8) 
Glc mM 1.54 ± 0.13 (8.54) 1.55 ± 0.06 (3.85) 1.15 ± 0.06 (5.63) 1.58 ± 0.10 (6.61) 
Gln nM 485 ± 37.3 (7.69) 417 ± 49.1 (11.8) 357 ± 10.5 (2.95) 512 ± 58.6 (11.5) 
Glu μM 12.8 ± 1.06 (8.28) 15.5 ± 0.58 (3.71) 11.7 ± 0.27 (2.34) 17.6 ± 1.43 (8.10) 
Gly μM 18.9 ± 1.68 (8.90) 20.8 ± 1.71 (8.22) 13.01 ± 1.03 (7.90) 20.2 ± 3.35 (16.6) 
His μM 16.4 ± 1.80 (11.0) 14.1 ± 0.88 (6.23) 10.07 ± 0.09 (0.90) 12.1 ± 0.69 (5.70) 
Hist μM 1.49 ± 0.24 (15.8) 1.16 ± 0.11 (9.57) 0.35 ± 0.003 (0.94) 0.36 ± 0.02 (4.33) 
HVA nM 50.2 ± 3.22 (6.41) 52.7 ± 2.62 (4.98) 64.6 ± 3.13 (4.85) 66.7 ± 6.51 (9.76) 
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Compound Units Australia Cabernet Australia Merlot California Cabernet California Merlot 
Lys μM 8.03 ± 0.57 (7.09) 8.92 ± 0.96 (10.8) 4.50 ± 0.06 (1.34) 5.49 ± 0.33 (5.94) 
Met nM 946 ± 99.6 (10.5) 981 ± 54.6 (5.57) 799 ± 12.9 (1.61) 911 ± 67.5 (7.40) 
MOPEG nM 9.84 ± 1.15 (11.7) 15.0 ± 2.35 (15.7) 13.6 ± 1.42 (10.5) 13.2 ± 2.64 (20.1) 
NAP nM 406 ± 32.3 (7.96) 171 ± 26.2 (15.3) 402 ± 5.57 (1.39) 170 ± 7.09 (4.18) 
Orn μM 4.01 ± 0.42 (10.4) 4.04 ± 0.32 (7.90) 5.13 ± 0.05 (0.93) 7.76 ± 0.53 (6.89) 
PCA μM 10.8 ± 1.14 (10.6) 15.2 ± 1.89 (12.4) 7.20 ± 0.51 (7.06) 6.36 ± 0.45 (7.03) 
Phe μM 4.89 ± 0.47 (9.66) 5.20 ± 0.20 (3.87) 2.55 ± 0.07 (2.88) 3.11 ± 0.29 (9.38) 
PhEt nM 79.9 ± 10.5 (13.1) 49.7 ± 4.79 (9.64) 34.3 ± 1.38 (4.03) 9.89 ± 0.86 (8.74) 
Pro mM 2.57 ± 0.20 (7.66) 2.52 ± 0.17 (6.58) 3.16 ± 0.19 (5.92) 2.51 ± 0.12 (4.76) 
Put μM 8.23 ± 1.01 (12.2) 4.30 ± 0.55 (12.7) 11.5 ± 0.24 (2.08) 4.50 ± 0.46 (10.1) 
Ser μM 8.61 ± 0.27 (3.14) 10.1 ± 0.79 (7.87) 5.62 ± 0.23 (4.08) 7.09 ± 0.77 (10.8) 
Sin nM 38.3 ± 16.9 (44.2) 35.6 ± 11.7 (32.9) 46.4 ± 8.10 (17.5) 35.9 ± 0.84 (2.34) 
Spd nM 690 ± 82.6 (12.0) 605 ± 51.3 (8.48) 434 ± 10.4 (2.39) 450 ± 22.5 (5.00) 
Spm nM 61.0 ± 8.37 (13.7) 75.3 ± 6.27 (8.33) 119 ± 7.44 (6.24) 141 ± 14.6 (10.4) 
Tau nM 167 ± 20.9 (12.6) 174 ± 16.5 (9.50) 239 ± 37.3 (15.6) 165 ± 19.2 (11.7) 
Thr μM 2.18 ± 0.37 (17.0) 2.53 ± 0.23 (8.89) 1.24 ± 0.01 (0.73) 1.49 ± 0.18 (12.0) 
TOH μM 34.6 ± 5.53 (16.0) 29.4 ± 0.32 (1.08) 28.2 ± 1.90 (6.75) 19.0 ± 1.93 (10.2) 
Trp nM 467 ± 57.6 (12.4) 717 ± 17.3 (2.42) 286 ± 23.7 (8.28) 508 ± 35.5 (6.98) 
TrpA nM 1.17 ± 0.21 (17.6) 1.44 ± 0.04 (3.04) 0.52 ± 0.05 (9.81) 0.44 ± 0.03 (6.55) 
Tyr nM 2.71 ± 0.26 (9.45) 3.01 ± 0.16 (5.22) 1.87 ± 0.01 (0.57) 2.28 ± 0.16 (6.85) 
TyrA nM 640 ± 108 (16.9) 591 ± 58.2 (9.85) 163 ± 17.0 (10.4) 244 ± 20.2 (8.29) 
VA μM 3.10 ± 0.26 (8.41) 3.31 ± 0.22 (6.75) 1.50 ± 0.08 (5.36) 2.45 ± 0.60 (24.5) 
Val μM 4.14 ± 0.46 (11.2) 4.37 ± 0.34 (7.75) 2.40 ± 0.09 (3.78) 2.86 ± 0.17 (6.09) 
VMA nM 53.3 ± 9.79 (18.4) 49.4 ± 8.24 (16.7) 36.3 ± 7.32 (20.2) 55.6 ± 0.77 (1.39) 
VN nM 128 ± 22.9 (17.9) 235 ± 23.4 (9.93) 101 ± 1.81 (1.79) 120 ± 7.86 (6.53) 
Xle μM 5.59 ± 0.10 (1.79) 5.16 ± 0.29 (5.71) 2.79 ± 0.08 (2.84) 3.10 ± 0.27 (8.71) 
Table 5-4:  Concentrations of amine and phenolic metabolites in wine. Concentrations are not corrected for dilution. Data is average ± standard deviation (RSD), n = 3. 
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up 75% of the composition in the United States, or 85% in Australia. Without knowing what the 
remaining composition is, we cannot draw conclusions of the relationship between these 
metabolites and the specific varietals. Larger sample sizes would be required to determine if 
these differences are generalizable among the different varietals; however, these results show the 
feasibility of distinguishing the different types of wine used here by the 56 compounds measured. 
 
Figure 5-4:  Metabolites showing significant differences between wine varietals. A. Metabolites at nanomolar concentrations. B. 
Metabolites at micromolar concentrations. Unpaired, two-tailed Student's t-tests were performed and the Holm-Bonferroni 
correction was used. Data shown is uncorrected for dilution. * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. CS:  Cabernet Sauvingnon; 
M:  Merlot; NAP:  N-acetylputrescine; Cad:  cadaverine; Glu:  glutamic acid; Put:  putrescine; Fer:  ferulic acid. 
 
Comparison to current methods 
 Comparison of the BzCl-LC-MS/MS method to other methods used for measurement of 
phenols and amines in wine reveals that it has substantial advantages for quantitative, 
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multiplexed assays that can provide significant information on the wine. LC-UV is a commonly 
used technique for the analysis of amines and phenols in wine. It is particularly well suited to 
phenols, which are naturally UV active. Methods for up to 20 phenols have been established.
22
 
2D-LC can increase selectivity, at the cost of analysis time and complexity of the fluidics.
11
 
Amines can be detected by UV after derivatization, and methods for up to 33 amines have been 
established.
23
 UV detection is simple and inexpensive, but LC-MS/MS offers greater flexibility, 
because both amines and phenols can be detected. Additionally, while trace amines such as 
tryptamine, phenethylamine, and agmatine are not consistently detected with UV, these 
metabolites were above our LODs in all samples tested. 
 Studies on using LC-MS for analysis of wine have been reported as the technique is 
becoming more widely available. Untargeted metabolomics has been performed in wine,
29
 
though we have focused on targeted methods as they are more reproducible and allow for 
absolute quantification. As with LC-UV, existing targeted LC-MS methods focus on either 
amines or phenols. Biogenic amine analysis has been limited to fewer than 10 amines while still 
requiring 20 min for separation.
17,28
 Over 40 phenols have been detected in wine using 2D-LC-
MS, but analysis time is over 60 min.
12
 Our assay covers a combination of 56 amines and 
phenols with a 20 minute gradient. Benzoyl chloride derivatization allows for accurate 
quantification using easily generated stable isotope labeled internal standards, while adding 
minimal time for sample preparation per sample. Additionally, with the low limits of detection 
afforded by mass spectrometry and benzoyl chloride derivatization, we were able to detect trace 
metabolites, such as tryptamine, which are not routinely detected with other methods. 
 
Conclusions 
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 Benzoyl chloride derivatization with LC-MS/MS is a powerful technique for 
determination of amine and phenol metabolites in biological samples. To demonstrate its 
potential in wine, we have developed a quantitative assay for 56 metabolites in wine. It is likely 
that the method can be extended to many more amines and phenols in wine (and other foods) as 
needed for a given application. Combining phenols and amines in one assay is useful because 
they provide complementary information on the wine. Phenolic acids contribute to the flavor and 
aroma of wine, and are believed to have positive health benefits as well. High concentrations of 
biogenic amines are associated with spoilage and poor quality.  
 As a proof of concept, we applied our method to four wines of two varietals and from two 
locations of production. We identified five metabolites which were significantly different based 
on varietal, and twenty-four which were significantly different based on location. A broader, 
more rigorous study may allow for the distinction of wines by varietal and location of production 
using the observed metabolite profiles. 
 As previously demonstrated with biological samples, BzCl derivatization with LC-
MS/MS is a powerful technique for food analysis. The derivatization process improves 
sensitivity and quantification, which is well worth the minimal added sample preparation time. 
Wine was selected for analysis; however, this method could be easily adapted to other beverages 
or even solid foods following appropriate extraction techniques.  
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CHAPTER 6 
Combination of benzoyl chloride and benzylamine derivatization to increase coverage of 
targeted metabolomics with liquid chromatography - mass spectrometry  
 
Introduction 
 Metabolomics is a rapidly growing field which can play an important role in biological 
studies as it can connect both internal and external effects to observed phenotypes. Despite the 
growing interest, no current instrumentation is capable of measuring the entire metabolome. The 
Human Metabolome Database (HMDB) contains entries for nearly 40,000 endogenous 
metabolites and over 70,000 total metabolites.
1
 Physical properties of the metabolites are highly 
variable, ranging from small polar sugars to large hydrophobic steroids. Additionally, 
endogenous concentrations range from sub-nanomolar to millimolar in biological samples. This 
variability limits the scope of untargeted metabolomics. NMR is capable of unbiased detection 
but is limited in sensitivity. Mass spectrometry is better suited for analysis of trace metabolites, 
but detection is biased by the coupled separation technique. 
 Rather than try to detect all metabolites, targeted metabolomics methods focus on a pre-
determined selection of metabolites. These methods are more limited in scope but provide better 
reproducibility and quantification. Advances in HPLC-MS/MS technologies have made it 
possible to measure as many as 300 metabolites within a single assay.
2–5
 However, detection is 
still biased by the chosen separation technique. Reversed phase chromatography is widely used, 
but is a poor choice for the analysis of polar metabolites, while HILIC is unsuited for analysis of 
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hydrophobic metabolites. It is desirable to overcome this bias to further increase the scope of 
these targeted methods. 
 A relatively simple method to improve the polarity range that can be analyzed is to 
perform a biphasic metabolite extraction and analyze the aqueous and organic phases 
separately.
6–8
 This strategy is effective but can increase analysis time as multiple column 
chemistries and ionization polarities are commonly used for each phase. Another commonly used 
technique is chemical derivatization.
5,9–14
 Labeling polar functional groups with a hydrophobic 
tag makes it possible to separate polar metabolites using RPLC, while providing enhanced 
ionization efficiency and the capability to easily generate internal standards through the use of 
stable isotope labeled derivatization reagents. These internal standards account for instrument 
drift over time, improving quantification. A stable isotope labeled derivatizing reagent can be 
used with calibration standards to create internal standards for each targeted metabolite without 
needing to obtain a stable isotope labeled version of each metabolite. Such derivatization 
methods make it possible to detect a wider range of metabolites with RPLC, but analysis is 
typically limited to metabolites possessing a specific functional group. Derivatization reagents 
for several functional groups have been developed so it is possible to use multiple techniques on 
a single sample, but this requires separate reactions and analyses. 
 We have previously explored benzoyl chloride (BzCl) derivatization of amines and 
phenols for a number of applications.
5,11,15,16
 BzCl has been valuable for monitoring 
neurochemicals, as nearly all common neurotransmitters and related metabolites contain an 
amine or phenol group. Although BzCl is useful, amines and phenols make up only a fraction of 
the metabolome, e.g., roughly 25%, based on the metabolite library at the Michigan Regional 
Comprehensive Metabolomics Resource Core (MRC
2
). Other functional groups are more 
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common, such as carboxylic acids, which compose approximately 50% of the metabolite library. 
Several derivatization techniques have been established for carboxylic acids, but these methods 
often require synthesis of the reagent and long reaction times with heating.
9,12,17,18
 
 Of these reagents, aniline seems the most promising.
9,19
 Aniline reacts with carboxylic 
acids through EDC-catalyzed amidation. The reaction requires only three reagents and no 
heating, so it is relatively simple. 
13
C6-aniline is commercially available and can be used for 
internal standards. In addition to carboxylic acids, aniline reacts with carbonyls and phosphates, 
making its scope complimentary to BzCl. However, aniline suffers from poor solubility and is a 
toxic environmental pollutant. Additionally, compared to other amines, aniline has limited 
reactivity as a result of modest nucleophilicity due to resonance stabilization.  We hypothesized 
that benzylamine (BnA), which is not resonance stabilized, would be a more reactive, greener 
alternative to aniline derivatization. 
 BnA derivatization has been reported previously for hydroxyindoles, catechols, and 
oligosaccharides, but not for carboxylic acids.
20,21
 Here we report BnA as a derivatization 
reagent for carboxylic acids, carbonyls, and phosphates. d2-BnA is commercially available and 
is used to create individual internal standards for each targeted metabolite. Additionally, BnA 
derivatization can be used in conjunction with BzCl for simultaneous analysis of amines, 
phenols, and carboxylic acids. This combination has the potential to significantly increase the 
number of metabolites which can be determined quantitatively in a single LC-MS run. 
 
Experimental 
Chemicals and reagents 
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 All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless otherwise 
noted. Water and acetonitrile were Budick and Jackson HPLC grade from VWR (Radnor, PA). 
Stock solutions of 1 M glucose and 
13
C6-glucose (Cambridge Isotope Laboratories, Andover, 
MA); 50 mM α-ketoglutarate, malate, citrate, isocitrate, and cis-aconitate; 20 mM glutamate, 
aspartate, succinate, glucose-6-phosphate, fructose-6-phosphate, fructose-1,6-bisphosphate, 3-
phosphoglycerate, 2-phosphoglycerate, 6-phosphogluconate, and phenylpyruvate; 10 mM 2-
hydroxyphenylacetate, 4-hydroxyphenylacetate, homogentisate, phenethylamine (MP 
Biomedicals, Santa Ana, CA), phenylalanine, and tyramine; 5 mM ATP, ADP, and 
phenylacetate; 2 mM tyrosine; 1 mM AMP were prepared in water and stored at -80 °C. A 20 
mM stock of 4-hydroxyphenylpyruvate was prepared in ethanol and stored at -80 °C. 
 Standard mixtures were prepared in water for use in calibration standards. Internal 
standards were prepared by derivatizing standard mixtures using 
13
C6-BzCl or d2-BnA (CDN 
Isotopes, Pointe-Claire, Quebec, Canada). For internal standards, 
13
C6-glucose was used instead 
of glucose. Single use aliquots of standards and internal standards were prepared and stored at -
80 °C. On the day of use, internal standard aliquots were thawed and diluted 100-fold (BzCl) and 
50-fold (BnA) into 20% (v/v) acetonitrile containing 1% (v/v) H2SO4. This is referred to as the 
internal standard solution. The BnA reagent was prepared by mixing 328 μL BnA, 972 μL water, 
and 258 μL HCl. The solution was then adjusted to pH 4.5. Fresh solutions of BzCl and N-
dimethylaminopropyl-N'-ethylcarbodiimide (EDC) were prepared daily. 
 
Benzylamine reaction optimization 
 A standard mixture of 100 μM α-ketoglutarate, malate, succinate, AMP, 2-
phospoglycerate, and glucose was used for reaction optimization. BnA volume was optimized by 
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derivatizing 20 μL aliquots with 2 μL 200 mg/mL EDC followed by 1, 2, 4, or 10 μL of the BnA 
solution. Reaction time was optimized by allowing the reaction to proceed for 0, 30, 60, 120, and 
240 minutes at room temperature. The reaction was stopped by addition of 1 μL triethylamine 
(TEA). Peak areas from LC-MS/MS analysis were used to compare reaction conditions. 
 
Mobile phase A optimization 
 A mixture of 100 μM glucose, AMP, fructose-1,6-phosphate, 6-phosphogluconate, 
succinate, and α-ketoglutarate was used for mobile phase optimization. Standards were 
derivatized with BnA. Mobile phase A was either 0.1% formic acid, 10 mM ammonium formate 
with 0.15% formic acid, or 10 mM ammonium acetate with 0.1% acetic acid. Mobile phase B 
was acetonitrile. Peak area following LC-MS/MS analysis was used to compare mobile phase 
compositions. 
 
Sample derivatization 
 The reaction scheme is shown in Figure 6-1a. For standalone BnA derivatization, 20 μL 
of samples or calibration standards were derivatized by addition of 2 μL 200 mg/mL EDC 
followed by addition of 10 μL of BnA solution. The mixture was incubated at room temperature 
for 1 h, with shaking. The reaction was stopped by addition of 1 μL of TEA. Internal standards 
were prepared in the same manner, using d2-BnA. A 25 μL portion of each calibration standard 
or sample was mixed with 1 μL of the internal standards. 
 For dual derivatization, 20 μL of samples or calibration standards were derivatized by 
addition of 2 μL 200 mg/mL EDC followed by addition of 10 μL of BnA solution. The mixture 
was incubated at room temperature for 1 h, with shaking. While incubating, an additional 20 μL 
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aliquot was derivatized with BzCl by sequential addition of 10 μL 100 mM sodium carbonate, 10 
μL 2% (v/v) BzCl in acetonitrile, and 10 μL of the internal standard solution. Following the 1 h 
incubation, the BnA reaction was stopped by addition of 3.5 μL of the internal standard solution. 
5 μL of the BnA-derivatized sample was mixed with 25 μL of the BzCl-derivatized sample. This 
procedure is outlined in Figure 6-1b. 
 
Figure 6-1:  a. Schematic showing the reaction of benzylamine with carbonyls, carboxylic acids, and phosphates through EDC 
catalysis.  b. Procedure for dual derivatization method.  A sample is split, and portions are labeled with benzoyl chloride (BzCl) 
or benzylamine (BnA).  After the reaction finishes, the two are mixed back together in a 5:1 BzCl:BnA ratio prior to LC-MS/MS 
analysis. 
 
Metabolite analysis by LC-MS/MS 
 Analysis was performed using a Waters (Milford, MA) nanoAcquity UPLC. An Acquity 
HSS T3 C18 column (1 mm x 100 mm, 1.8 μm particle, 100 Å pore size) was used. The 
autosampler was at ambient temperature and the column was held at 27 °C. Partial loop injection 
mode was used for 5 μL injections. For standalone BnA samples, mobile phase A was 10 mM 
ammonium acetate with 0.1% acetic acid and mobile phase B was acetonitrile. The flow rate was 
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100 μL/min and the gradient was:  initial, 0% B; 4.9 min, 80% B; 5 min, 100% B; 6 min, 100% 
B; 6.1 min, 0% B; 8 min, 0% B. For dual derivatization samples, mobile phase A was 10 mM 
ammonium formate with 0.15% formic acid, and mobile phase B was acetonitrile. The flow rate 
was 100 μL/min and the gradient was:  initial, 0% B; 0.5 min, 45% B; 4 min, 55% B; 4.1 min; 
65% B; 4.9 min, 75% B; 5 min, 100% B; 6 min, 100% B; 6.1 min, 0% B; 8 min, 0% B. 
 Detection was performed using an Aglient (Santa Clara, CA) G6410B triple quadrupole 
mass spectrometer in dynamic reaction monitoring (dMRM) mode. For standalone BnA 
derivatization, electrospray ionization was used in negative mode at -3 kV. For dual derivatized 
samples, electrospray ionization was used in positive mode at 4 kV. The gas temperature was 
350 °C, gas flow was 11 L/min, and the nebulizer was at 15 psi. MRM conditions are listed in 
Supplemental 1. Automated peak integration was performed using Agilent MassHunter 
Quantitative Analysis for QQQ, version B.08.00. All peaks were visually inspected to ensure 
proper integration. 
 
Method evaluation 
 Signal from BnA derivatization was determined by comparing peak area from a 
derivatized sample to an underivatized sample at the same concentration. Limits of detection 
(LOD) were calculated as three standard deviations of the blank using a six point calibration with 
three replicates. The same calibration was used to determine linearity (R
2
). Repeatability was 
defined as the relative standard deviation (RSD) from triplicate runs of the calibration midpoint. 
 
Sample preparation 
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 Pooled human serum from the American Red Cross Detroit National Testing Lab was 
provided by the MRC
2
. Proteins were removed from 10 μL aliquots by addition of 40 μL of cold 
acetonitrile, followed by centrifugation at 12,100g for 5 min. The supernatant was removed and 
derivatized. 
 Pancreatic islets were isolated from C57BL/6 (B6) mice using previously described 
collagenase digestion. 100 islets were isolated per mouse and recovered in culture media (RPMI 
1640, 1.7 mM glucose, 10% FBS) for two hours at 37 °C with 5% CO2. Islets received either no 
treatment, L-DOPA treatment, or tyrosine treatment. The islets were then washed twice with 
PBS, and frozen with liquid nitrogen. Metabolite extraction was performed by addition of 50 μL 
80% (v/v) acetonitrile followed by sonication. The resulting extract was centrifuged for 5 min at 
12,100g. The supernatant was removed and derivatized. 
 
Results and discussion 
Benzylamine reaction optimization 
 We first aimed to determine suitable BnA reaction conditions for a range of metabolites. 
Carboxylic acids α-ketoglutarate, malate, and succinate; phosphates AMP and 2-
phospoglycerate; and carbonyl glucose were selected as representatives of each functional group 
for optimzation of reaction time (0, 30, 60, 120, 240 min) and BnA reagent volume (1, 2, 4, 10 
μL per 20 μL sample). Peak area for each metabolite at these conditions were compared to 
determine optimal reaction conditions (Figure 6-2a-b). For most metabolites tested, signal went 
up with increasing volume of BnA added. This increase was most prominent with glucose. For 
carboxylic acids malate and succinate, signal decreased with increasing BnA, likely due to 
increased sample dilution. This decrease was relatively small (< 20%) compared to the increase 
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for glucose (90%). Additionally, calibrations prepared with low BnA volumes were not 
consistently linear, likely due to an insufficient concentration of BnA. Thus, 10 μL of BnA, or a 
2:1 ratio (v/v) of sample:BnA reagent, was determined to be optimal. 
 
Figure 6-2:  Optimization of benzylamine (BnA) derivatization.  Reagent volume (a) and reaction time (b) were optimized for 20 
μL samples of a 100 μM mix of α-ketoglutarate (aKG), malate (Mal), succinate (Suc), AMP, 2-phosphoglycerate (2PG), and 
glucose (Glc).  Signal generally increased with additional reagent volume, while increasing reaction time had variable effects.  A 
reagent volume of 10 μL and a reaction time of 60 min was selected as optimal.  Mobile phase A (c) was optimized using a 100 
μM mix of Glc, AMP, fructose-1,6-bisphosphate (F16P), 6-phosphogluconate (6PG), Suc, and aKG.  Water with 0.1% formic 
acid was optimal for phosphates, but 10 mM ammonium acetate with 0.1% acetic acid performed better as a general purpose 
mobile phase than 10 mM ammonium formate with 0.15% formic acid. 
 
 For most metabolites, peak area increased with increasing reaction time. Low signal was 
generally observed with no incubation period, as expected, although phosphates AMP and 2-
phosphoglycerate had highest signal at 0 min. For other metabolites, signal increased sharply 
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between 0 and 30 min, followed by a gradual increase thereafter. A small decrease was observed 
for AMP over time, while 2-phosphoglycerate signal dropped significantly. Further investigation 
is required to determine if this effect is general to all phosphates. Degradation of the derivatized 
phosphates in the acidic environment could explain this decrease with time. Once quenched to a 
basic pH, the phosphates appear stable and no decrease in signal was observed over the course of 
the injection batch. To maximize signal for most metabolites while not sacrificing too much 
signal for phosphates, a reaction time of 60 min was chosen. 
 
Mobile phase A optimization 
 We next considered the effect of mobile phase A composition on signal for the 
derivatized analytes (Figure 6-2c). Glucose, AMP, fructose-1,6-bisphosphate, 6-
phospogluconate, succinate, and α-ketoglutarate were selected as representatives of their 
functional groups. Water with formic acid, the general purpose mobile phase used by the MRC
2
, 
gave the highest peak area for all phosphates tested, but the lowest area for carboxylic acids, and 
glucose was virtually undetectable. This mobile phase is recommended if only phosphates are of 
interest, but it is inadequate for a general purpose benzylamine method. Ammonium formate 
with formic acid, the mobile phase we prefer for BzCl derivatization, gave the lowest peak area 
for phosphates, and moderate performance for carboxylic acids and carbonyls. 
 Ammonium acetate with acetic acid, which was selected as an alternative additive to 
formate, performed better than the formate/formic acid mobile phase for all tested metabolites, 
so it was selected as the best general purpose mobile phase. The acetate/acetic acid mobile phase 
had the highest pH. Basic mobile phases are preferred for negative ESI mode, though too high of 
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a pH can degrade silica columns. The pH of the acetate/acetic acid mobile phase was 4.5, which 
seemed to be a good compromise between ESI efficiency and column integrity. 
 
Method evaluation 
 Signal and chromatographic retention enhancement from BnA derivatization was 
evaluated for carbonyl glucose, phosphates AMP and glucose-6-phosphate, and carboxylic acids 
α-ketoglutarate, isocitrate, and citrate. Peak areas from unlabeled and labeled metabolites at the 
same concentration were compared (Figure 6-3). Retention time was increased for all 
metabolites tested. Signal was increased 10 - 2,000 fold for all metabolites except the 
phosphates, AMP and glucose-6-phosphate, though this decrease was less than 5 fold. It has been 
established that the selected mobile phase was not optimal for derivatized phosphates, so a more 
compatible mobile phase could be used if greater sensitivity is needed for phosphates. Even with 
a small decrease in signal, derivatization offers advantages in retention and quantification with 
easily generated internal standards. 
 
Figure 6-3:  Comparison of retention time and signal between unlabeled and benzylamine labeled metabolites.  All metabolites 
tested showed an increase in retention upon derivatization.  Increases in signal of up to 2,000-fold were observed for a. glucose 
(Glc), d. α-ketoglutarate (aKG), e. isocitrate (ICA), and f. citrate (CA).  Decreases in signal up to 3-fold were observered for 
phosphates b. AMP and c. glucose-6-phosphate (G6P). 
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 The increase in retention time is especially important for energy metabolites, which tend 
to be very polar, as evidenced by only unlabeled AMP eluting significantly past the dead time 
with a 45% organic mobile phase. Increasing the retention time allows for less colelution and ion 
suppression, as well as better separation of isomers such as citrate and isocitrate. Unlabeled 
citrate and isocitrate coelute, while baseline resolution was achieved following derivatization 
(Figure 6-3e-f). The increase in signal allows for better detection of these metabolites which is  
particularly important in negative ESI where lower signal than in positive ESI is observed. 
 To test the utility of the BnA labeling, we developed two methods:  1) a standalone BnA 
derivatization method for TCA cycle metabolites and sugar phosphates, and 2) a dual 
derivatization method using BnA and BzCl derivatization for the analysis of phenylalanine 
metabolites. The selected energy metabolites demonstrate the broad applicability of BnA 
derivatization, as carboxylic acids, carbonyls, and phosphates are all represented. We also 
propose the combination of the two derivatization techniques within a single LC-MS/MS run as a 
means to increase the scope of targeted metabolomics using derivatization. The phenylalanine 
metabolic pathways demonstrates the need for such a method - a single derivatization method 
would not be sufficient to target all of the relevant metabolites in the pathway (Figure 6-4). 
Phenylalanine is an essential amino acid for humans and must be obtained through diet. Defects 
in phenylalanine metabolism can lead to seizures, learning disabilities, and mental disorders. By 
measuring the entire pathway, it would be possible to determine which step in the pathway is 
defective so appropriate treatment can be determined.
22
 Example chromatograms for both 
methods are shown in Figure 6-5. 
 Figures of merit for the BnA energy metabolites method are listed in Table 6-1, while 
those for the phenylalanine dual derivatization method are listed in Table 6-2. Linearity was 
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good (R
2
 > 0.98) for all metabolites in both methods. Repeatability, calculated as RSDs for the 
calibration midpoint, was below 11% for all metabolites. For the energy metabolites method, 
LODs were in the nanomolar or low micromolar range, with only fructose-6-phosphate, fructose-
1,6-bisphosphate, and ATP having LODs over 10 μM. Using the fomic acid mobile phase 
instead of the acetate/acetic acid mobile phase would likely achieve lower LODs for these 
phosphates if greater sensitivity is needed.  
 
Figure 6-4:  Metabolic pathway for catabolism of phenylalanine.  Functional groups which are colored can be labeled by either 
benzylamine or benzoyl chloride.  Neither reagent is capable of labeling the entire pathway, thus both techniques are required for 
full pathway coverage. 
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 For the phenylalanine dual 
derivatization method, most metabolites had 
LODs between 50 nM and 2 μM. Only 4-
hydroxyphenylpyruvate had an LOD over 2 
μM. Balancing the ratio of BnA and BzCl 
derivatized samples when mixing back 
together for analysis can have a significant 
impact on resulting signal for each metabolite, 
so this can be adjusted if greater sensitivity for 
a specific metabolite is desired. 
 
Metabolite analysis in biological samples 
 To demonstrate the application of 
these methods in biological samples, both 
were applied to pooled human serum. 
Calculated concentrations for the energy 
metabolites method are listed in Table 6-1, while concentrations for the phenylalanine dual 
derivatization method are in Table 6-2. While many of these concentrations for both methods fall 
within the range expected for serum according to the HMDB, some are lower than expected, 
particularly within the phosphates. The pooled serum used is several years old, so despite proper 
precautions being taken to store individual aliquots at -80 °C, it is possible some degradation of 
the sample has occurred. 
 
Figure 6-5:  Example chromatograms from standards for the 
a. standalone benzylamine method for energy metabolites 
and b. the dual derivatization method for phenylalanine 
metabolites using benzylamine and BzCl.  Elution gradients 
are overlaid as % B. 
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Metabolite LOD (μM) RSD (%) R2 Serum Concentration (μM) 
Fructose-1,6-bisphosphate 10 6.84 0.978 ND 
ADP 2 3.03 0.999 ND 
ATP 26 11.0 0.989 ND 
2-Phosphoglycerate 2 4.58 0.998 ND 
AMP 5 2.96 0.989 ND 
Glucose 8 7.35 0.992 868 ± 61 
Fructose-6-phosphate 25 2.17 0.994 ND 
6-Phosphogluconate 1 8.51 0.999 ND 
3-Phosphoglycerate 0.2 1.58 0.995 ND 
Glutamate 2 8.35 0.999 65.7 ± 4.5 
Glucose-6-phosphate 8 4.48 0.997 ND 
Aspartate 0.9 3.55 0.999 25.8 ± 0.1 
Malate 0.4 2.48 0.999 1.41 ± 0.13 
Succinate 1 8.42 0.999 1.87 ± 0.23 
α-Ketoglutarate 0.3 3.21 0.997 4.60 ± 0.30 
Isocitrate 1 6.66 0.996 1.45 ± 0.05 
cis-Aconitate 0.1 2.61 0.989 ND 
Citrate 0.09 4.68 0.994 3.13 ± 0.41 
Table 6-1:  Figures of merit for standalone benzylamine derivatization of energy metabolites.  Limits of detection (LOD), 
repeatability (RSD), and linearity (R2) were calculated from triplicate calibration curves.  Concentrations in serum are listed as 
average ± standard deviation.  ND indicates not detected. 
 
 Alternatively, it is possible that the reaction and separation conditions are not well suited 
for analysis of phosphates in biological samples. The mobile phase and reaction time used were 
not optimal for phosphates, but these conditions were still adequate for phosphate standard 
solutions. It is possible a matrix component is interfering with ionization efficiency or limiting 
reaction yield. A standard addition of phosphates to serum could determine if the low 
concentrations in biological samples are the result of a matrix component.  
 Furthermore, to demonstrate the potential of the dual derivatization method for detecting 
changes, we also applied this method to islets of Langerhans from mice, exposed to different 
culture conditions. Of the ten tested metabolites, seven were detected in at least one of the 
samples, and five of these were found to be significantly different between the groups using 
single factor ANOVA (Figure 6-6). The islets treated with tyrosine showed an expected increase 
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in tyrosine, as well as the tyrosine metabolite tyramine. Islets treated with L-DOPA, a metabolite 
of tyrosine, also showed an increase in tyramine relative to untreated islets. A feedback 
mechanism may be present, shifting tyrosine metabolism towards tyramine to prevent an excess 
buildup of L-DOPA. Homogentisate was only observed in the islets treated with L-DOPA. 
Homogentisate and L-DOPA are not closely connected so further investigation is needed to 
explain this result.  
Metabolite LOD (μM) RSD (%) R2 Serum Concentration (μM) 
4-Hydroxyphenylpyruvate 25 7.5 0.995 ND 
Phenylalanine 0.1 3.9 0.997 63.2 ± 6.8 
Phenylacetate 0.2 0.084 0.992 0.29 ± 0.06 
2-Hydroxyphenylacetate 0.1 6.2 0.999 ND 
Phenethylamine 0.1 6.4 0.999 0.111 ± 0.004 
4-Hydroxyphenylacetate 1 8.1 0.999 1.31 ± 0.04 
Tyrosine 0.1 1.9 0.998 59.8 ± 6.5 
Phenylpyruvate 2 3.9 0.994 ND 
Tyramine 0.05 0.78 0.996 0.0183 ± 0.0013 
Homogentisate 2 8.3 0.991 3.21 ± 0.66 
Table 5-2:  Figures of merit for benzylamine and BzCl dual derivatization of phenylalanine metabolites.  Limits of detection 
(LOD), repeatability (RSD), and linearity (R2) were calculated from triplicate calibration curves.  Concentrations in serum are 
listed as average ± standard deviation.  ND indicates not detected. 
 
Comparison to other derivatization reagents 
 BnA derivatization is closely related to aniline derivatization. Both act as derivatization 
reagents through EDC-catalyzed reactions.
9,19
 We anticipated that BnA would have greater 
reactivity than aniline, and this was observed as the BnA reaction time was optimized to 60 min, 
while 120 minute were required for aniline derivatization. Limits of detection for carboxylic 
acids were similar between aniline and BnA, but LODs were higher for phosphates with BnA 
than with aniline. A higher aniline concentration was used than BnA, so increasing the BnA 
concentration might compensate for this. Additionally, ion pairing reagents were added to the 
aniline mobile phase. Ion pairing in LC can aid in separation of polar metabolites with reversed 
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phase chromatography, but they are difficult to fully remove from the instrumentation. We 
choice to forego ion pairing reagents but they may be considered for future work with BnA. BnA 
has the advantage over aniline of being compatible with acid quenching; aniline crashes out of 
solution when acid is added. Quenching with acid makes BnA compatible with BzCl 
derivatization, so both reagents can be used for a single LC-MS/MS run. 
 2-Hydrazinoquinoline (2-HQ) is another reagent that has been used for LC-MS 
derivatization of carboxylic acids and carbonyls.
12
 2-HQ reacts with carbonyls to form 
hydrazones, and with carboxylic acids to form hydrazides following activation with 2,2'-
dipyridyl disulfide and triphenylphosphine. Like aniline and BnA, 2-HQ is compatible with 
aqueous biological samples. Ion pairing reagents are not used and the reaction time is only an 
hour, which is consistent with BnA derivatization. However, the reaction mixture is heated, 
which may cause degradation of thermally sensitive metabolites. No stable isotope labeled 
version of 2-HQ is currently available for use in internal standards. Limits of detection were not 
evaluated for 2-HQ as the reagent was used to expand metabolome coverage rather than to 
increase sensitivity. This work was performed on a qTOF MS and MS/MS was only used to 
determine structural information. Our preliminary attempts at 2-HQ derivatization with a QQQ 
MS yielded poor fragmentation and inconsistent derivatization. 
 Phenylhydrazine has also been used for derivatization of carboxylic acids and 
phosphates.
23
 This reaction takes two hours but does not require heating. Although not utilized in 
this work, deuterated phenylhydrazine is commercially available and could be used for internal 
standards. Limits of detection were also not evaluated. A major disadvantage of this method is its 
reliance on ion pairing reagents for the chromatography. While this allowed for the 
chromatographic separation of isomers such as glucose-6-phosphate and fructose-6-phosphate, 
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this was also achieved with aniline and BnA derivatization. Due to the difficulty of fully 
removing ion pairing reagents from instrumentation, we have not yet worked with 
phenylhydrazine as a potential derivatization reagent. 
 
Figure 6-6:  Concentrations of phenylalanine metabolites in extract from islets of Langerhans from mice with no treatment, L-
DOPA treatment, or tyrosine treatement.  Significant differences were observed between groups for phenylalanine (Phe), 
phenylacetate (PA), tyrosine (Tyr), tyramine (TyrA), and homogentisate (HGA).  No differences were observed between 
phenethylamine (PhEt) or 4-hydroxyphenylacetate (4HPA).  The remaining metabolites were not detected in any samples. * p ≤ 
0.05; ** p ≤ 0.01 
 
Conclusions 
 Reliable detection of a large number of metabolites is a persistent challenge in 
metabolomics. While a variety of approaches are being developed to address this, most require 
lengthy analysis times or suffer from poor sensitivity. Chemical derivatization is a way to 
increase the scope of targeted metabolomics while also increasing sensitivity. Methods are 
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limited to the functional groups which can be labeled, but the combination of complimentary 
reagents can greatly increase this. While any combination can be used for separate analysis, here 
we describe BnA as a novel derivatization reagent which can be used with BzCl derivatization 
within a single LC-MS/MS run. 
 A method for the analysis of 18 energy metabolites with BnA was developed. 
Furthermore, this reagent was combined with BzCl for the analysis of 10 metabolites related to 
phenylalanine metabolism, a pathway which could not be analyzed by either BnA or BzCl alone. 
These methods were demonstrated in both standard solutions and biological samples, though 
room for improvement remains. The methods described here are not particularly large in scope, 
and detection in biological samples, especially of phosphates, is still challenging. Comparison of 
additional mobile phases may find a solvent that works well for both carboxylic acids and 
phosphates. Further optimization of reaction conditions may also increase signal for phosphates. 
Samples can be extracted in lower volumes to achieve higher concentrations, or the extract could 
be dried down and reconstituted in a smaller volume to allow for preconcentration. If none of 
these options pan out, it may be best to focus solely on carboxylic acids and carbonyls. 
 Although these methods do not target a large number of metabolites, they demonstrate 
the potential of BnA as a derivatization reagent. Used alone with negative ESI, carboxylic acids, 
carbonyls, and phosphates can be labeled, though further optimization is needed for phosphates. 
More details on addressing the poor sensitivity for phosphates are provided in Chapter 7. With 
positive ESI, only carboxylic acids are detectable with BnA, but the derivatized samples are 
compatible with BzCl derivatized samples, allowing detection of amines and phenols in addition 
to carboxylic acids. The combination of these two reagents could allow for analysis of up to 75% 
of the metabolite library at the MRC
2
. 
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CHAPTER 7 
Future directions 
 
Optimization of benzylamine derivatization for phosphates 
 Reaction conditions for benzylamine derivatization were optimized and work well for 
carboxylic acids and carbonyls, but limits of detection for phosphates were relatively high and 
they were generally not detected in the biological samples tested. During optimization, 
sensitivity for phosphates was sacrificed to improve sensitivity for other metabolites, so further 
optimization may lead to conditions which are better suited for all functional groups. 
 Despite the lower sensitivity for phosphates, calibration standards still gave adequate 
signal. It is unclear whether the lack of signal in biological samples is because they simply are 
not present, or if matrix effects are limiting sensitivity. To test this, phosphate standards can be 
spiked into pooled serum, followed by protein precipitation and derivatization. If the spiked 
phosphates are undetectable, or at a lower concentration than expected, matrix effects are likely 
causing loss of signal. Using a different protein precipitation may help reduce matrix effects, or 
another extraction strategy, such as solid phase extraction, could be used. 
 It was also observed that signal for phosphates decreased with increasing reaction time, 
but the reason for this is unknown. Reaction progress was tracked by monitoring only the labeled 
species, so the labeled species may be converting back into the unlabeled species as reaction time 
increases. Tracking both the labeled and unlabeled species would help determine if this is the 
case or not. If an increase in the unlabeled species over time is not observed, the labeled species 
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may still be degrading into another product. Labeled species are stable in the final solution, 
which is basic, but the reaction occurs at acidic pH. If degradation is occurring, reaction time 
may need to be further reduced, or the reaction mixture could be optimized. 
 Additionally, while signal enhancement was observed for derivatized carboxylic acids 
and phosphates relative to unlabeled species, this was not the case for phosphates. For these 
experiments, only the labeled species was monitored, so it is unclear if the reaction is going to 
completion or not. If not, this could explain the decrease in signal. Monitoring both the labeled 
and unlabeled species would help determine if this is the case. If the reaction is not going to 
completion, adjusting reaction conditions may help increase the yield. 
 The mobile phase used was also not optimal for phosphates. Water with formic acid 
worked best for phosphates, but gave very poor signal for carboxylic acids and carbonyls. 
Ammonium formate with formic acid was chosen as a compromise. However, another mobile 
phase might work better for phosphates while maintaining adequate signal for the other 
metabolites. The tests outlined here would provide insight into the poor signal for phosphates 
and may allow for further optimization of reaction conditions to work for all functional groups. 
However, if the conditions required for phosphates are too different from those for carboxylic 
acids and carbonyls, it might be necessary to focus primarily on the carboxylic acids and 
carbonyls with benzylamine derivatization. When phosphates are of interest, a separate reaction 
can be used with conditions optimized specifically for the phosphates. 
 
Development of derivatized metabolite library 
 Method development for targeted metabolomics can be slow, as MRMs must be 
determined and optimized for each metabolite of interest. Derivatized metabolites are well 
141 
 
retained with reversed phase chromatography, so time does not need to be spent comparing 
column chemistries. However, MRMs still must be determined for the derivatized metabolites. 
Currently, MRMs for derivatized metabolites are established on an "as needed" basis and general 
purpose methods are used for most applications. Using this approach, metabolites of interest for 
a particular study might not be measured while metabolites not relevant to the study are. 
Development of methods specific to each study would ensure that all relevant metabolites are 
being analyzed but the labor involved could create delays before sample analysis can occur. 
 To reduce method development time for custom targeted methods, a library of MRMs for 
derivatized metabolites using a general gradient could be established. When a specific method is 
desired, MRM conditions can be retrieved from the library, leaving only gradient optimization to 
be completed if the conditions used to create the library are inadequate. An approach like this 
would require significant effort up front, but could greatly reduce subsequent method 
development time. 
 MRMs for approximately 100 benzoylated metabolites have already been established. A 
potentially limiting factor for expanding upon that is standard availability. However, the 
Michigan Comprehensive Regional Metabolomics Resource Core (MRC
2
) maintains a 
metabolite library with approximately 1,000 authentic standards. Roughly a quarter of the 
metabolites within this library can be derivatized with benzoyl chloride (BzCl), while up to two 
thirds could be derivatized with benzylamine (BnA). Accounting for overlap between these 
groups, a library of up to 750 metabolites could be established using standards from the MRC
2
 
alone. When a study requires a new method, MRMs for as many or a few metabolites as desired 
can be pulled from the library to create the method in a matter of minutes. The creation of such a 
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library would be beneficial for both in-lab and collaborative projects and could aid in metabolite 
identification if untargeted methods are used with derivatization. 
 
Untargeted metabolomics with derivatization 
 All of the work in this dissertation has been targeted metabolomic methods, which 
quantify known metabolites based on MRMs developed using authentic standards. This approach 
leads to more reproducible results as well as simpler data analysis and the potential for absolute 
quantification. However, only known metabolites with accessible standards can be targeted, so 
novel or unexpected metabolites cannot be discovered. Thus, untargeted methods are still the 
gold standard for hypothesis generation. 
 Derivatization can still be used for untargeted methods with high resolution mass 
spectrometry (HRMS) to provide greater retention and ionization efficiency in reversed phase 
LC-MS. Data analysis and metabolite identification in untargeted metabolomics is challenging, 
however, and derivatization creates additional challenges. The information provided in HRMS is 
not sufficient to differentiate between unlabeled and labeled metabolites, nor can it tell how 
many labels are on a labeled metabolites. For BzCl, there is a correlation between number of 
labels and both retention time and precursor ion mass, but these factors are not enough to 
accurately assign a number of labels to each feature detected (Figure 7-1). If the goal is to 
distinguish groups based on metabolic profile, the number of labels should not matter, but 
metabolite identification becomes increasingly difficult without this information. Databases such 
as XCMS
1
 or HMDB
2
 do not include derivatized metabolites so they cannot be used without 
subtracting off a known number of labels. 
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Figure 7-1:  Factors such as precursor ion mass (a) and retention time (b) are correlated to the number of benzoyl groups on 
labeled metabolites 
 
 Liang Li's group has developed a number of approaches to overcome these challenges 
using dansyl chloride (DnsCl) derivatization for untargeted metabolomics.
3–5
 By labeling a 
sample with both "light" DnsCl and "heavy" d2-DnsCl, a signature peak pair profile is created in 
the mass spectrum for any labeled metabolite. The difference between peak pairs will be a 
multiple of 2, based on the number of labels. From this data, it is easy to determine the number 
of labels on a specific feature. Additionally, software has been developed to automate peak pair 
picking, and a dansylated library has been developed to aid in metabolite identification. 
 A similar approach could be taken with BzCl. Using HRMS with 
12
C and 
13
C6 BzCl, the 
same peak pair profile could be created, though peak pairs would differ by a multiple of 6 instead 
of 2. The peak pair picking software is open source and factors could be modified to 
accommodate BzCl derivatization. Preliminary work on a q-TOF mass spectrometer using 
human plasma shows a number of peaks in the base peak chromatogram and the expected peak 
pair patterns in extracted mass spectra (Figure 7-2). The derivatized library described earlier 
would aid in metabolite confirmation though MS/MS fragmentation patterns, but HRMS would 
need to be used for these standards to obtain precise enough masses for initial searches.  
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Figure 7-2:  Untargeted metabolomics with benzoyl chloride (BzCl( derivatization using ultra high pressure liquid 
chromatography and qTOF mass spectrometry. a. Base peak chromatogram of human serum. b. Extracted mass spectrum from 
15.7 min showing peak pair resulting from 12C- and 13C-BzCl derivatization. 
 
Pseudotargeted metabolomics with benzoyl chloride 
 In addition to targeted and untargeted metabolomics, new approaches are being 
developed which combine features of each. One such approach, "widely targeted" metabolomics, 
has already demonstrated with BzCl. While widely targeted metabolomics still depends on 
authentic standards, another approach called "pseudotargeted" metabolomics does not.
6–9
 Instead, 
pseudotargeted methods develop MRMs directly from the samples to be analyzed. Candidate 
precursor ions are selected though scanning methods or incremental SIMs. These precursors can 
then be fragmented and conditions can be optimized for the resulting MRMs. Method 
development in this manner can be time consuming, but it allows for a reproducible MRM 
method which does not depend on the availability of authentic standards. 
 Pseudotargeted metabolomics with derivatization has previously been described with ω-
bromoacetonylquinolinium bromide (BQB), a derivatization reagent for thiols.
10,11
 Using BQB 
and d7-BQB, peak pairs in the mass spectra were used to identify candidate thiols. However, 
rather than using a MS2 scan, a double precursor ion scan was used. BQB and d7-BQB labeled 
metabolites produce a characteristic product ions of 218 and 225 respectively. Precursor scans 
for each product ion were used to identify candidate precursor ions, limiting background from 
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unlabeled metabolites, and reducing method development time as product ions for the precursor 
ions do not need to be determined. Using this method, 103 thiol candidates have been discovered 
in human urine, and nearly 20 have been identified through the use of standards.  
 Based on the success of this method, we started to explore the potential of using this 
approach with BzCl derivatization, which produces characteristic product ions of 105 and 111 
for light and heavy labeled metabolites. A double precursor scan method was established to 
cover a range of 100 - 600 m/z. This method was first applied to pooled human serum from the 
American Red Cross National Testing Lab, 
provided by the MRC
2
. Serum was 
derivatized with both 
12
C- and 
13
C-BzCl, and 
the resulting solutions were mixed in equal 
proportions. The resulting total ion 
chromatogram (TIC) is shown in Figure 7-3. 
Mass spectra were extracted for each 
observed peak in the TIC (7-3b). In the mass 
spectrum, five peak pairs can be identified 
with a difference of 6, corresponding to 
singly labeled metabolites. At a higher m/z, 
three peak pairs are seen with a difference of 
12, corresponding to doubly labeled 
metabolites. From the serum, 62 potential 
precursor ions were identified. 
Figure 7-3:  Pseudotargeted metabolomics with benzoyl 
chloride (BzCl) derivatization. a. Total ion chromatogram 
from human serum and mouse brain tissue. b. Extracted 
mass spectra from 9.9 min from serum. Separate spectra are 
extracted for 12C- and 13C-BzCl. Peak pairs are observed 
with m/z differences of 6 or 12, corresponding to singly or 
doubly labeled metabolites. 
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 The double precursor scan was also 
applied to brain tissue extract. Samples from 
two brain regions, the hypothalamus and 
midbrain, were available from two strains of 
mice, B6 and CAST. Portions of each extract 
were pooled and the pooled extract was 
derivatized with both 
12
C- and 
13
C-BzCl. The 
resulting solutions were mixed in equal 
proportions. The TIC from the double 
precursor ion scan is shown in Figure 7-3. The 
brain tissue was less rich in metabolites than the serum, but 45 potential precursors were still 
identified. An MRM method was created based on these potential precursors. Individual brain 
tissue extracts were then labeled with 
12
C-BzCl, and mixed with 
13
C-BzCl derivatized pooled 
extract. 
 Of the 45 potential MRMs, only 30 were reliably detected. Of these 30, all showed 
significant differences between the four sample types (Figure 7-4). Only preliminary work has 
been performed, so it is unclear why the remaining 15 were undetected. However, using 
narrower m/z ranges for the precursor ion scan and optimizing conditions for the resulting 
MRMs should increase sensitivity as well as the number of features detected. This approach 
combines the sensitive, reliable MRMs of targeted metabolomics with the ability to discover 
novel or unexpected metabolites typical of untargeted metabolomics and would be a powerful 
complement to the current targeted work done with BzCl derivatization. 
 
Figure 7-4:  Relative quantification of pseudotargeted 
metabolomics in hypothalamus (H) and midbrain (M) tissue 
extract of B6 and CAST strains of mice. Individual samples 
were labeled with 12C-BzCl and quantified relative to pooled 
tissue labeled with 13C-BzCl. 30 of 45 candidate MRMs 
were detected, and four representative MRMs are shown.  
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